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PREFACE 
Since its identification in 1964, the feline retroviral family 
has been Unplicated as the group of etiological agents responsible 
for a number of clinically diverse disorders. Though historically 
preceded by the identification and description of avian and murine 
retroviruses, it represents the first retroviral family characterized 
for an out-bred mammalian species, and has served as an important 
precedent and model for the recently described retroviruses of human 
concern. Retroviruses have been etiologically linked with both the 
malignant proliferation of and the selective depletion and/or 
dysfunction of hematopoietic and lymphoreticular cells. These 
retroviral effects manifest as leukemias, lymphoma, anemia and/or 
immunodeficiencies. It is not clear to what extent the clinical, 
pathological and immunological manifestations subsequent to retro-
viral infection are a result of discrete genetic events between the 
infecting retrovirus and the host cellular DNA, or are indirectly 
initiated by extraneous viral debree. 
My involvement in the feline-retroviral-leukemia-immunodefi-
ciency model was initiated by an invitation to join in studies 
evaluating a new form of anti-malignancy therapy utilizing a purified 
bacterial protein. Cats with overt malignancy were to be charac-
terized as to their presenting status, treated by way of plasma 
filtration over the purified bacterial protein, and monitored for 
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changes in their clinical condition. From this basis, and because 
of my curiosities concerning the extent of deficient immune function 
produced by retroviruses which I developed during the anti-malignancy 
therapy work, discrete observations were made concerning the mani-
festations and therapy of retroviral (FeLV) associated malignancy and 
immunodeficiency. These distinct findings were recorded as published 
manuscripts in scientific journals, and are presented in this disser-
tation as separate chapters. 
When persistently feline leukemia virus infected cats were 
treated with staphylococcal protein A, the incidence of clearance of 
evidence of FeLV infection increased and FeLV-associated diseases 
regressed. 
This loss of evidence of FeLV infection and regression of FeLV-
associated disease occurred in some cats that first experienced an 
increased in plasma interferon level, followed by the appearance and 
increase of a cytotoxic antibody specific for the major retroviral 
envelope glycoprotein gp70. 
The initial mean serum calcium concentration of cats that 
presented with hematopoietic malignancy was significantly higher 
than that of healthy control cats or FeLV-infected cats without 
malignancy, and three cases of overt hypercalcemia were identified. 
During therapy with staphylococcal protein A, shifts were 
observed in the morphological manifestations of a case of chronic 
feline hematopoietic malignancy with sequential changes in the 
predominant cell lineage. 
iv 
A new FeLV-replicating lymphoma-derived cell line was isolated 
from a cat presenting with anterior mediastinal lymphoma and was 
characterized as lacking T and B-lymphocyte surface markers. 
The synthesis of gamma interferon by normal feline lymphocytes 
stimulated with staphylococcal enterotoxin A in vitro was reduced 
when UV-light inactivated FeLV was also present in culture during the 
period of stimulation. 
In addition, immunological methods and reagents were developed 
which are likely to prove useful in the identification of quantita-
tive and qualitative aberrations in specific subsets of !-lymphocytes 
in the cat with retroviremia, immunodeficiency and leukemia. The 
optimal conditions of culture and assay for identification of feline 
immunoglobulin secreting mononuclear cells were determined for the 
staphylococcal protein A - reverse hemolytic plaque assay. Initial 
steps were taken toward the devlopment of monoclonal antibodies which 
characterize !-lymphocyte subpopulations by their pattern of reac-
tivity with cell surface antigens. 
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CHAPTER I 
BACKGROUND LITERATURE 
A. Taxonomy, Terminology and Molecular Biology of Retroviridae 
1. Introduction 
All retroviruses share morphological, physical and chemical 
features which justify their inclusion in a single viral family 
(Table I). Their RNA genome is copied into DNA by the viral enzyme, 
RNA-dependent DNA polymerase and this DNA copy, called a provirus, is 
inserted into one of the host's chromosomes. The integrated provirus 
is transcribed into RNA by host enzymes, giving rise to both viral 
genomic RNA and viral messenger RNA. 
The viral genes,~·~. ~' encode internal-structural, 
enzymatic (reverse transcriptase), and envelope proteins, respec-
tively. Additional sequences created during proviral synthesis from 
viral genomic RNA, flank the viral genes and are similar at each 
termini, forming a direct repeat. These repeated sequences found 
at the termini of the provirus are termed long terminal repeats 
(LTRs) and are made up of three segments: the u3 region (a sequence 
unique to the 3' end of viral genomic RNA), a redundant region (R) 
found at both ends of genomic RNA, and the u5 region (unique to the 
5' genomic end). Within the LTRs are elements which enhance and 
1 
Nucleic acid 
Protein 
Lipid 
Carbohydrate 
Physiochemical 
properties 
Morphology 
2 
TABLE I 
TAXONOMIC FEATURES OF RETROVIRIDAE* 
linear positive-sense single-stranded RNA (60S-
70S) composed of identical subunits (30S-35S); 
5' structure m7G5ppp5NmpNp; polyadenylated 3' 
end; repeated sequences at 3' and 5' ends; 
tRNA base-paired to genome complex 
about 60% by weight; gag, internal structural 
proteins (4-5); ~' reverse transcriptase 
(1-2); env, envelope proteins (1-2) 
about 35% by weight; derived from cell membrane 
about 4% by weight; associated with env pro-
teins 
sensitive to lipid solvents, detergents, and 
heat inactivation (56°C, 30 min); highly 
resistant to UV- and X-irradiation 
spherical enveloped virions (80-120 nm diam-
eter), variable surface projections (8 nm 
diameter), icosahedral capsid containing a 
ribonucleoprotein complex 
* adapted from Teich, 1982. 
promote transcriptional initiation, the initiation start site and a 
polyadenylation signal. 
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Host cellular DNA sequences which show homology to the 
exogenously acquired provirus are termed endogenous retroviral-
related sequences and are a type of endogenous provirus. Other 
endogenous proviruses that lack sequence homology to the retrovirus 
of the species may also be present within the host cellular DNA but 
are activated only in heterologous cells. In addition, certain other 
cellular sequences which are expressed at low levels in the normal 
host cell, but at high levels when activated or recombined with an 
infecting retroviral provirus, confer on the virus cellular trans-
forming properties both in vitro and in vivo, and have been termed 
oncogenes. 
The retroviral genome not only encodes information required for 
viral synthesis but apparently may also influence cellular regulatory 
elements or activate cellular genes. Trans-transcriptional activa-
ting substances induced or encoded by the provirus may recognize host 
DNA sequences in addition to those within the proviral LTR. The 
downstream LTR may promote initiation of transcripts primarily com-
prised of host sequences, and in some cases, these sequences are 
frequently oncogenes. In addition, the integrating provirus may 
recombine with and activate host cellular DNA (either endogenous 
proviral or oncogenic DNA) resulting at times in the loss of proviral 
structural sequences, but also in the enhancement of the oncogenicity 
of the virus. 
Evidently, it is the retroviral genome's mobility and abilities 
to at least recombine with, transfer, and promote the transcription 
of host cellular DNA that destines the retroviral infected cell to 
immortality, dysfunction and/or nonviability. Whether the induced 
cellular changes manifest clinically as a specific form of neoplasm 
or as a state of deficient immunity may be a function of the iso-
lates' cellular tropisms, their sites of DNA integration, the 
specificities of the transcriptional activating factors that are 
produced, the combination and degree to which normally quiescent 
cellular DNA is activated, and the products resulting from proviral 
recombination with the DNA of the host. 
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Regardless of these intracacies, retroviruses in general share 
common features and a mode of replication. The following summarizes 
these features as well as the mechanisms of proviral synthesis, 
integration, transcription and oncogenesis. The discussion is 
general, lacks species-specific information, is in no way exhaustive, 
and is intended only as an introduction to terminology, taxonomy and 
the molecular biology of retroviruses. 
2. Morphology 
The original formulation of the Retroviridae family was based 
on similarities in viral morphology revealed by electron microscopy 
(Bernhard, 1958, 1960). They are roughly spherical, approximately 
80-120 nm in diameter, have an inner proteinacious nucleocapsid (core 
or nucleoid) with apparent icosahedral symetry and an outer lipid-
bilayer envelope from which glycoprotein "spikes" variably project. 
On the basis of morphology, retroviruses are classified as either 
type-A, type-B, type-Cor type-D particles (Figure 1). 
Figure 1: Morphology of intracellular and extracellular retroviral 
particles. Intracellular type A particles have an electron-lucent 
center surrounded by a double shell. Type B, particles when budding 
from the plasma membrane, have doughnut-shaped cores and long enve-
lope-associated spikes. Extracellular, mature type B particles have 
electron-dense, eccentrically located cores. Budding type C 
particles have crescent-shaped cores and short envelope-associated 
spikes. When mature, the extracellular type C particle has a 
centrally located electron-dense core and short, indistinct envelope-
associated spikes. Type D particles have doughnut-shaped cores and 
moderately sized surface spikes when budding, while mature forms have 
bar-shaped cores. 
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Type-A particles occur as intracellular, non-infectious elements 
with an electron-lucent center surrounded by a double shell. They 
are further subdivided based on their intracellular location as 
intracisternal and intracytoplasmic. Intracisternal type-A particles 
are occasionally found in cells producing type-C or type-D particles 
but their function is unknown. The intracytoplasmic type-A particles 
are apparently precursor forms of type-B virions. 
Type-B particles. when budding at the plasma membrane have 
toroidal (doughnut-shaped) electron dense cores and long spikes at 
the envelope surface. After budding, mature virions contain elec-
tron-dense eccentrically-located nucleoids within the envelope. The 
mouse mammary tumor virus (MMTV) is the prototype member of the type-
B particle group. 
Most retroviruses are type-C particles, which when budding have 
crescent-shaped electron-dense cores. After budding, they have short 
ill-defined spikes and centrally-located cores that mature progres-
sively from electron-lucent to electron-dense. 
Type-D intracellular particles are ring-shaped and abundant near 
the plasma membrane. Budding and extracellular type-D forms have 
eccentrically-located, at times bar-shaped, electron-dense nucleoids 
and the envelope spikes are short. The Mason-Pfizer monkey virus 
(MPMV) is the prototype member of the type-D particle group. 
3. Pathobiology 
Viruses of the Retroviridae family have also been classified as 
members of one of three subfamilies based on their apparent in vitro 
and in vivo pathobiology. The subfamily Oncovirinae consists of 
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those retroviruses that are naturally oncogen~c, and closely-related 
non-onocogenic isolates. The Lentivirinae or "slow" viruses are 
cytopathic in culture producing syncytia and cell lysis, and produce 
slowly progressive debilitating diseases in ungulates. The 
Spumavirinae or "foamy" viruses produce vacuolizations in cultured 
cells, and induce persistent infections but no known clincial 
disease. 
4. Genomic Analysis 
Nucleic acid hybridization and nucleotide sequence analysis have 
also been used to identify and classify retroviruses and are useful 
for proposing evolutionary relationships between apparently closely-
related species of retroviruses which demonstrate polynucleotide 
sequence homology (Rabson and Martin, 1985). A feature which com-
plicates these studies is the frequent presence of host cellular DNA 
sequences which hybridize with some proviral eDNA probes (Benveniste, 
et al., 1975) (Koshy, et al., 1980). These endogeneous retroviral-
related sequences are homologous in part with the exogenously derived 
provirus, are stably integrated in the host cellular DNA as multiple, 
discrete. nontandem copies, are not inducible as virus and are in 
some cases distinquished from exogenously acquired proviruses by 
their incompleteness (Casey. et al., 1981). Sequence organization 
and location of endogeneous proviral-related sequences are the same 
among different tissues of an individual but unique when compared to 
other individuals, suggesting that inheritance is via the germ cell 
line. Endogenous proviral-related genes comprise an extensive 
multigene family. They have been variously described as entities 
ancestral to infectious retroviruses, as evidence of historical 
retroviral exposure, and as agents encoding normal cell functions. 
They are not necessarily quiescent. In fact, some of the major 
differentiation-specific glycoproteins of the mouse are encoded by 
endogenous proviral sequences (Lerner, 1978). 
5. Transmission 
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Three modes of retroviral transmission, horizontal-infectious, 
congenital-infectious and genetic can occur. All three modes of 
transmission may occur in an individual species but with differing 
consequences. For example, the horizontal exposure of a susceptible 
chick to avian leukosis virus (ALV) results in transient viremia, 
immunity and the rare development of leukemia, while the congenitally 
infected chick develops viremia, is immunologically tolerant to viral 
antigens and frequently develops leukemia (Rubin, et al., 1962). The 
congenital transmission of mouse mammary tumor virus (MMTV) parti-
cles, shed in the milk, to newborn C3H mice leads to the subsequent 
development of mammary tumors (Bittner, 1942a,b). Horizontally 
feline leukemia virus (FeLV) infected cats frequently develop a state 
of immunodeficiency, anemia or leukemia, but congenital infection 
results in abortion or fatal runting of the newborn (Jarrett, 1971). 
Certain in-bred strains of mice have a great numer of complete, 
endogenous proviruses which are naturally spread genetically and are 
inducible as infectious virus. Mic~ of the AKR strain have a great 
number of complete and incomplete endogenous murine leukemia viral 
(MuLV) proviruses and a high incidence of leukemia, and GR mice, 
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which experience a high incidence of mammary carcinoma, have numerous 
endogenous MMTVs (Chattopadhyay, et al., 1982). 
6. Host Range 
Host range is apparently defined in part by a retrovirus's 
cellular tropism. Ecotropic viruses are those which replicate in 
cells of the species from which they were isolated. Xenotropic 
viruses do not replicate well in cells of their host species, but 
when activated can replicate in a wide range of heterologous species. 
Cellular tropisms may be controlled at the genomic level by 
regulatory sequences or cell-specific transcriptional promotors 
(Lenz, et al., 1984) (Chen, et al., 1984) (Derse, et al., 1985). 
Alternatively or concomitantly, productive infection may be 
controlled at the membrane level requiring viral interaction with a 
specific cellular receptor (Fingeroth, et al , 1984) (Klatzmann, et 
al., 1984a,b). However, even cells totally resistant to infection 
can bind retroviruses suggesting that viral tropism for certain cells 
may be influenced by subsequent events such as viral penetration, and 
proviral synthesis, integration and transcription (Piraino, 1967). 
7. Proviral Synthesis and Integration 
When a retrovirus virion penetrates a susceptible cell, 
presumably in some form of an unenveloped core structure, viral DNA 
synthesis is initiated in the cytoplasm and requires only viral 
enzymes. When supplied only with deoxynucleoside triphosphates and 
appropriate salts in vitro, the virion core contains all the elements 
needed for complete viral DNA synthesis (Junghans, et al., 1975). 
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Within the virion core, genomic RNA is present as a dimer, hydrogen-
bonded together via palindromic sequences, and 1s associated with 
several low molecular weight nucleic acids (Haseltine, et al., 1977) 
(Sawyer and Dahlberg, 1973) (Levinson, et al., 1972). One such 
nucleic acid is a tRNA molecule which is hydrogen-bonded to the 5' 
end of viral genomic RNA (Taylor and Illmensee, 1975). The partic-
ular tRNA bound is species specific; tRNA tryptophan is bound in the 
avian leukosis virus, and tRNA proline is bound in the murine 
leukemia virus (Harada, et al., 1975, 1979). This tRNA serves as a 
primer for RNA-dependent DNA polymerase and identifies the point of 
initiation for synthesis of the first viral DNA strand (Baltimore and 
Smoler, 1971). 
The retroviral RNA genome is positive-sensed (+), that is, of 
same polarity as viral mRNA and capable of direct protein synthesis 
in in vitro translation systems. The first viral DNA strand to be 
synthesized then is negative-sensed (-) or of opposite polarity. Of 
course DNA strands are synthesized in the 5' to 3' direction, that 
is, deoxyribonucleotides are added to the 3' end of the growing DNA 
chain. Since the site of initiation for (-) strand DNA synthesis is 
at the 5' end of the template viral RNA strand, DNA synthesis would 
seem to run out of template almost immediately. There is, therefore, 
a strong theoretical requirement to transfer the growing (-) DNA 
strand to the 3' end of either the same RNA molecule or the second 
genomic RNA found 1n the virion. Though molecular details are lack-
ing, the transfer apparently does take place and can be accomplished 
only because both ends of the viral genomic RNA molecule contains 
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regions of redundancy (R) which can align (Sutcliffe, et al., 1980) 
(Amer, et al., 1981) (Swanstrom, et al., 198la,b). 
Soon after the initiation and transfer of the (-) strand DNA, 
synthesis of the (+) strand is initiated near the 3' end of the 
genomic RNA using the(-) strand DNA as template (Donehower, et al., 
1981). Though a specific primer for (+) strand initiation has not 
been identified, conjectures have been made that a 3' endonuclease 
activity of the RNA-dependent DNA polymerase leaves an appropriate 
primer when it degrades a site near the 3' end of viral genomic RNA. 
Following (+) strand initiation, a second transfer of the growing (-) 
strand occurs, this time its 3' end is transferred to and binds with 
the recently initiated (+) strand (Gilboa, et al., 1979). This 
positive strand serves as template for the completion of the (-) 
strand DNA which in turn serves as template for the synthesis of a 
majority of the (+) DNA strand. 
The consequence of this series of events is a linear double-
stranded DNA copy of viral genomic RNA which is known as the provirus 
(Figure 2). Synthesis of all linear proviruses occurs within the 
cytoplasm (except the Visna provirus which is made in the nucleus). 
The linear viral DNA then migrates from the cytoplasm to the nucleus 
where it serves as precursor to two forms of supercoiled circular 
provirus (Shank and Varmus, 1978). Proviruses join a defined pair 
of sites in their own DNA to a large number of different sites in the 
genomes of their host (Hughes, et al., 1978). Though it is not clear 
whether all potential proviral integration sites in the host genome 
are equally favored, the consequences of integration at some sites is 
apparently widely divergent from others. 
Figure 2: The relationship of retrovirus genomic RNA, unintegrated 
viral DNA and the integrated provirus. The viral genomic RNA is 
single-stranded, positive-sensed, capped at the 5' end, has a 3' 
poly-A tail and is hydrogen-bonded to a tRNA primer near its 5' end. 
Reverse transcription of this genome is accomplished with only viral 
enzymes. The process includes two separate initiation events, two 
transcriptional-jumps or transfer events, and results in a linear 
double-stranded DNA copy. After migration from the cytoplasm to the 
nucleus, this linear copy forms one of two circular supercoiled forms 
as indicated. The integrated provirus contains viral genes flanked 
by long terminal repeat (LTR) sequences. Single-stranded RNA is 
denoted by a dotted bar, and the LTR regions as open bars. Cellular 
DNA is represented by bars with slashes. Diagrams are not to scale. 
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The integration event does not lead to the loss of host 
sequences, rather insertion of viral DNA is accompanied by the 
duplication of a small region of host cellular DNA at the integration 
site (Majors and Varmus, 1981). Because of this duplication, the 
host sequences immediately flanking the provirus form a small direct 
repeat ranging in size from 4-6 base pairs (Dhar, et al., 1980). In 
contrast, the joining of host and viral DNAs results in the loss of 
2 base pairs from each end of the viral DNA (Dhar, et al., 1980) 
(Majors and Varmus, 1981). 
Viral genes within the provirus are flanked by a long terminal 
repeat (LTR) which is comprised of sequences reversely transcribed 
from and unique to the 3' and 5' ends of viral genomic RNA (U3 and 
u5 ) and a redundancy region (R) (Figure 3). The(+) and(-) strand 
DNA initiation sites define the extent of the LTRs, which show 
sequence homology among all retroviruses. Although host factors are 
not required for proviral synthesis, host cells must divide before 
integration of the provirus takes place (Varmus, et al., 1977). 
While the majority of the integrated proviruses are complete and 
contain two LTRs, integrated incomplete proviruses, some lacking 
internal viral sequences and others a LTR, have been demonstrated and 
are especially common in certain retroviral species (Martin, et al., 
1979). 
8. Proviral Transcription 
The normal cellular transcriptional machinery transcribes the 
provirus and processes the mRNAs. The transcriptional start site 
and the polyadenylation (poly-A) site define the redundancy region 
Figure 3: Functional features of the long terminal repeats (LTR). 
Reverse transcriptional initiation sites define the extent of the 
LTR. The messenger and genomic RNA transcriptional initiation site 
and polyadenylation signal define the extent of the redundancy (R) 
region. 
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(R) of the proviral LTR, and identifies the terminal ends of the 
viral genomic RNA (Figure 3) (Stoll. et al., 1977). Presumably, the 
proximity of the start signal and the poly-A addition site prevents 
the poly-A site from being used efficiently until the entire viral 
genome has been copied. Promoter sequences (TATAA boxes, etc .•. ) 
are found appropriately located within both of the LTRs near the 
transcriptional start site (Sutcliffe, et al., 1980). Apparently, 
start sites within both LTRs can be active and give rise to both 
viral mRNA and to transcripts of those host sequences which lie to 
the right of the provirus (Figure 4) (Hayward, et al., 1981) (Payne, 
et al., 1981, 1982). Proviral transcribed mRNAs either closely 
resemble mature viral genomic RNA or are spliced (Mellon and 
Duesberg, 1977) (Weiss, et al., 1977). 
9. Molecular Mechanisms of Retroviral Oncogenesis 
It is increasingly apparent that the evolution of a neoplasm 
involves, at some point, specific genetic alterations in individual 
cells whose progeny eventually predominate (Cairns, 1975, 1980). 
Eucaryotic transposable genetic elements, or transposons, and retro-
viruses share structural and functional features (Baltimore, 1985). 
Conceptually, retroviruses may be viewed as mobile genetic elements 
which integrate at any number of sites in the host genome, carry 
strong enhancer and promoter elements which in some cases show 
cellular specificity, are capable of recombination with host cellular 
sequences, can activate and transduce normally quiescent genes, and 
in some cases encode or induce the production of transcriptional 
activating substances (Holland, et al., 1985) (Neel, et al., 1981) 
Figure 4: Transcriptional initiation from the right LTR results in 
downstream transcripts which include message from cellular DNA. 
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(Derse, et al., 1985) (Gallo, 1985) (Hess, et al., 1985). In 
general, it seems likely that retroviruses possess not only an 
ability to infect and replicate within host cells but can potentially 
reshape the eucaryotic genome. 
Oncogenic retroviruses can be grouped into two categories based 
on their biological properties. The acutely oncogenic isolates 
transform appropriate target cells in culture and rapidly induce 
neoplastic disease with high efficiency. The chronic viruses fail to 
transform cells in vitro and induce neoplasia with lower efficiency 
only after a long latency period. Elucidation of the genomic struc-
ture of both classes of oncogenic retroviruses has shown that the 
acutely transforming isolates are genetic recombinants that acquired 
DNA sequences from the host genome, typically with loss of viral 
genes required for replication (Rous sarcoma virus, RSV, is an 
exception) (Stehelin, et al., 1976) (Roussel, et al., 1979). These 
transduced host DNA sequences confer upon the recombinant virus the 
properties of cellular transformation in vitro and tumor formation 
in vivo and are referred to as oncogenic (one) sequences. They are 
expressed in the host at high levels normally during growth and 
differentiation, are otherwise expressed at only low levels, and are 
thought to be involved in regulating development and embryogenesis 
(Bishop, 1985) (Bishop and Varmus, 1982). These cellular sequences 
(c-one) are not viral genes or defective, endogenous proviruses since 
they are evolutionarily conserved, occupy a constant genetic loci in 
every member of a species, many have introns, and none have been 
found linked to endogenous proviruses (Hughes, et al., 1980) (Bishop 
and Varmus, 1982). By comparing the~ regions of acutely trans-
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forming retroviruses (v-onc) and host DNA, over seventeen distinct 
cellular genes have been identified which apparently serve as 
progenitors of v-onc sequences (Table II) (Bishop, 1985). The 
proteins encoded by v-oncs are diverse and include tyrosine-specific 
protein kinases, nuclear binding proteins, a membrane glycoprotein 
which resembles the receptor for epidermal growth factor, and a 
homologue of platelet-derived growth factor (Hunter, 1984). Though 
it has been shown that the normal cellular one is capable of in vitro 
transformation if experimentally expressed within the cell at high 
levels, and that the v-oncs are expressed at very high levels in the 
acutely oncogenic retroviral-infected, transformed cell, the actual 
role of the v-onc products in oncogenesis is largely unknown 
(Oskarsson, et al., 1980) (Hunter, 1984). 
Though recent observations suggest that cellular oncogene 
transduction may occur in some chronic retroviral-induced neoplasms 
(Neil, et al., 1984) (Mullins, et al., 1984) (Levy, et al., 1984), in 
general, the weakly oncogenic viruses have been thought not to carry 
oncogenes. Instead, mechanisms for chronic retroviral oncogenesis 
that have been proposed include the selective recombination between 
endogenous proviral-related sequences and the integrating, exogenous-
ly acquired provirus (Evans and Cloyd, 1985) (Chattopadhyay, et al., 
1982) (Lerner, 1978), the activation of a cellular oncogene by 
promoter insertion or through the effects of enhancer elements, both 
of which are contained within the LTR (Neel, et al., 1981) (Payne, 
et al., 1981) (Fung, et al., 1981), the alteration of transcriptional 
regulation or mutagenesis of gene sequences subsequent to proviral 
integration (Jenkins, et al., 1981) (Varmus, et al., 1981), the 
TABLE II 
THE PRODUCTS OF RETROVIRAL ONCOGENES* 
TUMORIGENICITY 
Sarcomas 
B-lymphoma 
Erythroleukemias 
Sarcomas 
Sarcomas 
Erythroleukemias and 
sarcomas 
ONCOGENE 
src 
yes 
fps/fes 
ros 
fgr 
fms 
abl 
erb-B 
raf/mil 
mos 
ras 
Carcinomas, sarcomas and myc 
myelocytic leukemia 
Myeloblastic leukemia 
Osteosarcomas 
Sarcomas 
myb 
fos 
ski 
PROPERTIES OF PRODUCT 
TYR-specific protein kinase 
on/in plasma membrane 
Membrane glycoprotein: 
truncated EGF receptor 
SER/THR protein kinase 
Phosphoprotein in cytosol 
GTP-binding protein/GTPase 
on/in plasma membrane 
Nuclear Proteins 
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Sarcomas sis Cytoplasmic homologue of PDGF 
* adapted from Bishop, 1985. 
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influence of retroviral encoded or induced trans-transcriptional 
activating substances on regulatory elements (Rosen, et al., 1985) 
(Derse, et al., 1985) (Felber, et al., 1985) (Sodroski, et al., 
1985), the mitogenic effects of replicative gene products on a rare 
target cell (McGrath and Weissman, 1979), the uncoupling of the T-
cell growth factor (TCGF) - TCGF receptor system (Wong-Stall, 1985), 
the increased risk of developing specific chromosomal translocations 
by expansion of the viral infected cell population (Rowley, 1983) 
(Erickson, et al, 1985), or, finally, the transduction and/or 
rearrangement of a cellular oncogene by the infecting retrovirus 
(Figure 5) (Neil, et al., 1984) (Mullins, et al., 1984) (Levy, et 
al., 1984). 
Regardless of the mechanism, site-specific proviral integration 
is thought not to occur. Though the integrated provirus may 
frequently reside at a given site, this is thought to represent a 
process of selection, which favors the few integration events 
associated with neoplastic transformation (Gallo, 1985) (Neel, et 
al., 1981) (Hayward, et al, 1981) (Payne, et al, 1981) (Neil, et al., 
1984). Depending on the neoplasm and species involved, the acquired 
proviral genome may commonly be complete or may be extensively 
deleted, yet retain a LTR and its influential promoter and enhancer 
elements (Yoshida, et al., 1985) (Hayward, et al., 1981). Further 
selective pressure in the form of immunological surveilance may then 
favor cells which contain only a deleted provirus acquired subsequent 
to retroviral infection, and which do not express viral proteins at 
the infected cell's surface. 
Figure 5: Molecular models of retroviral oncogenesis. Some of the 
proposed events at the proviral level which are thought to contribute 
to cellular transformation are diagramatically represented here and 
include interactions between oncogenes (dark solid bar), newly formed 
viral genes (dotted bar), regulatory elements including the retro-
viral LTR (open bar), and cellular DNA (slashed bar). A. Recom-
binant-derived sarcoma viruses loose sequences encoding viral struc-
tural proteins but obtain an oncogene. B. Recombination between 
endogenous retroviral-related sequences and a retrovirus's structural 
genes may result in a retrovirus with enhanced leukemogenicity. MCF 
isolates of murine leukemia virus are an example. C. Enhanced 
transcription of downstream cellular DNA (c-one) apparently occurs 
with avian leukosis virus. D. Recombination between proviral and 
cellular DNA, with the addition of a v-onc has been proposed for FeLV 
and is the general structure of the replication effective Rous 
sarcoma virus. E. Products encoded by extra retroviral genes or 
open reading frames (orf) may activate transcripti~n not only at the 
LTR but also at other remote cellular regulatory sites as proposed 
for the human T-lymphotropic virus isolates, the bovine leukemia 
virus and the Viana virus of sheep. 
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B. Leukemia, Anemia and Immunodeficiency-inducing 
Feline Retroviruses 
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Five different types of retroviral prov1ruses may be found 
within the feline cellular genomic DNA. The feline syncytial virus 
is a member of the Spumavirinae subfamily and causes inapparent 
infection of little clinical significance. At least two different 
types of endogenous proviruses exist; the RD114 and FeLV-related 
proviruses. In addition, two exogenous type C retroviruses of the 
Oncovirinae subfamily may leave integrated proviruses within the 
genome subsequent to viral infection. These exogenous retroviruses 
are classified, as described in the previous section, as acutely 
oncogenic or potentially oncogenic after a long period of latency, 
and have been named the feline sarcoma virus (FeSV) and the feline 
leukemia virus (FeLV), respectively. 
1. RD114 
The RD114 endogenous provirus encodes complete infectious virus 
with a xenotropic host range and was discovered following the passage 
of human rhabdomyosarcoma cells (the RD cell line) in the brain of a 
kitten (McAllister, et al., 1972). It is not infectious for feline 
cells and shows no detectable relationship to exogenous feline 
retroviruses (Livingston and Todaro, 1973). Enhanced expression of 
RD114 mRNA does occur in embryonic thymocytes, placenta, and some 
lymphomas (Niman, et al., 1977a,b). 
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2. FeLV-related Proviruses 
Endogenous FeLV-related sequences, recognized by DNA hybridiza-
tion and FeLV eDNA, are arranged as 8-12 discrete genetic elements in 
a nontandem fashion within normal feline DNA (Koshy, et al., 1980). 
Sequences homologous to the u5 segment of the LTR are present in 
uninfected feline cells at much higher numbers, approximately 150 
copies per cell (Casey, et al., 1981). Though exogenously acquired 
and endogenous proviruses show similarities in their centrally 
located regions (parts of gag, pol, env), the endogenous and 
exogenous proviruses are substantially unrelated in the u3 region of 
the LTR. This divergent region may be used to identify exogenously 
acquired proviruses, and may be used as a probe for studying provirus 
number and location (Casey, et al., 1981). The transcriptional 
inactivity of many endogenous proviruses may be related to the 
absence of endogenous sequences which show homology to the u3 segment 
of the LTR, where enhancer and promoter sequences for viral tran-
scription occur (Casey, et al., 1981). In addition, endogenous 
sequences are variably deleted in the gag, pol and env regions, and 
this may render them incapable of encoding infectious virus 
(Benveniste, et al., 1975). The feline endogenous retroviral-related 
proviruses appear to behave as stable mendelian elements with the 
number and distribution of proviruses common in all tissues of an 
individual, but with evolutionary instability so that patterns vary 
greatly from one individual to another. It is less clear to what 
extent the endogenous retroviral-related proviruses of the cat are 
expressed and whether their expression 1s essential for cellular 
growth and development. 
3. Feline Sarcoma Viruses 
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The feline sarcoma viruses (FeSV) are rare genetic recombinants 
that have transduced cellular oncogene sequences in the feline 
leukemia virus (FeLV) infected cat (Snyder and Theilen, 1969) 
(Gardner, et al., 1970) (McDonough, et al., 1971) (Hardy, et al., 
1982). At least six cellular DNA sequences, proposed as oncogenes, 
have been shown to recombine with the infectious FeLV (Table III). 
In each case, the newly acquired oncogene (v-onc) combines with the 
viral genome at the expense of sequences within the gag, ~ or~ 
viral structural genes (Figures 6 and 7) (Sherr, et al., 1984). 
Often, virtually all of the viral ~ gene and much of the env gene 
have been deleted. Since FeSV genomes lack sequences required for 
replication, they can only be propagated in.the presence of a 
"helper" virus which provides the needed functions. In natural FeLV 
infections where FeSV arises as a recombinant, the defective sarcoma 
virus genome is replicated in complex with, and packaged into virions 
encoded by the "helper" (FeLV) virus. Cells infected with FeSV alone 
acquire the provirus, express viral RNA, undergo morphological 
transformation apparently as a result of v-onc expression, but cannot 
produce infectious viral particles (Sarma and Log, 1971). The 
sarcoma v1ruses can transform fibroblasts and epithelial cells in 
culture, and induce multicentric subcutaneous fibrosarcomas in young 
animals after a 2-3 week latency period. Malignant melanomas of the 
skin or uvea, and rhabdomyosarcomas have rarely developed following 
Viral 
Oncogene 
v-fes 
v-abl 
v-fgr 
v-fms 
v-sis 
v-kit 
TABLE III 
ONCOGENES OF FELINE SARCOMA VIRUSES* 
FeSV Strain 
Snyder-Theilen (ST) 
Gardner-Arnstein (GA) 
Hardy-Zuckerman 1 (HZ-1) 
Hardy-Zuckerman 2 (HZ-2) 
Gardner-Rasheed (GR) 
Susan McDonough (SM) 
Parodi-Irgens (PI) 
Hardy-Zuckerman 4 (HZ-4) 
* adapted from Sherr, 1984; Besmer, 1983. 
Viral 
Polyprotein 
P85gag-fes 
PllOgag-fes 
P95gag-fes 
P95gag-ab1 
P70gag-fgr 
gP180gag-fms 
P75gag-sis 
unreported 
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Figure 6: Feline retrovirus prov1ruses and their cellular 
oncogenes. Relative size. in kilobases (kb). of feline proviruses 
including the endogenous RD114 provirus, as well as exogenously 
acquired feline leukemia virus proviruses and recombinants of FeLV 
with cellular DNA known as feline sarcoma viruses. Oncogenes are 
denoted by a dark solid bar, viral genes as dotted bars and the LTR 
as an open bar. Diagrams are adapted from restriction endonuclease 
maps of feline proviruses. 
FELINE RETROVIRAL PROVIRUS 
AND THEIR CELLULAR ONCOGENES 
AD 114 
rro.:.:.:.:.:.:.:.:.:.:.;.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.: ... ;.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.;.:.:.:.:.:.:.:.:.:·.·.·.·.·.·.·=·=·=~ Ill 
STeFeLV 
I II t·=·········=···=·=···=·=·=·=·=·=·······=·=·=·=·.·.·.·=·=·=··· ..... ·.·=······· ..... ·.··· ................................................. ·.·LLO 
CJD!·!·!·.·!·!·!·!·!·:·!·:·!·:·:·:·!· 
·:·=·=·=·=·1 Ill 
v-fes 
GA-FeLV 
on=·=·=·=·:·=·=·=·=·=·=·:.:·=·=·=·=·=·:-:-=-=·=·=·=·=·=···=·=·=·=·:-:.:-=·=·=·=·=·:·=·=·=·=·=·=·=·=·=·=·=-:·=·=·=·=·=·=·=·=·=·=·=·=·:.:·=·=·=·=·[]l] 
GA-FeSV [JIJ:.;.;.;.;.;.;.·.··:···:·:·· 
SM-FeSV 
CITl:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·: 
·······=·:·=·=···=···=····-:.·.·.·.·.·n 
v-fes 
:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·:·CJil 
v-fms 
kb ~I~~~~~~~~~~~~~~~~~~~~~~~~~~~~~! 
0 1 2 3 4 5 6 7 8 9 10 
Figure 6 
32 
Figure 7: Deletions ~n the exogenously acquired FeLV proviral DNA 
and the acceptance of new cellular DNA may result in the formation of 
a recombinant provirus with acutely oncogenic properties; feline 
sarcoma virus (FeSV). 
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Figure 7 
experimental innoculation of FeSV isolates (McCullough, et al., 
1972). 
4. Feline Leukemia Virus 
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The feline leukemia virus (FeLV) is a contagious type C 
retrovirus of the subfamily Oncovirinae whose spread can be reduced 
by eliminating contacts between infected and uninfected animals 
(Jarrett, et al., 1964 a,b) (Hardy, et al., 1969, 1973) (Essex et 
al., 1975). In about half of the natural feline population, evidence 
of FeLV exposure is demonstrable by the presence of anti-viral 
antibodies, but viremia is evident in only 1-2%. The incidence of 
serological evidence of virus exposure and the evidence of viremia 
increase to approximately 70% and 28% in multiple cat households, 
respectively (Essex, et al., 1975) (Hardy, 1980). Isolation of FeLV 
is possible from the infected eat's salivary secretions and to a much 
lesser extent from the urine (Hardy, 1980) (Francis, et al., 1977). 
Cogenital transmission is possible, but a minor mode of viral spread 
(Cotter, et al., 1975) (Hoover, et al., 1983). 
Since the most common vehicle of transmission is saliva, FeLV 
initially replicates in the lymphoid tissues of the head and neck 
(Francis, et al., 1977) (Gardner, et al., 1971). Within a few days, 
viral antigen, primarily the major internal structural protein of the 
viral core (p27), becomes detectable by indirect immunofluorescence 
(IFA) within a small population of peripheral blood mononuclear cells 
(Figures 8 and 9) (Rojko, et al., 1979). This initial mononuclear 
cell-associated viremia leads to extensions of virus replication to 
the other lymphoid organs including the thymus, spleen, lymph nodes, 
Figure 8: Diagrammatic representation of a budding feline leukemia 
virus. Precursor polypeptides (Pr) aggregate and are modified near 
the plasma membrane and give rise to virus structural proteins (p), 
some of which are glycosolated (gp). Proteins which play major roles 
in serological assays are marked with an astericks. The gp70 mole-
cule participates in virus neutralization, interference and virus-
infected cell cytotoxic events. The p27 molecule contributes in a 
maJor way to retroviral-associated antigenemias. The trans-envelope 
bound pl5E molecule has been implicated 1n FeLV-mediated immunodefi-
c1ency. 
cell 
membrane 
*gp70 ---~ 
Pr 90 Pr 7 5 Pr180 s-RNA 
CYTOPLASM *p27, p15 
Figure 8 
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Figure 9: The systemic cycle of feline leukemia v~rus replication. 
An idealized sequence of the systemic foci of FeLV replication, if 
immunologically unchallenged, is diagramatically represented here. 
Numbers indicate days post-exposure. Pharyngeal lymphoid tissue and 
epithelia (1-7); draining lymph nodes, mononuclear cell-associated 
viremia (1-14); systemic lymphoid tissue (3-12); bone marrow, intes-
tinal crypt epithelium (7-21); marrow-origin viremia (14-28); 
epithelia (28-56). 
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3-12 
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and Peyer's patches. In the young animal twenty-one days after 
exposure, the hematopoietic cells of the bone marrow and intestinal 
crypt epithelial cells become positive by !FA for viral antigen, and 
a marrow-derived primarily polymorphonuclear cell-associated viremia 
develops. The detection of p27 in circulating neutrophils and 
platelets by fixed cell !FA has a 90% correlation with recovery of 
infectious virus from plasma and is considered diagnostic of viremia 
(Hoover, et al., 1977) (Hardy, et al., 1973). Subsequent to the 
establishment of marrow derived viremia, multiple mucosal and glan-
dular epithelial tissues become infected and include the oropharynx, 
nasopharynx, larynx, trachea, stomach, pancreas, urinary bladder and 
salivary glands (Figure 9). 
Viral infection is often more restricted in the older cat with 
the initial mononuclear cell associated viremia lasting several weeks 
and fequently followed by the elimination of virus and virus infected 
cells from the bloodstream. The elimination of viremia is temporally 
associated with the production of antibodies directed at determinants 
on the major viral envelope glyproprotein, gp70. Animals that 
develop sufficient virus neutralizing antibody titers generally 
remain immune to that FeLV subgroup, though viremia and antibody to 
gp70 can co-exist. Different epitopes of the gp70 molecule are 
involved in virus interference, virus neutralization and the lysis of 
virus infected cells by antibody and complement (Lutz, et al., 1980) 
(Grant et al., 1983). Cell mediated responses may play important 
adjunct roles to this antiviral humoral response but to date have 
received little attention. Resistance to experimental virus 
infection is apparently influenced by the age of the animal as well 
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as the strain of virus innoculated, and may be attributable in part 
to the degree of permissiveness by macrophages and lymphocytes for 
FeLV replication (Hoover, et al., 1976, 1981) (Rojko, et al., 1979, 
1981). 
Elimination of virus infected cells and virus from the blood, 
as evidenced by a negative !FA test, does not necessarily terminate 
the exogenously acquired proviruses' influence. An enzyme-linked 
immunosorbent assay (ELISA) of feline plasma detects circulating p27 
and correlates with viremia only 68% of the time. Reasons for these 
discordent serological results have been proposed, but not resolved, 
and include an early phase of infection, a regressive viremia, a 
persistent site of replication from a remote epithelial foci, inte-
gration of an incomplete provirus with continuous antigen shedding, 
and derepressed endogenous FeLV-related sequences (Lutz, et al., 
1983). It appears likely though that in at least some cases, cells 
from FeLV immune cats are persistently integrated with exogenously 
acquired FeLV proviruses (Rojko, et al., 1982) (Madewell and Jarrett, 
1983). Persistent, nonproductive, exogenously acquired proviruses 
could account not only for antigenemias in the absence of viremia, 
but also for persistently high antiviral antibody titers, relapsing 
viremias, and the occurrence of FeLV-negative leukemia-lymphomas 
(Lutz, et al., 1980) (Essex, et al., 1975) (Post, et al., 1980) 
(Rojko, et al., 1982). 
Subcloning of FeLV field isolates has revealed the existence 
of three serologically distinct FeLV subgroups which are capable of 
replication in cultured feline embryo cells. These FeLV subgroups 
(A. B, C) have been identified by interference and neutralization 
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tests which reflect properties of the envelope glycoproteins, gp70(s) 
(Sarma and Log, 1973). Studies indicate that viruses of subgroup A 
are monotypic, always present in natural isolates, and are the most 
readily transmitted FeLV subgroup. In contrast, FeLV B and C viruses 
are present in natural isolates only in association with A, have 
expanded in vitro host ranges, and demonstrate antigenic polymorphism 
and cross reactivity. It is these findings, and the reported env 
gene sequence homologies between FeLV-B and recombinant MCF mur1ne 
leukemia virus isolates, that have led to the proposal that B and C 
v1ruses are recombinants between FeLV-A and endogenous proviral 
sequences related to FeLV (Elder and Mullins, 1983). Attempts to 
attribute specific clinical disease to a single or a combination of 
FeLV subgroups have been inconclusive, but evidence suggests that 
FeLV-C is frequently associated with neoplasia and that immunity to 
this subgroup may underlie resistance to FeLV-induced tumors 
(Vedbrat, et al., 1983) (Grant, et al., 1983). Additionally, partial 
nucleotide sequence analysis of viruses classified within a single 
subgroup reveals significant differences among viruses (Rosenberg, 
et al., 1980). 
Persistent viremia is recognized when sequential IFA tests of 
fixed leukocytes are positive over a twelve week period of time. 
Persistently infected cats are at a much higher risk of developing 
clinical disease then uninfected cats (Essex, 1982). The most fre-
quent sequelae to persistant infection is an immunodeficient state 
with multiple intercurrent infections or immune-mediated diseases. 
Aregenerative anemia is considered the second most common sequelae, 
and lymphoid leukemia-lymphoma the third. 
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5. Induction of an Immunodeficient State 
Persistently retroviremic cats often have suppressed lymphocyte 
blastogenic responses toT-cell mitogens (Cockerell, et al., 1976), 
delayed and prolonged antibody responses to a T-cell specific 
synthetic polypeptide (Trainin, et al., 1983), prolonged allograft 
rejection times (Perryman, et al., 1972), reduced lymphocyte membrane 
con A receptor mobility (Dunlap, et al., 1979), exhibit varying 
degrees of hypocomplementia, thymic atrophy and depletion of the 
paracortical zones of lymph nodes (Kobilinsky, et al., 1979) lack or 
only minimally convert from a predominantly IgM to a IgG antiviral 
antibody response, and have variably elevated levels of circulating 
immune complexes (CIC) consisting of viral antigen and anti-viral 
antibodies (Snyder, et al., 1982) (Day, et al., 1980). In addition, 
persistently viremic cats are at high risk for the development of 
multiple intercurrent diseases such as enteritis, gingivitis, 
pneumonia, bacterial sepsis, infectious peritonitis of coronaviral 
origin (FIP), parastitic infestations such as Hemobartonella felis or 
Toxoplasma gondi, glomerulonephritis and autoimmune hemolytic anemia 
(Cotter, et al., 1975) (Essex, 1982). 
Although little is known about the way in which FeLV initiates 
immunosuppression, the virus may mediate immunomodulating events 
independent of cellular infection since UV-light inactivated FeLV 
(FeLV-UV) and certain FeLV structural proteins (pl5E) have been shown 
to impair lymphocyte proliferative responses and membrane receptor 
capping to con A in vitro (Hebebrand, et al., 1977) (Mathes, et al., 
1979). UV-inactivated FeLV has been shown to reduce the synthesis of 
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feline gamma-like interferon (y-IFN) by lymphocytes from normal cats 
(Engelman, et al., 1985). and in mur~ne or human systems of assay 
FeLV-UV and pl5E have been shown to reduce the synthesis of inter-
leukin-2 (IL-2) and responsiveness by lymphocytes to IL-2 (Orosz, et 
al., 1985) (Wainberg, et al, 1983, 1984) (Copelan, et al., 1983). 
Some studies have suggested that the unresponsiveness of lymphocytes 
to mitogen may be reversed with the addition of exogenously derived 
T-cell growth factor-like (interleukin-2-like) supplement (Wainberg, 
et al., 1983, 1984), but other studies disagree (Orosz, et al., 
1985). Proliferation of cells in mixed lymphocyte cultures and the 
generation of alloantigen-induced cell-mediated lympholysis (CML) is 
also impaired by FeLV-UV in murine systems of assay (Orosz, et al., 
1985). In addition, FeLV-UV activates the classical scheme of 
complement and can generate FeLV-specific suppressor cells in vitro 
(Langweiler and Cockerell, 1982) (Langweiler, et al., 1983). 
The concept of the potential role of retroviral envelope 
proteins in the pathogenesis of immunosuppression is additionally 
supported by two observations. The transmembrane envelope protein 
of HTLV-I and HTLV-II, gp21E, shares significant amino acid sequence 
homology with p15E of murine and feline leukemia viruses as well as 
with the transmembrane proteins of the bovine leukemia virus and Rous 
sarcoma virus, and the full-length endogenous retroviral provirus of 
humans. Further, it has recently been reported that a peptide 
synthesized to correspond to a portion of this region of sequence 
homology inhibits the proliferation of both murine and human lympho-
cytes in mixed lymphocyte cultures (Cianciolo et al., 1985). 
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FeLV-UV and purified pl5E apprently have no affect on preformed 
CML, interleukin-1 (IL-l), IL-2, or y-IFN nor do they interfere with 
receptors for IL-l, IL-2 or y-IFN (Orosz, et al., 1985) (Engelman, et 
al., 1985) (Copelan, et al., 1983). In addition, monocyte-macrophage 
functions including chemotaxis, phagocytic and bactericidal activi-
ties, and the synthesis of interleukin-1 are not apparently impaired 
by FeLV-UV or pl5E in vivo or in vitro (Hoover, et al., 1981) 
(Copelan, et al., 1983). Cytopathic effects which contribute to 
immunodeficiency, as demonstrated with human T-lymphotropic virus-III 
(HTLV-III) isolates which selectively deplete T-lymphocytes of the 
helper subpopulation thereby contributing to the state of immuno-
deficiency in the human patient with the acquired immunodeficiency 
syndrome (AIDS), have not been demonstrated with any isolate of the 
feline leukimia virus (Klatzmann, et al., 1984) (Lane and Fauci, 
1985). 
Interest in the concept that inactivated FeLV or FeLV structural 
components could abrogate immunological responsiveness was initiated 
by FeLV vaccine trial studies where virus structural components were 
used as the immunogen (Schaller, et al., 1977). Subsequent work has 
focused attention on the highly hydrophobic, trans-envelope bound 
pl5E molecule and its possible interaction with the lymphocyte 
surface membrane. Since the prostaglandin and cyclic nucleotide 
systems are both closely associated with cell membrane-mediated 
events and linked to the immune system (Stenson and Parker, 1980), 
pl5E abrogated immune responsiveness may be attributable to inter-
ference with one of these systems. Increased activity of prostaglan-
dins of the E series, abrogation of the calcium calmodulin-dependent 
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activation of adenylate cyclase, or interference with membrane 
microtubular functions are potential sequalae to cell membrane -
p15E interactions and may explain in part the FeLV induced state of 
deficient lymphocyte responsiveness in vitro. 
6. Anemiagenesis 
Persistently retroviremic or experimentally FeLV-inoculated cats 
frequently present with aregenerative anemia with hematocrits between 
5-15% and the bone marrow myeloid:erythoid (M:E) ratio shifted from 
the normal 1.6 to as high as 10.4 (Hoover, et al., 1974) (Onions, et 
al., 1982) (Boyce, et al., 1981) (Cotter, et al., 1975). The induced 
anemia has been described as normocytic-normochromic (Cotter, et al., 
1975) or macrocytic-normochromic (Weiser and Kociba, 1983). Affected 
cats have normal erythrocyte survival times, but markedly diminished 
plasma radioiron half times (Madewell, et al., 1983). Certain sub-
clones of FeLV subgroups, especially FeLV-C subclones, have been 
implicatd as etiological agents for pure red cell hypoplasias in the 
cat (Testa, et al., 1983) (Onions, et al., 1982) (Jarrett et al., 
1984). 
Colony forming assays for feline erythroid and myelomonocytic 
precursors have been used to investigate the pathogenesis of FeLV-
induced aregenerative anemia. Primitive and more mature erythroid 
precursors, designated BFU-e and CFU-e (burst- and colony- forming 
units - erythroid) are rapidly depleted in the FeLV-innoculated cat 
prior to the onset of anemia, while the proportion of the myeloid 
precursors CFU-c (granulocyte-monocyte-colony-forming units) remains 
normal (Onions, et al., 1982) (Testa, et al., 1983). These 
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erythrosuppressive effects may be attributable to v1rus structural 
components since similar findings have been reported when inactivated 
FeLV or p15E are present during the period of culture (Wellman, et 
al., 1984). 
7. Leukemogenesis 
Three independent, but simultaneously reported studies recently 
found FeLV proviruses containing the oncogene v-myc in the DNA of a 
small proportion of cats with FeLV-positive lymphomas (Neil, et al., 
1984) (Mullins, et al., 1984) (Levy, et al., 1984). These reports 
suggest that transduction of the v-myc oncogene by exogenously 
acquired FeLV proviruses may be possible subsequent to a recombinant 
event, and imply that this oncogene carrying recombinant may be 
transmitted contagiously between cats. 
Although serological and epidermiological evidence suggests FeLV 
involvement in the development of the 30% of feline lymphomas which 
do not actively produce FeLV (Hardy, et al., 1980) (Rojko, et al., 
1982), viral proteins are absent and sequences homologous to the u3 
portion of the exogenously acquired proviral LTR are not present in 
the tumor cells (Casey, et al., 1981). 
CHAPTER II 
CLINICOPATHOLOGIC RESPONSES IN CATS WITH FELINE LEUKEMIA 
VIRUS-ASSOCIATED LEUKEMIA-LYMPHOMA TREATED 
WITH STAPHYLOCOCCAL PROTEIN A 
A. Summary 
Purified protein A from Staphylococcus aureus Cowan I was 
injected intraperitoneally or was incorporated in filters~ vivo 
through which plasma from cats with feline leukemia virus (FeLV) 
associated leukemia-lymphoma was passed. Prior to treatment, 65% of 
the FeLV infected cats were anemic and 70% were thrombocytopenic. 
Concomitant infections or immune-mediated disease were common. 
During treatment, 50% of the cats with FeLV associated disease 
improved objectively with normal post-treatment hematocrits, throm-
bocyte and leukocyte counts, disappearance of dysplastic hematologic 
elements and correction of marrow dyscrasias. A 33% response to 
treatment occurred in cats with unequivocal manifestations of malig-
nant disease and was characterized by reductions in tumor size and 
marrow and peripheral blood neoplastic cell populations. Clearance 
of FeLV viremia was documented in 28% of the treated cats. The 
several possible mechanisms by which treatment with staphylococcal 
protein A causes reduction in the extent of malignant disease are 
considered. 
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B. Introduction 
Staphylococcal protein A (SpA), a cell wall constituent of S. 
aureus Cowan I (SAC), is a single polypeptide with three homologous 
regions which have the capacity to bind the Fe region of IgG and to 
combine rapidly and with great affinity with immune complexes 
(Kessler, 1975) (Goding, 1978). Other regions of the molecule 
initiate proliferative responses of T or B lymphocytes and stimulate 
elaboration of soluble products by lymphocytes including interferon 
and leukocytic migration inhibition factor (Sumija et al., 1982) 
(McCool et al., 1981). Extracorporeal perfusion of plasma from 
patients or animals with malignancy over whole SAC organisms or 
through filters containing purified SpA has led to reductions in 
tumor size and to decreased levels of circulating immune complexes 
(CICs) (Ray. 1982). This treatment has also been shown to induce the 
appearance of cytotoxic antibodies directed toward the neoplastic 
cells (Ray, 1982). Regression of malignancy has occurred following 
this treatment in patients with metastatic colon carcinoma (Bansal et 
al., 1978) (Ray et al., 1982a) and breast ductal cell adenocarcinoma 
(Terman et al., 1981), in dogs with anaplastic mammary adenocarcinoma 
(Terman et al., 1980), lymphoma or rectal carcinoma (Ray, 1982), and 
in rats with dimethylbenzanthracene (DMBA)-induced mammary adenocar-
cinoma (Ray et al., 1982b). However, many of the reports presented 
have been criticized for lack of information concerning the patients 
or animals with the malignancy and for inadequacy of controls. 
Further, they have been somewhat difficult to interpret because in 
many cases other more conventional forms of anti-cancer treatment 
were also administered (Hellstrom & Hellstrom, 1981). 
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The feline leukemia virus (FeLV) is a contagious retrovirus of 
cats that causes leukemia-lymphoma and various non-neoplastic 
diseases including immunosuppression and aregenerative anemia (Hardy, 
1980a). Exposed cats may develop an adequate neutralizing antibody 
titer to FeLV envelope antigens and may eliminate the virus (Hardy, 
1980b). An inadequate anti-FeLV immunologic response occurs in about 
28% of infected cats and results in a persistent viremia (Hardy, 
1980b). Persistently infected cats often have suppressed blastogenic 
responses toT cell mitogens (Cockerell et al., 1976b), suppressed 
antibody responses to synthetic polypeptides (Trainin et al., 1983), 
prolonged allograft rejection times (Olsen et al., 1981), and they 
exhibit varying degrees of hypocomplementemia (Kobilinsky et al., 
1979). Immunosuppression and secondary infections or immune-mediated 
disease is the most frequent sequelae of persistent FeLV infection 
and accounts for a majority of the FeLV-related deaths (Hardy, 
1982a). Leukemia-lymphoma is the most common neoplasm of cats and 
accounts for 90% of the hematopoietic malignancies (Moulton, 1978). 
Feline lymphoblastic leukemia has been proposed as a model for human 
acute lymphoblastic leukemia (Cotter & Essex, 1977). In addition, 
myeloproliferative disease is a more frequent disorder in cats than 
in other domestic animals and is often associated with FeLV infection 
(Harvey, 1981). 
Extracorporeal perfusion of plasma from cats with FeLV associ-
ated leukemia-lymphoma over SAC has resulted in the clearance of FeLV 
viremia and in clinical improvement of some of the cats (Jones et 
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al., 1980) (Snyder et al., 1984). However, many of these cats were 
exposed to a dose of whole-body irradiation prior to immunotherapy. 
Further, the clinicopathologic status of cats prior to treatment and 
consequences of treatment were inadequately characterized. Similar 
clearance of viremia and clinical improvement after the perfusion of 
plasma through filters containing SpA or after the intraperitoneal 
injection of SpA has occurred without adjunct therapy in cats treated 
in our laboratories (Day et al., 1984) (Liu et al., 1984a) (Liu et 
al., 1984b). It is the purpose of the present report to provide a 
description of the clinicopathologic status of cats prior to 
treatment and to record details of responses which occurred during 
treatment with staphylococcal protein A. In addition, the responses 
of healthy cats to similar manipulations with SAC, SpA columns or 
injections of SpA are described. 
C. Material and Methods 
Clinically ill, FeLV-infected cats were referred by Oklahoma 
veterinarians to the Department of Pathology, College of Veterinary 
Medicine, Oklahoma State University, and to the Oklahoma Medical 
Research Foundation. All cats were characterized by cytologic 
examination of bone marrow, lymph node. tumor and peripheral blood 
aspirates, and on the basis of results of the indirect 1mmuno-
fluorescent antibody (IFA) test for FeLV in leukocytes (Hardy et al., 
1973b) (Antibodies, Inc., Davis, CA), and the enzyme-linked immuno-
sorbent assay (ELISA) for the detection of FeLV antigen in serum (Mia 
et al., 1981) (Pitman-Moore, Inc., Washington Crossing, NJ). Tumors 
were measured in at least two diameters by ultrasonography employing 
a Mark II Pulsed Echo System Model 600B (Advanced Technology 
Laboratories, Bellevue, WA). Thoracic and abdominal radiographs, 
complete blood counts, serum chemical profiles, serum protein 
electrophoresis and urinalyses were performed. Cytologic prepara-
tions were stained with Wright's Dip-Stat (Medi-Chem, Inc., Santa 
Monica, CA). 
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Cats were treated twice weekly with ex vivo perfusion of their 
plasma through filters containing purified SpA (Pharmacia Fine Chemi-
cals, Uppsala, Sweden), or by direct intraperitoneal injection of 
SpA. In the case of treatment by ex vivo plasma filtration, for each 
cat a filter column containing SpA covalently bound to a zetachrome 
matrix of cellulose (AMF/Specialty Materials Group, Talcotville, CN) 
was used to filter plasma clarified from 10-30 ml of heparinized 
blood twice a week. At each treatment, 1.0 ml aliquots of the pre-
filtered and post-filtered plasma were frozen for future analysis. 
The remaining filtered plasma and autologous cells were returned to 
the cat. In the case of treatment by SpA injection, cats were 
injected intraperitoneally with 20 ~g/2.75 kg body weight of purified 
SpA twice a week. Pre- and post-treatment plasma samples were 
retained for analysis. Control cats given SpA intraperitoneally or 
intravenously were injected with either 100 ng, 10, 20 or 50 ~g/2.75 
kg body weight twice weekly. Except for six cats with bone marrow 
dyscrasia and/or dysplasia, FeLV infected cats without unequivocal 
manifestation of hematopoietic or lymphoreticular malignancy were not 
treated. Adjunct therapy consisted in some cases of isotonic fluids, 
and in cases with concomitant infections, antibiotics. In five cats 
transfusions of washed leukocyte-poor packed red blood cells were 
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g1ven. Transfused blood was washed and filtered through cotton wool 
(Imugard IGSOO, Terumo Corp., Tokyo, Japan) prior to administration. 
During treatment hemograms and serologic examinations were performed 
weekly and serum chemistry, cytologic. sonographic and radiographic 
examinations were repeated every 3rd or 4th treatment. Cats were 
given up to 32 treatments. Cats which died or were sacrificed were 
subjected to thorough post-mortem examination, tissues were fixed in 
10% buffered formalin, embedded in paraffin, sectioned at 8 pm, and 
stained with hematoxylin and eosin. Additional sections of some 
tissues were stained with either periodic acid-Schiff or methenamine 
silver. 
D. Results 
Forty-three cats were evaluated. Of these, 17 served as 
controls, 26 were FeLV infected, 10 had lymphoma, 5 leukemia, 5 
myeloproliferative disorders, and 6 had other forms of abnormality 
which we grouped together as bone marrow dyscrasia-dysplasia. All 
FeLV infected cats presented with advanced disease and many had a 
variety of concurrent infections or Unmune-mediated disease. Four of 
the 26 FeLV infected cats (113,117.105.116) had concurrent infections 
with corona-virus and had titers against antigens of this virus of 
greater than 400. Cats of either sex ranging in age from 6 months 
to 7 years were represented. They were primarily domestic short- or 
long-haired cats. Most of the common morphologic forms of feline 
leukemia-lymphoma and myeloproliferative disorders were represented 
(Table IV). Cats given more than three treatments employing SpA are 
listed in Table V. 
Cat Classification 
Lymphomad 
112 Multicentric 
109 Alimentary 
106 Mediastinal 
111 Mediastinal 
Leukemiae 
102 Lymphoblastic 
110 Lymphoblastic 
103 Lymphocytic 
TABLE IV 
FELINE LEUKEMIA VIRAL INFECTED CATS ADMINISTERED IMMUNOTHERAPY 
USING STAPHYLOCOCCAL PROTEIN A 
Treatment a 
EVSpA(2) 
EVSpA(1) 
EVSpA(lO) 
EVSpA(1) 
EVSpA(24) 
EVSpA(3) 
EVSpA(6) 
Concurrent Diseaseb 
ARA, pleuritis, 
peritonitis 
ARA 
ARA, hemob. 
ARA 
ARA, hemob., 
cystitis 
Bronchopneumonia 
ARA 
Adjunct Therapyc 
OT(S-10) 
OT(l8-24); Amp 
(12-15); T(l2, 
13,18,24) 
\J1 
.p-
Myeloeroliferative disorderf 
113 Erythroleukemia 
117 Erythroleukemia 
152 Erythroleukemia 
121 Granulocytic 
119 Undiff. stem cell 
Other Abnormalitiesg 
101 Dyscrasia-dysplasia 
105 Dyscrasia-dysplasia 
116 Dyscrasia-dysplasia 
153 Dyscrasia-dysplasia 
154 Dyscrasia-dysplasia 
155 Dyscrasia-dysplasia 
TABLE IV (Continued) 
EVSpA(5) ARA 
EVSpA(9) FIP 
IPSpA(20) ARA 
EVSpA(2) ARA, nephritis 
EVSpA(3) ARA, myelofibrosis 
EVSpA(20) ARA 
EVSpA(20) 
EVSpA(20) AIHA, hemob., FIP 
IPSpA(23) 
IPSpA(30) 
IPSpA(32) hemob. 
T(l,3) 
T(7) 
T(O) 
T(1,2) 
VI 
VI 
TABLE IV (Continued) 
Excluded from Table IV are 8 cats with leukemia-lymphoma that were evaluated but died prior to the 
administration of treatment with SpA. 
a 
b 
c 
d 
Purified Protein A (SpA) from Staphylococcus aureus Cowan I (SAC) was injected intraperitoneally (IP) or 
was incorporated in filters ex vivo (EV) through which plasma was passed. The number of treatments 
administered is indicated in-parentheses. 
ARA- aregenerative anemia; hemob. - Hemobartonella felis, an eperythrocytic richettsiae; FIP - feline 
infectious peritonitis, a corona-viral immune-mediated disease; AIHA - autoimmune hemolytic anemia. 
OT- tetracycline per os; Amp- ampicillin I.M.; T- transfusion of washed leukocyte-poor, packed red 
blood cells. Antibiotics and transfusions were administered following the treatment indicated in 
parentheses. 
Cats with lymphoma were classified based on the anatomical location of the tumor. 
e 
Cats with leukemia were classified based on the predominant cell type. 
f 
Cats with myeloproliferative disorders were classified based on the predominant cell type. 
g 
FeLV infected cats without frankly diagnosable malignancy but with bone marrow dyscrasia and/or 
dysplasia. 
VI 
0\ 
TABLE V 
OBJECTIVE RESPONSES IN CATS GIVEN MORE THAN THREE TREATMENTS USING PROTEIN A 
IFA/FeLVd 
Hematocrit (%)f 
Time Perioda Reduction inc % Change ine Pre- and Post-
Cat (Days) Treatmentb Malignancy Post-treatment Body Weight Treatment 
106 47 EVSpA( 10) +++ -- -29 30, 10 
102 124 EVSpA(24) ++g + -33 22, 14 
103 26 EVSpA(6) +++ + -18 23, 7 
113 21 EVSpA(5) -- + -14 11, 7 
117 46 EVSpA(9) -- + +17 12, 7 
152 )365(S) IPSpA(20) +++ ND +17 22, 35 
101 >730(S) EVSpA(20) +++ -- +30 10, 35 
105 >365(S) EVSpA(20) +++ + +24 20, 37 
116 248 EVSpA(20) -- -- -5 32, 20 
153 )270(S) IPSpA(23) ++ + +20 19, 29 
154 >365(S) IPSpA(30) ++ -- +8 24, 29 
155 )330(S) IPSpA(32) ++ -- +13 8, 20 
IJ1 
...... 
TABLE V (Continued) 
aNumber of days the cat survived from the time of presentation. (S) = surviving. 
bSee Table IV. 
cReduction in tumor size or bone marrow neoplastic population during treatment was judged mild +, moderate 
++, or marked +++. No response to treatment is indicated by --. In the case of cats with bone marrow 
dyscrasia-dysplasia, +, ++ and +++ indicate clearance of dysplastic cells and the correction of 
dyscrasias. 
dAll cats were positive by IFA for FeLV pre-treatment (except cat 113). 
viremia post-treatment. -- indicates clearance of FeLV viremia during 
eBody weight at the time of the first and last treatments were compared 
decrease (-). 
£Hematocrit prior to the treatment period and after the last treatment. 
+ indicates persistent FeLV 
treatment. ND = not done. 
to determine % increase (+) or 
gFrank and extensive lymphoid neoplasia underwent dramatic regression but was followed by successive 
changes in morphology of the expression of malignant disease reflecting myeloproliferative features. 
V1 
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1. Lymphoma 
Of the 10 cats with anterior mediastinal alimentary (jejunum-
illeum), or multicentric lymphoma, 6 presented with aregenerative 
anemia and thrombocytopenia, and 4 cats were febrile. All cats were 
thin and lethargic. Six cats died during the pretreatment screening 
period. Of the 4 cats with lymphoma that were g1ven immunotherapy 
using SpA, 3 died before the 3rd treatment. Cat 106 with lymphoma 
was administered 10 treatments of extracorporeal perfusion of plasma 
through filters bearing SpA. 
Cat 106 presented with dyspnea, dysphagia and an anterior 
mediastinal mass 4.0 x 6.5 em, marked pleural effusion, low serum 
albumin (1.6 g/dl) and elevated serum calcium (12.2 mg/dl) (Figures 
10,11). Aspirates of this mass consisted predominantly of large 
lymphoid cells with scant cytoplasm and large nuclei containing 
multiple nucleoli. 200 ml of a modified transudate consisting of 89% 
or more lymphoid cells were removed from the thorax between treat-
ments 1 and 4. Clearance of FeLV viremia, as indicated by a negative 
IFA test, occurred after the 6th treatment and was documented weekly 
from the 6th through the lOth treatment. Following the 7th treat-
ment, the mediastinal mass was no longer demonstrable, although a 
thickened mediastinum and a small amount of effusion remained in the 
anterior thorax (Figures 12,13). Concurrent with this reduction in 
tumor size, the elevated serum calcium concentration was also reduced 
(11.5 mg/dl). Following the 8th treatment, the cat developed a 
rapidly progressive aregenerative anemia. A 29% reduction in body 
Figure 10: Left lateral thoracic radiograph of cat 106 with anterior 
mediastinal lymphoma prior to treatment. Marked pleural effusion is 
evident. 
Figure 11: Pretreatment anterior thoracic sonogram of cat 106. A 
cellular mediastinal mass measures 4.0 x 6.2 em. 
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Figure 10 
Figure 11 
Figure 12: Left lateral thoracic radiograph of cat 106 after 7 
treatments employing staphylococcal protein A. A small amount of 
increased fluid density remains in the anterior thorax. 
Figure 13: Anterior thoracic sonogram of cat 106 after 7 treatments. 
The mediastinal mass was not identified. 
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Figure 12 
Figure 13 
Figure 14: Histosection of the anterior mediastinum of cat 106 post-
mortem after 10 protein A treatments. A scantly cellular thymic 
remnant is.surrounded by an edematous connective, granulation tissue. 
No evidence of neoplasia was present post-mortem (H&E x64). 
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Figure 14 
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weight occurred during the 47-day treatment period and the cat died 
following the lOth treatment. 
Post-mortem, the mediastinum consisted of an edematous and 
hemorrhagic connective, granulation tissue diffusely infiltrated with 
macrophages, which encompassed occasional small remnants of scantly 
cellular thymic tissue (Figure 14). The sinuses of hypocellular 
thoracic lymph nodes were filled with erythrocytes and macrophages. 
No recognizable evidence of neoplasia could be demonstrated in any 
location at post mortem. 
2. Leukemia 
Three of the 5 cats with lymphoblastic or lymphocytic leukemia 
presented with fever and anem1a. Four of the 5 cats were thrombo-
cytopenic. Two died during the pretreatment screening period. A 
third cat died after 3 treatments with concurrent bronchopneumonia. 
Cats 102 and 103 with leukemia received more than three extracorpo-
real SpA treatments (Table V). 
Cat 103 presented with a massive lymphoid marrow population 
(>80%), marked lymphocytosis, 14.2 x 103/~1 (83% of the total 
peripheral leukocyte count TWBC), mild aregenerative anemia and 
thrombocytopenia (Figure 15). Marrow myeloid and erythroid cell 
lines were hypoplastic and cells of these lineages were sparse. No 
megakaryocytes were observed. A marked reduction in peripheral blood 
lymphocytes to 1.7 x 103/~1 (58% of the TWBC) occurred after two 
treatments, and after six treatments only 0.95 x 103/~1 lymphocytes 
were present in the blood (34% of the TWBC). A marked increase in 
megakaryopoiesis. granulopoiesis, and erythropoiesis was present in 
Figure 15: Bone marrow cytology of cat 103 with lymphocytic leukemia 
prior to treatment. Note the massive lymphoid infiltration, lack of 
megakaryocytes and sparsity of myeloid and erythroid elements 
(Wright's x720). 
Figure 16: Bone marrow cytology of cat 103 after 6 protein A treat-
ments. The lymphoid infiltrate is markedly reduced and myelo-
erythroid elements have increased from pre-treatment numbers 
(Wright's x720). 
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Figure 15 
Figure 16 
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marrow after the 6th treatment (Figure 16). The massive lymphoid 
infiltrate was no longer evident (<20%). The anemia, now normocytic-
hyperchromic, progressed and the cat died with a terminal hematocrit 
of 7%. An 18% loss in body weight occurred during the 26-day treat-
ment period. 
Cat 102 presented emaciated with mild peripheral lymph node 
enlargement. aregenerative anemia and bilateral intraocular lymphoma. 
Prior to treatment the cat was classified cytologically as having 
lymphoblastic leukemia based upon the morphology of blasts which 
represented 50% of the nucleated cells within the bone marrow 
aspirate. and an absolute lymphocytosis which ranged during the first 
40 treatment days from 7,575-29,755/~1. Granulocyte maturation 1n 
the marrow was normal and erythroid cells were sparse. However, the 
pretreatment lymph node aspirate contained not only numerous lymphoid 
cells, but also smaller numbers of erythrocytic and granulocytic 
precursors and megakaryocytes. During the prolonged 124-day treat-
ment period, successive changes in the cytological patterns of 
peripheral blood and bone marrow occurred (Figures 17,18,19,20,21, 
22). In the marrow aspirate on day 41, erythroid cells were markedly 
increased in number and showed dyscrasia with excessive rubriblasts 
and prorubricytes and dysplasia with megaloblastoid change and 
erythroid gigantism. Numerous nucleated red blood cells were present 
within the peripheral blood. On day 67, excessive numbers of 
myeloblastic and progranulocytic cells were now present in the marrow 
and the peripheral blood showed a left shift to the level of myelo-
cytes. On day 120, 27 days after the 24th treatment, approximately 
20% of the nucleated cells within the marrow aspirate were again 
Figure 17: Bone marrow cytology of cat 102 prior to treatment. 
Greater than 50% of the nucleated cells are blasts, most similar 
morphologically to lymphoblasts (Wright's x720). 
Figure 18: Higher magnification of the blasts present in the bone 
marrow of cat 102 prior to treatment. Lymphoblastic leukemia was 
considered the appropriate cytologic classification for this stage of 
the eat's proliferative disease (Wright's xl600). 
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Figure 17 
Figure 18 
Figure 19: After 10 protein A treatments, a dyscrastic and dysplastic 
erythroid predominance was present in hypercellular marrow 
flecks of cat 102 (Wright's x920). 
Figure 20: Higher magnification of the marrow of cat 102 after 10 
treatments showing rubriblasts and prorubricytes which were 
present in excessive numbers (Wright's x2050). 
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Figure 19 
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Figure 20 
Figure 21: Bone marrow cytology of cat 102 after 18 treatments. 
Granulocytic elements predominate with excessive myeloblasts and 
progranulocytes (Wright's x720). 
Figure 22: Higher magnification of the marrow of cat 102 after 18 
treatments. This myeloid predominance was followed terminally by a 
lymphoblastic transformation similar morphologically to marrow cytol-
ogy in Figure 17 (Wright's xl600). 
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75 
76 
lymphoblasts. An absolute lymphocytosis ranged during the final 27 
days from 12,833-16,728/~1. The progressive transition of this eat's 
hematopoietic proliferative disease from erythroid to myeloid 
predominance was preceded by and associated terminally with lympho-
blastic transformation. Widespread organ infiltration and a large 
pelvic-abdominal mass of neoplastic cells were present post-mortem. 
The cells in this mass were predominantly lymphoid in morphology but 
also contained numerous megakaryocytes and both erythroid and myeloid 
neoplastic elements. Four red cell transfusions administered late in 
the treatment period did little to correct the aregenerative anemia 
and the cat died on day 124 with a terminal hematocrit of 14%. 
Weight loss during the treatment period was 33%. A membraneous 
glomerulonephritis and cystitis were identified post-mortem. The 
course of the disease according to several veterinarians who observed 
the cat had been much prolonged by treatment. 
3. Myeloproliferative Disorders 
Of the 5 cats with myeloproliferative disease, four were febrile 
at presentation and had aregenerative anemia and thrombocytopenia. 
The fifth cat presented with a responding anemia and concurrent 
feline infectious peritonitis (FIP). Cats 113, 117 and 152 were 
given more than three treatments using SpA. Cat 113 with erythro-
leukemia did not improve and died with a terminal hematocrit of 7% 
after 21 days, five treatments with SpA filters and two packed red 
blood cell transfusions. 
Cat 117 was hypercalcemic and erythroleukemic upon presentation. 
Erythroid elements represented the predominant cell line prior to 
77 
treatment. Following the 8th treatment, a myeloid predominance was 
noted. A reduction in serum calcium occurred during treatment, from 
12.7 mg/dl prior to treatment, to 8.7 and 7.4 mg/dl after treatments 
7 and 9. The cat died after nine treatments with anemia and an 
extensive pyogranulomatous peritonitis (FIP). Weight gain during the 
46-day treatment period in cat 117 was in part attributable to 
ascites. 
Cat 152 was treated by intraperitoneal injection of SpA. Prior 
to treatment, the bone marrow aspirate was markedly hypercellular 
with excessive numbers of rubriblasts and prorubricytes (Figure 23). 
An appropriate increase in rubricyte and metarubricyte numbers were 
not present and megaloblastosis of erythroid cells was common. 
Numerous nucleated red blood cells, a few immature granulocytes, 
and an occasional atypical lymphocyte were present in the peripheral 
blood. The pretreatment predominance of immature erythroid cells 
was no longer present after 10 intraperitoneal injections with SpA 
(Figure 24); instead numerous dysplastic rubricytes and metarubri-
cytes were seen. The hematocrit had decreased during the first 48 
days from 22 to 13% with only slight polychromasia and anisocytosis 
evident. After 18 intraperitoneal SpA injections, the marrow 
aspirate was hypercellular, now without significant erythroid 
dyscrasia but with moderate megaloblastosis of rubricytes and 
metarubricytes. After the 20th and final treatment, significant 
abnormalities were not present in marrow or peripheral blood 
aspirates (Figure 25). All hematologic parameters were normal 
and the hematocrit was 35%. Unfortunately, post-treatment IFA for 
FeLV was not performed in this cat. After both the 19th and 20th 
Figure 23: Bone marrow cytology of cat 152 with erythroleukemia 
prior to treatment. Excessive numbers of rubriblasts and prorubri-
cytes and inappropriately few numbers of more mature erythrocytic 
precursors are present (Wright's x720). 
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Figure 23 
Figure 24: Bone marrow cytology of cat 152 after 10 intraperitoneal 
injections of protein A. Numerous megaloblastoid rubricytes and 
metarubricytes are present and the blast population is reduced from 
pretreatment numbers (Wright's x720). 
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Figure 24 
Figure 25: Post-treatment bone marrow cytology of cat 152. A 
heterogenous population of cells is present without significant 
abnormalities (Wright's x720). 
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Figure 25 
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treatment, however, ELISA examinations for FeLV antigen in serum were 
negative. A 17% gain in body weight occurred during the treatment 
period and this cat remains healthy, alert, active and negative for 
FeLV by ELISA examination greater than one year after presentation. 
4. Dyscrasia-Dysplasia 
Six cats lacking unequivocal manifestations of frank hemato-
poietic or lymphoreticular neoplasia but which showed significant 
FeLV-related abnormalities by bone marrow examination were also 
administered treatment with SpA. Three (101, 105, 116) were treated 
by plasma perfusion through SpA filters, and three (153, 154, 155) by 
intraperitoneal injection of 20 ~g/2.75 kg body weight of SpA. All 
six cats were FeLV infected and presented with, or soon after the 
initiation of treatment, became anemic, leukopenic and thrombocyto-
penic. Five of the 6 cats developed fevers during the treatment, had 
marked marrow myelo-erythroid dyscrasia and dysplasia characterized 
by erythroid hypoplasia or hyperplasia with megaloblastosis; in some 
cases numerous binucleate erythroid cells were present, and a 
moderate increase in immature granulocytic forms was seen. After 
treatment marrow aspirates in five of the six cats lacked significant 
abnormalities and all cats except 116 and 155 had normal post-treat-
ment hemograms. Clearance of FeLV viremia based upon a negative !FA 
test occurred following treatment in cats 101, 116, 154 and 155. 
All cats except cat 116 gained weight during the treatment period 
and have remained alert and active to date. Cat 116 died with a 4+ 
indirect Coomb's autoimmune hemolytic anemia, feline infectious 
peritonitis and hemobartonellosis. Cat 155 remained mildly anemic 
post-treatment. 
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Cat 101 presented with anorexia and aregenerative anemia, an 
initial hematocrit of 10%, and with numerous nucleated red blood 
cells in the peripheral blood. Pre-treatment bone marrow aspirates 
were mildly hypercellular with mild erythroid hyperplasia, numerous 
binucleate rubricytes and metarubricytes and frequent megaloblastoid 
erythroid cells (Figure 26). These findings prior to treatment may 
have represented an aleukemic state of a myeloproliferative disorder, 
but because of their equivocal nature the cat was grouped with other 
cats demonstrating varying degrees of bone marrow dyscrasia and/or 
dysplasia. Pre-treatment leukocyte and thrombocyte counts were 
normal. From the 12th through the 18th treatment, this cat was 
febrile (<107.6°F), leukopenic (>750/~1 TWBC) with a relative 
lymphocytosis (88%), thrombocytopenic (>49,000/~1) and anemic (>12%). 
Periodic vomiting, marked anorexia, and a 23% reduction from the 
initial body weight were observed during this period. By the 20th 
treatment, the appetite had improved, the animal was normothermic, 
negative by IFA for FeLV, and the hematocrit and white blood cell 
count were normal. Dysplastic erythroid cells were no longer present 
on bone marrow examination. Greater than 730 days after presenta-
tion, no significant cytologic or hematologic abnormalities were 
present, and a 30% gain from the initial body weight had occurred. 
The cat is currently alert and active and has been returned to its 
owner. 
Figure 26: Bone marrow cytology of cat 101 prior to treatment. Mild 
erythroid hyperplasia with numerous binucleate rubricytes and meta-
rubricytes (narrow arrowhead and high magnification insets) and 
frequent megaloblastoid erythroid cells (broad arrowhead) are 
present. No significant cytologic or hematologic abnormalities were 
present after treatment (Wright's x450, x2000). 
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5. Controls 
Seventeen healthy cats free of FeLV served as controls and were 
treated either by the perfusion of plasma over whole SAC organ1sms, 
the perfusion of plasma through filters bearing SpA, the intra-
peritoneal injection of 20 ~g/2.75 kg body weight of SpA, the 
intravenous injection of 100 ng, 10, 20 or SO ~g/2.75 kg body weight 
of SpA, the I.V. or I.P. injection of normal saline, or were not 
treated but handled as treated cats with twice weekly phlebotomy. 
All treatments were administered twice weekly with cats receiving 
between 8-21 treatments. All cats, except cat 115, remained healthy 
and normothermic and gained an average of 12% in body weight during 
the treatment period. Cytologic or serologic abnormalities were 
never present in any of the control cats, and only cat 115 experi-
enced a transient period of hematologic abnormality. Cat 115 was 
administered 21 treatments of extracorporeal plasma perfusion over 
whole SAC organisms and developed a transient anemia (hematocrit 
)12%), leukopenia and thrombocytopenia between treatments 15 and 
21. Weight loss in this cat during the treatment period was 9%. 
Eighteen days after the 21st and final treatment of cat 115, all 
parameters had returned to and have remained normal. 
E. Discussion 
Prior reports have described the regression of malignancy in 
patients and animals treated by the extracorporeal perfusion of 
plasma over whole SAC organisms or through filters containing 
covalently bound SpA (Ray, 1982) (Bansal et al., 1978) (Ray et al., 
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1982a,b) (Terman et al., 1980, 1981) (Jones et al., 1980) (Snyder 
et al., 1984) (Day et al., 1984) (Liu et al., 1984a,b). However, 
1n many cases other forms of anti-cancer treatment had already been 
given or were given concomitant with immunotherapy. Also, the 
presenting status and clinicopathologic responses of individual 
patients or animals to treatment with SAC or SpA were often incom-
pletely described. Careful characterization of FeLV associated 
malignancy is essential since FeLV viremic cats may remain hemato-
logically and clinically normal for long periods of time (Essex et 
al., 1975a), FeLV induced marrow dyscrasia-dysplasia can occur 
(Maggio et al., 1978), and immunosuppression is the most frequent 
adverse consequence of persistent FeLV viremia (Hardy, 1982a). 
In this report, only cats with advanced FeLV associated disease 
were treated. The severe disease status of the cats in this group 
is evidenced by the 31% (8 of 26) pretreatment mortality rate. Of 
the 18 cats with FeLV associated disease treated either by the 
extracorporeal perfusion of plasma through SpA filters or by the 
intraperitoneal injection of SpA, 9 (SO%) improved objectively. 
During treatment, tumor regressed, marrow and peripheral blood 
neoplastic cell populations were reduced, dysplastic forms were no 
longer present, marrow dyscrasias were corrected and hematologic 
values became normal. Long-term remission of disease occurred in 6 
of the 18 (33%) treated cats, and clearance of FeLV viremia occurred 
1n 5 cats (28%). If the six cats given three or fewer treatments are 
excluded from consideration (since the treatment period in these 
animals was less than 10 days), the response rate to treatment would 
then be 75% (9 of 12), with long-term remission in 50% of treated 
cats, and clearance of viremia in 42%. 
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FeLV associated bone marrow dyscrasia-dysplasia with anemia, 
leukopenia and thrombocytopenia has been proposed by some to 
represent a preleukemic syndrome (Maggio et al., 1978). Small 
numbers of neoplastic cells are thought to be present. In some cats, 
this syndrome eventually evolves into a lymphoproliferative or 
myeloproliferative disorder. It has also been suggested that this 
preleukemic state might be an appropriate setting for testing the 
hypothesis that immunotherapy is most effective when the tumor cell 
load is small (Pierre, 1974). Five of 6 cats (83%) with marrow 
dyscrasia-dysplasia treated either by the intraperitoneal injection 
of SpA or by the filtration of plasma over SpA experienced long-term 
remission and 67% (4 of 6) of these cats underwent clearance of FeLV 
viremia. 
If, on the other hand, the cats lacking evidence of neoplasia 
are excluded from consideration (i.e .. cats with marrow dyscrasia-
dysplasia), then 33% (4 of 12) of treated cats improved objectively, 
8% (1 of 12) are in long-term remission, and 18% (2 of 11) have 
cleared the FeLV infection. If those cats with neoplasia that were 
given three or fewer treatments are also excluded, then 66% (4 of 6) 
of cats with neoplasia responded to treatment, 16% (1 of 6) are in 
long-term remission, and clearance of viremia occurred in 40% (2 of 
5). 
Feline hematopoietic-lymphoreticular neoplasia with concurrent 
aregenerative anemia was a problem in 13 of the 20 cats with frank 
malignancy. Aregenerative anemia in the absence of neoplasia is a 
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common manifestation of naturally occurring FeLV infection. It has 
been experimentally induced by the injection of certain FeLV isolates 
which produce a rapid depletion of early erythroid precursors (Hoover 
et al., 1974) (Onions et al., 1982), and has been described as either 
normocytic-normochromic (Cotter, 1975) or macrocytic-normochromic 
(Weiser & Kociba, 1983). Affected cats have normal erythrocytic 
survival times, but markedly diminished plasma radioiron half times 
(Madewell et al., 1983). Our observed 65% incidence of concurrent 
anemia with malignancy is nearly identical (68%) with previous 
reports (Hardy, 1980a). Most of the anemias were normocytic-normo-
chromic and rapidly progressive. Adjunct therapy was purposefully 
minimal, but in those cats given leukocyte-poor packed red blood cell 
transfusions only a slight elevation in hematocrit occurred. 70% of 
the cats with malignancy were also thrombocytopenic, and one of these 
cats (102) showed a tendency to bleed following venipuncture. 
Although fever was not an uncommon finding in cats with FeLV induced 
disease, in only five cats was treatment associated with febrile 
reactions. These reactions occurred only in cats with various forms 
of marrow dyscrasia and/or dysplasia. None of the normal cats or 
cats with frank neoplasia developed fever as a consequence or 
manifestation of treatment. 
The reported incidence of immune complex glomerulonephritis 
associated with FeLV-induced malignancies ranges between 14-31% 
(Glick et al., 1978) (Anderson & Jarrett, 1971). Light microscopic 
evidence of mesangial proliferation and mild hypertrophy and hyper-
plasia of glomerular endothelium and epithelium was present in renal 
sections from six cats. However, only renal lesions in one cat (102) 
were considered indicative of membranous glomerulonephritis and 
consisted of moderate basement membrane thickening, as well as 
mesangial proliferation and glomerular adhesions. 
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The possible mechanisms by which treatment with staphylococcal 
protein A causes reduction in the extent of malignant disease have 
not been completely elucidated. Circulating immune complexes (CICs) 
have been implicated in the abrogation of cellular and humoral immune 
mechanisms (Baldwin et al., 1972) (Hellstrom et al., 1977) (Bansal et 
al., 1976). The immunoadsorption of CIC from plasma perfused over 
whole SAC organisms or through SpA-containing filters with subsequent 
reduction in malignancy has been reported (Snyder et al., 1982) (Day 
et al., 1983). In addition, certain FeLV proteins are known to be 
immunosuppressive and their removal along with or as part of CIC may 
result in the augmentation of anti-tumor and anti-viral immune 
mechanisms. Other immuno-reactive characteristics of SpA cannot be 
overlooked, however, especially in the light of our reported 
remissions in cats treated by the intraperitoneal injection of SpA. 
In vitro SpA-activated and SpA-dependent cell mediated cytotoxicity 
(Sumija et al., 1982), and SpA-induced lymphocyte proliferation with 
production of interferon and consequent generation of increased 
antibody-dependent cell mediated cytotoxicity (ADCC) and/or natural 
killer (NK) function have been reported (McCool et al., 1981) 
(Catalona et al., 1981). We have previously described a marked, 
though transient increase Ln circulating y interferon levels in cats 
responding to treatment with SpA (Liu et al., 1984b). Remission from 
FeLV-induced disease and clearance of viremia in SpA treated cats was 
associated not only with this transient rise in y interferon, but 
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also the subsequent appearance of a complement-dependent cytotoxic 
antibody which was shown by several analyses to be directed against 
the major viral envelope glycoprotein gp70, which is present on both 
free virus and on the membrane of virus infected cells (Liu et al., 
1984a,b). y interferon has been shown to increase human T cell-
dependent antibody synthesis by B cells (Reem et al., 1983). 
Increased antibody synthesis along with increased cytotoxic T cell 
function, enhancement of ADCC, and/or increased NK activity could 
account for both the anti-viral and anti-tumor influences demon-
strated. It seems likely to us that the injection of SpA induces 
the production and release of y interferon in vivo which subsequently 
increases anti-viral antibody synthesis which with complement can 
attack and reduce the virus itself, and the number of virus-producing 
neoplastic cells resulting in eventual clearance of viremia, as well 
as regression of malignancy. A similar sequence might occur in cats 
treated by the extracorporeal perfusion of plasma over whole SAC 
organisms or through filters bearing SpA if even small amounts of 
SpA are present in plasma which is returned to the cats. The exact 
mechanisms involved in both virus clearance and in regression of the 
neoplasias will, however, have to be worked out by subsequent 
experimental studies. There exists as indicated above a number of 
possibilities, none of which are necessarily exclusive of the others 
and each of which might play a crucial role in the recovery from 
neoplasia and elimination of persistent virus infection. 
CHAPTER III 
IMMUNOLOGICAL FINDINGS IN RESPONDING CATS 
DURING TREATMENT WITH STAPHYLOCCAL PROTEIN A 
A. Summary 
When persistently FeLV infected cats are treated with 
staphylococcal protein A (SpA) the incidence of clearance of FeLV 
infection is increased and FeLV associated malignancies regress. 
Loss of evidence of virus infection and regression of FeLV associated 
disease occurs in at least some cats that first experience an 
increase in plasma interferon (IFN) level which is followed by the 
appearance and progressive increase of a complement-dependent cyto-
toxic antibody specific for the FeLV envelope glycoprotein gp70 which 
is present on both free virus and on the membrane of virus infected 
cells. 
B. Introduction 
The prognosis of persistently FeLV-infected cats is poor, with 
only about 2% spontaneously clearing their viremia, and more than 83% 
dieing within 3.5 years from a FeLV associated disease (Hardy, et 
al., 1976a) (McClelland, et al., 1980). A majority of persistently 
viremic cats die as a consequence of multiple secondary diseases 
which develop as a sequelae to the immunosuppressive effects of the 
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persistent viremia. Cats with FeLV-positive lymphoma generally die 
within three months of the clinical diagnosis of the malignancy 
(Hardy, 1980a). 
Several forms of immunotherapy or multimodel chemotherapy have 
been unsuccessful in abrogating FeLV viremia in cats with persistent 
infection, and despite the occasional induction of partial or 
temporary remission from FeLV associated disease have not in most 
cases prolonged the survival of persistently infected cats. (Cotter, 
et al., 1980) (Squire and Bush, 1973) (Carpenter and Holzworth, 1971) 
(Haley, et al., 1985) (Brick, et al., 1968) (deNoronha, et al., 1978) 
(Langlois, et al., 1980) (Hardy, et al., 1976b) (Henness and Crow, 
1977a). 
Long term clinical remission occurred during treatment with SpA 
in 83% and the clearance of evidence of virus infection occurred in 
67% of the treated cats with chronic viral infection that had FeLV-
related abnormalities other than overt malignancy (Table VI). This 
is an approximately four-fold increase in the rate of clinical 
remission and more than 30 times greater clearance rate of FeLV 
infection compared to the incidence of remission and virus clearance 
in the cat receiving supportive therapy (Hardy, et al., 1976a) 
(McClelland, et al., 1980) (Cotter, et al., 1975, 1980). Actual 
clearance of v1rem1a occurred in 28% of all cats treated. Regression 
of malignancy occurred in 4 of 12 (33%) treated cats demonstrated by 
reductions in tumor size and bone marrow neoplastic cell 
populations. 
Immediately preceding or concurrent with these remissions from 
viral infection and disease, a marked though transient elevation in 
TABLE VI 
RATES OF REMISSION IN CATS RECEIVING PROTEIN A THERAPY 
I. All FeLV-infected cats 
50% clinical improvement 
33% long term remission 
28% clearance of viremia 
II. Leukemia-lymphoma 
33% clinical improvement 
8% long term remission 
18% clearance of viremia 
III. Non-neoplastic 
83% long term rem~ss1on 
67% clearance of viremia 
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the plasma level of circulating gamma-like interferon occurred in 
some responding cats and was followed by the appearance and rising 
titer of a complement-dependent cytotoxic antibody which reacted with 
FeLV-infected cells. This IgG antibody was shown by several analyses 
to be specific for the major viral envelope glycoprotein gp70. These 
findings may provide some clue to the responsiveness of individual 
cats to immunotherapy with staphylococcal protein A. 
C. Materials and Methods 
1. Detection of Antibodies to FL74 Cells in Cat Plasma During SpA 
Treatment. 
At each treatment, 1.0 ml aliquots of the pre-filtered and post-
filtered plasma were frozen for analysis. The remaining filtered 
plasma and autologous cells were returned to the cat. The plasma of 
treated and control cats were tested for antibodies directed toward 
determinants on the surface membrane of cells of the established 
lymphoma-derived, FeLV-producing FL74 cell line as- previously 
described (Liu, et al., 1984a,b). Briefly, a dilution of test plasma 
and between 2.5 x 106- 3 x 107/ml FL74 cells were coincubated at 
37°C for 30 minutes. The cells were then washed and resuspended in a 
dilution of either guinea pig serum or fluorescein-conjugated rabbit 
anti-cat IgG (Cappel, Cochranville, PA). Cell viabilities were 
determined by vital dye exclusion and by assay for LDHase release. 
Immuno-fluorescent preparations were scored with a Leitz (Dialux 20) 
microscope under epi-illumination. 
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2. Characterization of Cytotoxic Antibodies to FL74 as Specific for 
FeLV gp70. 
Several anaylses were used to show that antibodies cytotoxic for 
cells of the FL74 line that developed ~n cats during treatment with 
SpA were directed toward determinants of the major vital envelope 
glycoprotein gp70. Plasma samples positive for cytotoxic antibody 
to FL74 cells were absorbed with FeLV or mouse mammary tumor virus 
(MMTV) and evaluated for residual cytotoxic activity as described 
before (Liu, et al., 1984a,b). Monoclonal antibodies (MAbs) to FeLV 
and FL74 cells were produced and characterized by our laboratories 
(Wang, et al., 1983). Two of these MAbs, 73.5 and 6.5 were used in 
an assay for the inhibition of plasma cytotoxic activity as described 
before (Liu, et al., 1984a,b). MAbs 73.5 reacted with a FeLV 70,000 
dalton molecular weight glycoprotein, designated gp70, as well as 
with viable FL74 cells. MAb 6.5 reacted with a glycoprotein (43,000 
dalton molecular weight) on the surface of FL74 cells but not with 
FeLV. The inhibition of plasma cytotoxic activity by prior MAb 
treatment of FL74 cells was demonstrated by observing for the 
residual cytotoxicity of plasma samples using both the vital dye 
exclusion and LDHase release methods. 
D. Results 
1. Increase ~n Plasma Interferon Levels ~n Cats Responding to SpA 
Treatment. 
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Several responding cats that became FeLV seronegative as 
demonstrated by the IFA test, and that showed regression of FeLV 
associated disease had elevations in serum interferon levels as 
illustrated for two representative cats in Table VII. In contrast, 
cats that did not become virus negative had undetectable levels of 
IFN after SpA treatment. The plasma IFN produced by responding cats 
during treatment had properties of gamma interferon since only 30-40% 
of the antiviral activity remained after pH 2 or heat treatment of 
the plasma. 
2. Appearance of Cytotoxic Antibody to FeLV gp70 in Cats Responding 
to SpA Treatment. 
Prior to clinical improvement and conversion to FeLV sero-
negative status some responding cats developed complement-dependent 
FL74 directed cytotoxic antibodies as determined by both vital dye 
exclusion and LDHase release. The titer of cytotoxic antibody 
increased with additional treatments in these responding cats (Table 
VIII). An IFA test was used to detect IgG antibodies in responding 
cat plasma which reacted with the surface membrane of FL74 cells 
(data not shown). Absorbtion of responding cat plasma with 50 ~1 of 
FeLV reduced the cytotoxic activity of the plasma by approximately 
TABLE VII 
CIRCULATING PLASMA INTERFERON TITERS IN CATS 
RESPONDING TO TREATMENT WITH PROTEIN A 
Weeks after Initial 
Treatment 1 2 3 4 5 6 7 
Cat 154 <3 81 162 7 9 9 243* 
Cat 155 22 71 324 72 14 18 37 
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8 9 10 
9 <3 <3 
<3 ND* 27 
* 1 . C earance of v1ral infection as indicated by weekly negative IFA 
tests for FeLV began during weeks 7 and 9 for cats 154 and 155 
respectively. 
101 
TABLE VIII 
THE DEVELOPMENT OF CIRCULATING CYTOTOXIC ANTIBODY TO FL74 CELLS 
DURING PROTEIN A THERAPY 
Treatment Cells stained by % Specific 
no. vital dye, % LDHase released 
Cat 101 4 3 ND 
5 5 ND 
6 29 33.9 
10 49 51.6 
14 63 49.0 
16 39 45.1 
18 73 64.7 
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74%. No reduction in cytotoxic activity occurred after absorbtion 
with MMTV. 
When the FL74 cells were allowed to react prior to the addition 
of the cytotoxic antibody with various dilutions of ascites fluid 
containing the MAb 73.5 that was reactive with FeLV gp70, complement-
mediated lysis was almost completely abolished. MAb 6.5 failed to 
abolish cytotoxic activity against FL74 cells in the plasma samples. 
The inability of each of these two MAbs to mediate complement-depen-
dent lysis of FL74 cells on their own was shown in separate studies. 
When FL74 cells were incubated with ascites fluid containing the 
respective MAbs (73.5 and 6.5), followed by incubation with fresh 
guinea pig serum as a source of complement, the percentage of cell 
death was found to be 6-18% by trypan blue exclusion. No difference 
in the percentage of cell death was observed when fresh GPS was 
replaced by heat-inactivated (56°C for 30 min.) GPS. These results 
indicate that the cytotoxic antibody developed against cat lymphoma 
cells (FL74) is directed toward determinants on FeLV gp70 which is 
also expressed on the cell surface of FL74. 
E. Discussion 
The mechanisms by which remissions 1n patients with malignancy 
occur during treatment with staphylococcal protein A are unknown. 
Tumoricidal responses have been reported in human and animal trials 
following either the perfussion of the patient's plasma over 
Staphylococcus aureus Cowan I (SAC), which contains protein A on its 
surface, or over immunobilized purified protein A, or following the 
IV or IP infusion of protein A (Harper, et al., 1985) (Bertram, et 
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al., 1985) (Klausner, et al., 1985) (Liu, et al., 1984a,b) (Engelman, 
et al., 1985d) (Terman, et al., 1980, 1981). In general, tumoricidal 
responses may be attributed to either the removal, reduction or 
redistribution of plasma factors that are thought to abrogate humoral 
or cell-mediated immune responses (circulating immune complexes, 
immunoglobulin) or to the induction or addition of substances to the 
patient's plasma that enhance the antitumor response. Although 
protein A has been suggested as the mediator of both events, infusion 
of plasma incubated within the Wood 46 strain of Staphylococcus 
aureus, which does not contain protein A, resulted in tumor 
reductions in one study (Gordon, et al., 1983), but not in others 
(Ray, et al., 1982a) (Terman, et al., 1980). In addition, treatment 
by perfusion of plasma over protein A did not produce or only rarely 
produced a tumorcidal response in some studies (Klausner, et al., 
1985) (Gordon, et al., 1983). 
It has been suggested that 1mmune complexes alter immune 
responses and contribute to the genesis of malignancies. The removal 
by binding of such complexes to SAC or immobilized SpA may contribute 
to the induction of tumor regression. The conditions of plasma 
perfusion, such as volume of plasma, speed of perfusion and frequency 
of treatment, may be inappropriate for substantial immune complex 
removal. Yet, perfusion may allow for the removal of other plasma 
factors, including IgG. Alternatively, perfusion over SpA may 
generate new activity in the treated plasma which 1s highly mitogenic 
to normal lymphocytes, but not due to leakage of SpA from the filtra-
tion system (Bertram, et al., 1985). 
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Protein A has been shown to dissociate from SAC or from 
collodion charcoal during plasma perfusion (Balint and Jones, 1983) 
(Balint, et al., 1984). Numerous immunostimulatory activities have 
been attributed to SpA and include complement activation (Sjoquist 
and Stalenheim, 1969) (Verbrugh, et al., 1979), and the polyclonal 
induction of B-lymphocytes with synthesis of antibodies and the 
production of interferon and consequent generation of increased 
antibody-dependent cell mediated cytotoxicity and natural killer cell 
function (Smith, et al., 1983) (McCool, et al., 1981) (Catalona, et 
al., 1981) (Moller and Landwall, 1977). The intravenous injection of 
SpA alters the organ distribution of CIC and enhances their whole 
body elimination (Siag and Jones, 1982). The purposeful or inadver-
tant injection of SpA may contribute to a tumoricidal response by 
enhancing immunological systems and/or by the reduction or 
redistribution of CIC. 
It has also been reported that certain commercial preparations 
of SpA are contaminated with Staphylococcus aureus enterotoxin A 
(SEA), a potent T-lymphocyte mitogen and gamma interferon inducer 
(Smith, et al., 1983). It may be this contamination of SpA by SEA 
that is responsible for the conflicting reports that SpA behaves as 
a T-lymphocyte mitogen and induces gamma interferon. Even minor 
contamination of SpA would influence evaluations of its biological 
or clinical effects. It is possible that the SpA preparation used 
in this study was impure since the IFN generated in the plasma of 
treated cats was sensitive to pH2 and heat treatment. 
A final note of clarification should be made concerning the 
studies described above where cats with FeLV-associated disease were 
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treated with SpA. In no instance did the immunological findings, 
i.e. transient elevation in plasma interferon level folowed by the 
appearance and increasing titer of antibodies directed to gp70, 
correlate with clinical remission from malignancy in the SpA treated 
cat. Instead, these immunological findings were described in cats 
with myelodysplasias and dyscrasias, multiple hematological abnor-
malities, intercurrent infections and persistent FeLV viremia. 
Regardless, these rates of remission from FeLV-associated disease 
and clearance of retroviremia are much higher than similar rates in 
the supportively treated cat. In addition, the SpA therapy may have 
played a role in preventing the development of malignancy in these 
cats, since their clinical condition may have represented a state of 
preleukemia. The anti-gp70 antibodies, apparently of FeLV-C subgroup 
specificity (Liu, et al., 1984a,b), which developed in these cats has 
been shown to have a protective nature against the development of 
neoplasia (Essex, 1982). Other immunological means must be investi-
gated in order to explain the obvious reductions and, in some cases, 
complete remissions from malignancy during treatment with SpA which 
are described above. 
CHAPTER IV 
HYPERCALCEMIA IN CATS WITH FELINE LEUKEMIA 
VIRUS ASSOCIATED LEUKEMIA-LYMPHOMA 
A. Smnmary 
Three cases of hypercalcemia were recognized among eleven cats 
presenting with leukemia-lymphoma for ex vivo immunoadsorption 
therapy using staphylococcal protein A coated filters. In addition, 
the initial mean serum calcium concentration of cats with leukemia-
lymphoma was significantly higher (p <0.005) than that of healthy 
control cats or feline leukemia virus infected cats without malig-
nancy. During immunotherapy of the hypercalcemic cats, objective 
reduction in the extent of the malignancies was associated with a 
reduction ~n the serum calcium concentrations. This response to 
treatment, the lack of skeletal metastasis, and absence of renal and 
parathyroid pathology imply that humorally-mediated mechanisms may 
have been responsible for the production of the hypercalcemia. 
B. Introduction 
Hypercalcemia is a common complication ~n patients with certain 
carcinomas (breast, lung, kidney, pancreas, colon) or hematopoietic 
and lymphoreticular neoplasms (Mundy et al., 1974a). It occurs most 
frequently with overt skeletal metastasis and localized osteolysis 
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produced possibly by the presence of the tumor cells or by humoral 
products of the metastasis which stimulate osteoclastic resorbtion 
(Tashjian, 1978). However, a significant number of hypercalcemic 
malignancies lack honey metastasis. In such cases, removal of the 
tumor often leads to remission of the hypercalcemia and recurrence of 
tumor to the reappearance of hypercalcemia (Tashjian, 1978) (Metuen 
et al., 1981). Several humoral tumor products have been proposed as 
mediators of these hypercalcemic malignancies. Compounds implicated 
include parathyroid hormone-like peptides (Sherwood et al., 1967), 
osteoclast activating factor (Mundy et al., 1974a,b), prostaglandin 
E2 (Tashjian, 1978) (Seyberth et al., 1975), and provitamin n3-like 
sterols (Gordon et al., 1966). The relative importance and frequency 
of occurrence of each of these substances is not known. 
Hypercalcemic malignancy has been documented in dogs with 
lymphoma, testicular interstitial cell tumor, multiple myeloma and 
carcinoma of the mammary gland, stomach, lung or anal sac apocrine 
glands (MacEwen & Siegel, 1977) (Chew & Meuten, 1982) (Meuten et al., 
1982a). It occurs with the HSDM murine fibrosarcoma, the VX 
carcinoma in the rabbit and rarely with equine gastric carcinoma 
(Tashjian, 1978) (Meuten et al., 1978). In most cases, cause of the 
hypercalcemia is unknown. Bone resorbing compounds secreted by tumor 
cells are suspected in those cases which lack skeletal metastasis, 
parathyroid hyperactivity or renal insufficiency (Meuten et al., 
1981) (MacEwen & Siegel, 1977) (Meuten et al.~ 1982a). 
Lymphoma-leukemia is the most common neoplasm of cats, account-
ing for 90% of all feline hematopoietic malignancies. It occurs most 
frequently in feline leukemia virus (FeLV) infected cats (Hardy, 
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1980a,b). Hypercalcemic malignancy in the cat has been reported only 
twice, ~none case associated with mediastinal lymphoma (Chew et al., 
1975), and one aleukemic granulocytic leukemia with myelofibrosis 
(Zenoble & Rowland, 1979). Both animals were infected with FeLV. In 
a previous review of 27 cats with FeLV associated leukemia-lymphoma, 
none were found to have elevated serum calcium concentrations 
(Wilkins & Hurvitz, 1975). 
In the present study, cats receiving ex v~vo immunoadsorption 
were characterized clinicopathologically prior to and during treat-
ment. Three cases of hypercalcemia were recognized among 11 cats 
presenting with leukemia-lymphoma. During itrununotherapy with 
staphylococcal protein A, objective reduction in the extent of the 
malignancy was associated with a reduction in the serum calcium 
concentration. In addition, the presenting mean serum calcium 
concentration of cats with leukemia-lymphoma was significantly higher 
than that of either healthy control cats or FeLV infected cats 
without malignancy. 
C. Material and Methods 
Clinically ill, FeLV infected cats were referred by Oklahoma 
veterinarians. Controls were conventionally maintained, clinically 
healthy cats free of FeLV. All cats were characterized based on the 
cytologic examination of bone marrow, lymph node, tumor and 
peripheral blood aspirates, and on the results of the indirect 
immunofluorescent antibody (IFA) test for FeLV ~n leukocytes (Hardy 
et al., 1973b) (Antibodies, Inc., Davis, CA) and the enzyme-linked 
immunosorbent assay (ELISA) for the detection of FeLV antigen in 
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serum (Mia et al., 1981) (Pitman-Moore, Inc., Washington Crossing, 
NJ). Tumors were measured in at least two diameters by ultra-
sonography employing a Mark II Pulsed Echo System Model 600B 
(Advanced Technology Laboratories, Bellevue, WA). Thoracic and 
abdomin~l radiographs, complete blood counts, serum protein electro-
phoresis and urinalysis were performed. Serum chemical profiles 
included albumin, blood urea nitrogen, calcium, chloride, creatinine, 
glucose, phosphorus, potassium, alkaline phosphatase, sodium and 
alanine aminotransferase. Serum calcium was determined by a fluoro-
metric titration method employing a Corning Calcium Analyzer 940 
(Corning Scientific Instruments, Medfield, MA). Albumin (Coulter 
Diagnostics, Hialeah, FL) and phosphorus (Worthington Diagnostic 
Systems, Inc., Freehold, NJ) were determined by a colorimetric method 
and read on a spectrophotometer model 24 (Beckman Instruments, 
Fullerton, CA). Cytologic preparations were stained with Wright's 
Dip-Stat (Medi-Chem, Inc., Santa Monica, CA). 
Cats with malignancy and control cats were treated twice weekly 
with ex vivo immunoadsorption employing protein A (SpA) (Pharmacia 
Fine Chemicals, Uppsala, Sweden) purified from Staphylococcus aureus 
Cowan I as previously described (Day et al., 1984). For each cat, a 
filter column containing SpA covalently bound to a zetachrome matrix 
of cellulose (AMF/Specialty Materials Group, Talcotville, CN) was 
used to filter plasma clarified from 10-30 ml of heparinized blood 
twice a week. Filtered plasma and the autologous cells were returned 
to the cat. FeLV infected cats without unequivocal manifestation of 
hematopoietic or lymphoreticular malignancy were not treated. 
Adjunct therapy consisted only of isotonic fluids and, in cases of 
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concomitant infections, antibiotics. During treatment hemograms and 
serologic examinations were performed weekly and serum chemistry, 
cytologic, sonographic and radiographic examinations were repeated 
every third or fourth treatment. Cats were given up to 24 treat-
ments. All cats were examined macroscopically at euthanasia or upon 
death and all treated cats were also examined microscopically. 
Tissues from control and leukemia-lymphoma cats were fixed in 10% 
buffered formalin, embedded in paraffin, cut at 8 ~m, and stained 
with hematoxylin and eosin. Tissues examined microscopically 
included tumor, bone marrow, lymph node, kidney, liver, spleen, lung, 
heart, brain, intestine and urinary bladder. 
D. Results 
Thirty-one cats were evaluated. Of these, 8 served as controls. 
Twenty-three were FeLV infected, 11 had leukemia-lymphoma, and 12 had 
a variety of infections or immune-mediated disease. The 11 with 
malignancy represented cats of either sex. They ranged from 6 months 
to 7 years ~n age. They were primarily domestic, short- or long-
haired cats. Most of the common morphologic forms of feline 
leukemia-lymphoma were represented (Table IX). Approximately 1/3 of 
these cats showed significant response to treatment. 
Prior to ex vivo immunoadsorption, the mean serum calcium 
concentration of cats with leukemia-lymphoma was significantly 
greater (p <0.005) than the mean serum calcium concentration of 
either FeLV infected or control cats (Table X). Mean serum phos-
phorus and albumin concentrations of cats with malignancy were less 
than those of the other two groups, but were not significantly 
111 
TABLE IX 
CLINICAL STATUS OF CATS UPON PRESENTATION 
Cat Age Sex Clinical diagnosis IF A/ELISA 
128 4 M Multicentric lymphoma +/+ 
109 2 M Alimentary lymphoma +I+ 
106 4 M Mediastinal lymphoma +I+ 
111 2 M Mediastinal lymphoma +I+ 
131 2 F Mediastinal lymphoma +I+ 
102 7 F Lymphoblastic leukemia +I+ 
110 0.5 F Lymphoblastic leukemia +I+ 
127 M Lymphoblastic leukemia +/+ 
103 M Lymphoblastic leukemia +I+ 
113 4 M Erythroleukemia -I+ 
117 2 M Erythroleukemia +I+ 
TABLE X 
SERUM CALCIUM, PHOSPHORUS AND ALBUMIN CONCENTRATIONS PRIOR TO SpA IMMUNOADSORPTION TREATMENT IN CATS 
WITH FeLV VIREMIA OR FeLV ASSOCIATED LEUKEMIA-LYMPHOMA AND IN CLINICALLY NORMAL CATS 
A. LEUKEMIA-LYMPHOMA 
Cat 128 109 106 111 131 102 110 127 103 113 117 Mean 
Calcium mg/dl 9.8 8.9 12.2 9.8 9.7 9.4 9.5 8.9 10.9 8.4 12.7 10.01 (±1.37) 
Phosphorus mg/dl 4.4 3.9 5.3 3,6 4.5 6.8 6.5 4.6 3.8 4.2 5.8 4.85 (± 1.10) 
Albumin g/dl - 1.9 1.6 2.4 2.9 1.8 2.1 2.7 3.0 2.0 2.2 2.26 (±0.48) 
B. FeLV VIREMIC 
Cat 133 134 135 136 104 137 138 139 118 123 140 141 Mean 
Calcium mg/dl 9.8 8.9 9.3 8.0 8.4 8.5 8.7 7.6 8.1 9.2 8.5 8.5 8.63 (±0.61) 
Phosphorus mg/dl 6.7 5.9 6.9 5.3 4.1 4.6 5.5 5.0 6.5 5.5 5.8 4.5 5.52 (±0.89) 
Albumin g/dl 2.4 2.2 - 1.5 3.4 3.3 2.3 1.7 2.1 2.8 2.5 3.0 2.47 (±0.61) 
c. CONTROL 
Cat 107 122 114 120 108 132 142 143 Mean 
Calcium mg/dl 8.5 8.9 7.7 8.3 8.1 8.7 8.7 8.4 8.41 (±0.38) 
Phosphorus mg/dl 6.0 6.3 4.4 5.3 4.2 6.1 5.3 5.3 5.36 (±0. 77) 
Albumin g/dl 2.1 2.3 2.6 2.7 2.5 3.3 2.7 2.8 2.63 (±0.36) 
..... 
..... 
IV 
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different. All FeLV-infected and control cat calcium levels were 
within the normal reference range (6.2-10.2 mg/dl). Three cases of 
hypercalcemic malignancy were recognized (cats 106, 103, 117). 
Cat 106 presented with an anterior mediastinal lymphoma 4.0 x 
6.2 em, marked pleural effusion, low serum albumin (1.6 g/dl) and 
elevated serum calcium (12.2 mg/dl). 200 ml of a modified transudate 
were removed from the thorax between treatments 1 and 4. Following 
the 7th treatment, the mediastinal mass was no longer identifiable 
but the thickened mediastinum measured 1.0 x 1.6 em. Concurrent with 
this reduction in tumor size, the serum calcium concentration was 
mildly reduced (Table XI). After the 9th treatment, the calcium 
concentration was even lower. Serum chemical evaluation was not 
repeated and the cat died after 10 treatments. 
Cat 103 presented with a massive lymphoid marrow population 
()80%) and marked lymphocytosis, 14.2 x 103/~1 (83% of the total 
peripheral leukocyte count TWBC). Marrow myeloid and erythroid cell 
lines were hypoplastic and cells of these lineages were sparce. No 
megakaryocytes were present. A marked reduction in peripheral blood 
lymphocytes to 1.7 x 103/~1 (58% of the TWBC) occurred after two 
treatments, and after 6 treatments only 0.95 x 103/~1 lymphocytes 
were present (34% of the TWBC). A marked increase is megakaryo-
poiesis, granulopoiesis and erythropoiesis was present in marrow 
after the 6th treatment. The massive lymphoid infiltrate was no 
longer evident (<20%). Biochemical evaluation was performed pre-
treatment and following the 3rd treatment. The calcium concentration 
was mildly lower post-treatment (Table XI). The cat died after 
treatment #6. 
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TABLE XI 
CHANGES IN SERUM CALCIUM, PHOSPHORUS AND ALBUMIN CONCENTRATIONS 
IN THREE CATS WITH LEUKEMIA-LYMPHOMA AND TWO CONTROL CATS 
DURING SpA IMMUNOADSORPTION TREATMENT 
LEUKEMIA-LYMPHOMA 
Cat 106 103 117 
SpA treatments 0 5 9 0 3 0 7 9 
Calcium mg/dl 12.2 11.9 11.5 10.9 10.0 12.7 8.7 7.4 
Phosphorus mg/dl 5.3 5.5 4.0 3.8 6.0 5.8 4.9 5.0 
Albumin g/dl 1.6 1.2 1.9 3.0 3.6 2.2 1.7 2.1 
Adjusted calcium 14.1 13.1 11.4 10.1 14.0 8.8 
(mg/dl) 
CONTROL 
Cat 122 115 
SpA treatments 0 4 8 0 10 17 
Calcium mg/dl 8 9 9,3 9.7 7.7 8.6 8.2 
Phosphorus mg/dl 6.3 4.0 6.5 4.4 4.4 5.1 
Albumin g/dl 2.3 2.3 2.5 2.6 2.5 2.3 
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Cat 117 was erythroleukemic upon presentation with marked marrow 
myeloerythroid dyscrasia-dysplasia characterized by excessive 
immature forms and megaloblastosis. Erythroid was the predominant 
cell line prior to treatment. Following the 8th treatment, a myeloid 
predominance was noted. A reduction in serum calcium occurred during 
treatment, from 12.7 mg/dl prior to treatment to 8.7 and 7.4 mg/dl 
after treatments #7 and #9 (Table XI). Concurrent feline infectious 
peritonitis was diagnosed post-mortem when the cat died after 9 
treatments. 
Alkaline phosphatase, blood urea nitrogen and creatinine values 
were within normal ranges for all cats. Urinalyses were normal 
except in cat 102 which had cystitis. Survey radiographs of cats 
with leukemia-lymphoma failed to detect osteolytic lesions. Parathy-
roid glands were uniformly small and macroscopically unremarkable. 
Skeletal metastasis was not evident in any cat, though neoplastic 
marrow populations were present in cats with leukemia. Soft tissue 
mineralization was not present post-mortem in any cat. 
E. Discussion 
Elevated levels of parathyroid hormone-like peptides have been 
demonstrated in plasma and tumor tissue of patients with non-endo-
crine neoplasms (Sherwood et al., 1967). Osteoclast activating 
factor secreted by cultured normal leukocytes in response to antigen 
or mitogen stimulation is indistinguishable from substances produced 
by tumors of lymphoid or myeloma cell origin (Mundy et al., 1974b). 
Prostaglandin E2 acts systemically to enhance bone resorbtion in the 
116 
HSDM murine fibrosarcoma and VX carcinoma of the rabbit (Tashjian, 
1978). 
Although disorders in feline mineral metabolism are rarely 
reported, hypercalcemia and hypercalcemic malignancy are considered 
much less common in cats than in man or dogs (Chew & Meuten, 1982). 
By analogy to proposed mechanisms in man, serum calicum may become 
elevated in cats with leukemia-lymphoma as a result of skeletal 
metastasis and localized osteolysis, diffuse osteolysis caused by 
humoral products derived from the tumor, concurrent parathyroid 
hyperactivity or renal insufficiency. In addition, hypercalcemia has 
been documented in numerous cases of lymphoma associated with human 
T-cell leukemia-lymphoma virus (HTLV-I) (Blayney et al., 1983) (Bunn 
et al., 1983) (Yunoki et al., 1982). Similar etiologic mechanisms 
may play a role in the induction of hypercalcemia in both the feline 
and human retroviral-induced lymphomas. To our knowledge, feline 
primary hyperparathyroidism has not been reported. Skeletal metasta-
sis is considered to be less commonly associated with tumors in small 
animals than in man (Chew & Meuten, 1982) (Meuten et al., 1982a), and 
in the absence of renal insufficiency, it appears that the most 
likely cause of hypercalcemic malignancy in small animals is the 
production by the neoplasm of bone-resorbing compounds. 
All three cases of hypercalcemic malignancy reported here 
responded when the neoplasm was reduced by a form of immunotherapy. 
This reduction in serum calcium during treatment of malignancies did 
not occur in treated control cats which were not hypercalcemic (Table 
XI). The lack of skeletal metastasis and absence of overt parathy-
roid or renal pathology in cat 106 with mediastinal lymphoma, and the 
117 
simultaneous reduction in serum calcium and tumor s1ze imply that the 
tumor in this cat may have initiated a humorally-mediated mechanism 
for the elevation in serum calcium. Cat 103 also responded to treat-
ment with simultaneous reduction in both malignancy and serum 
calcium. This cat also lacked evidence of other causes of hyper-
calcemia, but presented with advanced leukemia and a massive lymphoid 
infiltration of the marrow. In this case, localized osteolysis 
resulting from the presence of the neoplastic marrow cells or a 
product of these cells may have contributed to the hypercalcemia. 
The change from erythroid to myeloid predominance in the myelopro-
liferative disorder of cat 117 may have selected against calcemia-
producing neoplastic cells. The possible means by which ex~ 
immunoadsorption employing staphylococcal protein A caused reduction 
in the extent of the malignant disease of these cats have been 
discussed elsewhere (Day et al., 1984) (Liu et al., 1984a,b). 
Approximately 50% of the measurable serum calcium is protein-
bound, primarily to albumin (90%) (Meuten et al., 1982a). Hypoalbu-
minemia can decrease the measured calcium. Correction formulas for 
calcium values have been derived for use in dogs that take into 
account changes in serum protein and albumin (Meuten et al., 1982b). 
The elevated mean serum calcium concentration 1n the cats with 
leukemia-lymphoma and the number of hypercalcemic malignancies in 
this study would have been even greater if the low serum albumin 
concentrations could have been considered. In the three cats which 
had elevated calcium levels and responded to treatment from our 
analyses application of correction factors derived from studies in 
dogs suggest that the calcium levels in each instance were almost 
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certainly pathologically elevated and declined with effective treat-
ment of the disease (Table XI). 
Although cases of feline hypercalcemic malignancy are rarely 
reported (Chew et al., 1975) (Zenoble & Rowland, 1979) (Wilkins & 
Hurvitz, 1975), the incidence of frank hypercalcemia in cats with 
malignancy in this study (3/11; 27%) was significantly greater (p < 
0.05 by Fisher's exact test) than that in cats without malignancy 
(0/20). In addition, cats with FeLV-associated leukemia-lymphoma in 
this study did, as a group, have a significantly greater mean serum 
calcium concentration than normal or FeLV-infected cats without 
malignancy. Our-observations indicate that hypercalcemia does occur 
with feline malignancy and can respond to ex vivo imrnunoadsorption 
treatment with SpA. In addition, it appears that cats with leukemia-
lymphoma are more likely to present with elevated calcium levels that 
fall within the upper range of normal or are only slightly elevated. 
These findings suggest that future studies should be carried out to 
identify cats in which frank hypercalcemia is associated with malig-
nancy. Definitive analyses must then be made, both in terms of the 
response to treatment and the identification in more precise terms of 
the basis of hypercalcemia. 
CHAPTER V 
CHANGING MANIFESTATIONS OF A CHRONIC FELINE HEMATOPOIETIC 
PROLIFERATIVE DISEASE DURING IMMUNOTHERAPY WITH 
STAPHYLOCOCCAL PROTEIN A 
A. Summary 
A cat presenting with feline leukemia v1rus associated malignant 
disease was treated by ex vivo immunoadsorption using staphylococcal 
protein A coated filters. During the twelve-week course of treat-
ment, the morphological manifestations of the hematopoietic disease 
exhibited a progressive transition from erythroid to myeloerythroid 
to myeloid predominance, and was preceded by and associated initially 
and terminally with a blast transformation of lymphoblastic morphol-
ogy. Necropsy revealed massive meningio-cerebral, as well as 
hepatic, renal, myeloid, lymphoid, peritoneal and pelvic infiltra-
tions largely consisting of lymphoblastic cells. Yet evidence of 
myeloid and erythroid differentiation was present in all the 
infiltrates. The several possible bases for this shifting of 
morphological expression are considered. 
B. Introduction 
The unifying concept of myeloproliferative disease as those 
proliferative disorders involving one, several or all of the bone 
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marrow cell lines is based on the premise of neoplastic stem cell 
clones which are capable of at least some degree of differentiation 
(Quesenberry & Levitt, 1979). In most cases, these neoplastic clones 
appear to arise from a pluripotential stem cell and differentiate 
into one of several cell lines, granulocytic, monocytic, erythrocytic 
or megakaryocytic (Figure 27) (Harvey, 1981). In some cases either 
an earlier stem cell common to the pluripotential and lymphoid stem 
cells, or a more committed stem cell common only to granulocytic and 
monocytic cell lines may be involved (Harvey, 1981) (Quesenberry & 
Levitt, 1979 (Schalm & Theilen, 1970). Classification of these 
disorders has been based on which cell line(s) predominate, presumed 
maturity of the cell type, and whether neoplastic cells are present 
in the blood or are confined to the hematopoietic tissue (Harvey, 
1981). Attempts to separate myeloproliferative disorders into 
distinct entities based upon morphologic features may be artificial 
since neoplastic stem cells appear to be able to differentiate into 
any of several cell types, manifestation of the disorder may vary 
with time, only rarely is a single marrow cell line affected, and 
disorders may often evolve from one morphologic form into another 
(Harvey et al., 1978) (Harvey, 1981) (Quesenberry & Levitt, 1979) 
(Schalm & Theilen, 1970) (Schalm et al., 1975) (Schalm, 1975). 
Myeloproliferative disease is a more frequent disorder in cats 
than in other domestic animals (Harvey, 1981). It may manifest as a 
proliferation of cells with predominantly granulocytic (Fraser et 
al., 1974), monocytic (Henness et al., 1977b) (Tsujimoto et al., 
1981)_, eosinophilic (Silverman, 1971) (Simon & Holzworth, 1967), 
megakaryocytic (Michel et al., 1976), or erythrocytic ((Harvey, 1981) 
Figure 27: The relationships between hematopoietic stem cells and 
mature blood cells. Used with permission, P.W. Kincade and R.A. 
Phillips, Fed. Proc. 44:2874-2881, 1985. 
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(Schalm et al., 1975) (Ward et al., 1969) (Zawidzka et al., 1964) 
characteristics. Simultaneous proliferation of more than one cell 
line may occur (Maede & Murata, 1980) (Stann, 1979), poorly 
differentiated cells may be encountered (Crow et al., 1977), and the 
transition from a disorder of predominantly one cell type into a 
disorder involving another cell type has been recognized (Harvey et 
al., 1978) (Harvey, 1981) (Schalm & Theilen, 1970) (Schalm, 1975) 
(Schalm et al., 1975) (Ward et al., 1969). In the present analysis, 
we consider a 7-year-old mixed breed female cat with hematopoietic 
proliferative disease which was referred to the Oklahoma State 
University, Department of Veterinary Pathology, for anti-cancer 
immunoadsorption treatment. This experimental therapy employed 
staphylococcal protein A filtration columns (Day et al., 1984). 
Sequential evaluation of bone marrow, lymph node and peripheral blood 
cytology during the course of treatment revealed changes in the mor-
phological manifestations of the proliferative disease and involved 
sequential changes in the predominant cell lineage. The observations 
support the view that neoplastic proliferation may involve multi-
potential stem cells and suggest that in some cases such clones may 
arise from a primitive pluripotential stem cell common to both the 
lymphoid and the myelo-erythroid cell lines. 
C. Material and Methods 
The cat which is reported herein was one of a series of pet cats 
referred to the Oklahoma State University Department of Veterinary 
Pathology and selected for treatment by ~ vivo immunoadsorption 
employing staphylococcal protein A filters (AMF/Specialty Materials 
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Group, Talcotville, CN) after cytologic and radiographic examination 
had revealed hematopoietic neoplasia (Day et al., 1984). Viral 
status for feline leukemia virus (FeLV) was determined using a fixed 
cell indirect immunofluorescent antibody test (IFA) and an enzyme-
linked immunosorbent assay (ELISA) as described (Hardy et al., 1973b) 
(Mia et al., 1981). This cat received ex vivo immunoadsorption 
treatment as previously described for 12 weeks (Day et al., 1984). 
Physical examination and body temperature were determined daily. 
Body weight, hemograms and serologic tests were performed weekly and 
bone marrow and lymph node cytology were analyzed at every 5th 
treatment. Periodic urinalysis and evaluation of serum chemistries 
and protein electrophoresis were also performed. Adjunct therapy was 
minimal and consisted only of I.V. or S.Q. fluids and antibiotics. 
Four transfusions of washed leukocyte-poor packed red blood cells 
were given late in the course of the disease. Cytologic preparations 
were stained with Wright's Dip-Stat (Medi-Chem, Inc., Santa Monica, 
CA). Post-mortem, tissues were fixed in 10% buffered formalin, 
embedded in paraffin, cut at 6-8 ~m, and stained with hematoxylin and 
eosin. Additional sections of some tissues were stained with either 
periodic acid-Schiff or methenamine silver. 
D. Results 
The cat studied presented with moderate peripheral lymphadenop-
athy, blindness resulting from ocular neoplastic infiltrates, and was 
infected with feline leukemia virus (FeLV). Approximately 40% of the 
cells in the pretreatment cytologic preps of the lymph node were 
lymphoblasts with scant, moderately blue cytoplasm, large, oval to 
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angular nuclei with smudged chromatin and one or more irregular 
nucleoli. A small number of megakaryocytes, occasional rubricyte, 
metarubricyte, and metamyelocyte and moderate numbers of bands and 
segmented granulocytes were also present. Flecks of bone marrow 
obtained by aspiration showed hypercellularity and abundant blasts, 
similar morphologically to those present in lymph node aspirates. 
These blast forms comprised approximately 50% of the nucleated cells 
in the marrow (Figure 28). Erythroid cells were few in number and 
proportion. Granulocytes were normal or slightly decreased but 
appeared to be maturing normally. Peripheral blood examination 
showed evidence of a mild, nonregenerative anemia, absolute leuko-
cytosis, neutrophilia, monocytosis and lymphocytosis with numerous 
blast forms (Table XII). 
Although a diagnosis of myeloproliferative disease was consid-
ered, the animal was classified cytologically as having multicentric 
lymphoma with lymphoblastic leukemia based upon the morphology of the 
blast forms within the marrow and lymph node. Supporting this con-
clusion was the absolute lymphocytosis which ranged during the first 
40 days from 7,575-29,755/~1 with a mean of 10,438/~1, the apparent 
normal maturation of marrow granulocytes, and the sparcity of 
erythroid cells in the marrow. The absolute neutrophilia and 
monocytosis were attributed to an abscess present on the ventral 
perineum, from which Streptococcus canis was cultured. The animal 
was treated with I.M. ampicillin, 10 mg/kg b.i.d. from days 40-56. 
Experimental ex vivo immunoadsorption treatments for the 
animal's hematopoietic proliferative disease were administered twice 
weekly for the next 12 weeks. During this time. the animal became 
Figure 28: Pretreatment marrow cytology. Prior to immunotherapy, 
lymphoblastic leukemia was considered the appropriate cytological 
classification for the eat's hematopoietic proliferative disease. 
Greater than 50% of the nucleated cells in the pretreatment bone 
marrow were lymphoblasts (x720, xl600). 
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TABLE XII 
HEMATOLOGIC TRENDS OF A CAT TREATED BY EX VIVO IMMUNOADSORPTION USING STAPHYLOCOCCAL PROTEIN A 
---
HCTa MCV MCHC Retics NRBC WBC Seg Band Lymph Mono Eos Meta Mye1o Pros Thromb 
---
% )J3 % % 100 WBC x103/JJ1 )J1 )J1 )J1 )J1 )J1 )Jl )J1 )J1 x103/)J1 Rxs 
24- 39- 30- 0 5.5- 2500- 0- 1500- 0- 0- 0 0 0 300-
45 55 36 19.5 12,500 300 7000 800 1500 700 
-
22 39 38.2 0 1 30.3 19,695 0 7575 1818 1212 0 0 0 651 0 
23 41 42.1 0.7 0 54.1 22,181 0 29,755 1623 541 0 0 0 300 4 
--
12 41 42.5 0 2 25.8 14' 190 0 8772 2322 516 0 0 0 189 9 
22 45 34.6 0.1 11 28.5 18,810 1425 5130 3135 0 0 0 0 290 14 
17 60 25.9 0.4 14 57.7 32,889 8655 5770 0 0 8655 1731 0 76 18 
12 44 41.7 0.3 5 30.0 22,200 900 4200 300 600 900 300 300 226 20 
12 46 35.0 0.2 17 31.3 12,500 4069 12,833 313 933 626 0 0 740 24 
14 43 36.4 0 2 24.6 3936 2460 16 '728 984 492 738 0 0 970 24 
....... 
N 
00 
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progressively more anemic with a hematocrit as low as 11 and with 
increasing numbers of nucleated red blood cells in the peripheral 
blood (Table XII). Peripheral lymph nodes became progressively 
smaller and could no longer be palpated easily after day 20. Lymph 
node cytology was not re-evaluated. Bone marrow flecks on day 41 
were markedly hypercellular with increased numbers of erythroid cells 
which showed dyscrastic (excessive rubriblasts and prorubricytes) and 
dysplastic (megaloblastoid change, and gigantism) features (Figure 
29). Granulocytic cells were moderately increased, but without 
apparent dyscrasia. Approximately 20% of the nucleated cells in the 
marrow at this juncture were lymphoblasts. 
The identification of megaloblastoid change, gigantism and 
preponderance of rubriblasts and prorubricytes suggested that the 
erythroid proliferation was of a neoplastic nature. A diagnosis of 
myeloproliferative disease with erythroid prominence and marrow 
infiltration by lymphoblasts was made. 
Washed leukocyte-poor packed red blood cell transfusions admin-
istered on days 46, 49, 67 and 93 caused only mild improvement in 
hematocrit. On day 67, a granulocytic left shift to the myelocyte 
level was recognized (Table XII). Marrow flecks at this stage showed 
marked hypercellularity, an increase of granulocytic cells with 
excessive numbers of myeloblasts and progranulocytes. Numerous 
rubriblasts and frequent megaloblastoid cells were also present. 
Erythroleukemia was considered to be the most appropriate cytologic 
classification for this stage of the animal's proliferative 
disorder. 
Figure 29: Mid-treatment marrow cytology. On day 41 after 10 
immunoadsorption treatments, a dyscrastic and dysplastic erythropro-
liferative predominance with excessive numbers of rubriblasts and 
prorubricytes were present in hypercellular marrow flecks (x920, 
x2050). 
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Other clinical problems included the identification of hemobar-
tonellosis on day 67, which was treated with oral tetracyclines until 
day 93, and abnormalities indicative of inflammation and glomerulo-
tubular damage present on urinalysis on days 65 and 76. 
On day 77 the left shift in the neutrophil series extended to 
the promyelocyte level. Markedly increased numbers of granulocytes 
with an excess of myeloblasts were present in hypercellular marrow 
flecks (Figure 30). At this stage, erythroid cells were present 
without dyscrasia and in approximately normal numbers, but megalo-
blastic forms were still readily identified. 
On day 120, 27 days after the 24th and final ex vivo 1mmuno-
adsorption treatment, the marrow was again populated (approximately 
20% of the nucleated cells) by lymphoblasts as previously described. 
Erythroid cells were moderately decreased in number and granulocytes 
were increased with an excessive proportion of myeloblasts. An 
absolute lymphocytosis of the peripheral blood which was present 
since the 24th treatment was recognized. The descriptive cytologic 
classification used for this stage of the animal's proliferative 
disease was granulocytic leukemia with lymphoblastic marrow infiltra-
tion. The sequential cytologic classifications of this hematopoietic 
proliferative disease and their basis are presented 1n Table XIII. 
The animal died on day 124 after a weight loss of 1.12 kg with a 
non-regenerative anemia, marked absolute thrombocytosis, and FeLV 
infection. Complete serum chemistry and electrophoretic evaluations 
on days 14, 29, 43, 56, 69, 77 and 93 did not identify significant or 
consistent abnormalities. 
Figure 30: Post-treatment marrow cytology. Hypercellular bone 
marrow aspirates on day 77 after 20 immunoadsorption treatments 
consisted of excessive numbers of myeloblasts and progranulocytes. 
At this stage of the disease, a left shift in the neutrophil series 
extended to the promyelocyte level (x720, xl600). 
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TABLE XIII 
SEQUENTIAL CYTOLOGIC CLASSIFICATIONS OF A CAT'S HEMATOPOIETIC PROLIFERATIVE DISORDER AND THEIR BASIS 
Day 
0 
41 
67 
77 
120 
Immuno 
Rxs 
0 
10 
18 
20 
24 
Classification 
Lymphoblastic leukemia 
Erythemic myelosis 
Erythroleukemia 
Granulocytic leukemia 
Lymphoblastic crLsLs 
with granulocytic 
leukemia 
Bone Marrowa 
)50% lymphoblasts 
Dyscrastic, dysplastic, 
erythroid predominance 
Dyscrastic, dysplastic, 
myeloerythroid prolif-
eration 
Dyscrastic, dysplastic, 
myeloid proliferation 
)20% lymphoblasts with 
dyscrastic, dysplastic, 
myeloid proliferation 
aAll bone marrow aspirates were markedly hypercellular. 
b All total blood leukocyte counts were elevated. 
Peripheral Bloodb 
Lymphocytosis (7575-
29,755/pl) 
NRBC's 
Left shift to myelocyte, 
NRBC's 
Left shift to promyelocyte, 
NRBC's 
Lymphocytosis (12,833-
16 '728/pl) 
1--' 
w 
VI 
136 
At necropsy, the animal was emaciated. Neoplastic infiltrates 
were identified in the meninges, ependyma, eyes and extending into 
the brain, lungs, and present multifocally in the liver and kidneys. 
The neoplastic material also formed a large caudal abdominal and 
pelvic mass which surrounded both kidneys, ureters, the urinary 
bladder and filled the pelvic cavity. Microscopically, similar cells 
comprised the pelvic-abdominal mass and the parenchymal infiltrates. 
Most of the cells were lymphoblasts. Mitotic figures were common. 
Numerous other cells were also present and appeared to represent all 
stages of myeloid and erythroid development. Megakaryocytes were 
frequently encountered. Large, extracapsular densely cellular 
aggregates were frequently encountered in lymph nodes, spleen and 
kidney. The bone marrow was markedly hypercellular with similar 
cells. A mild membranous glomerulonephritis was recognized using 
periodic acid-Schiff and methenamine silver stains. 
E. Discussion 
A number of hematopoietic proliferative disorders appear to 
represent neoplastic transformation of stem cells at one of three 
levels. Potentially neoplastic clones could be derived from a primi-
tive pluripotential stem cell with the capacity to differentiate to 
all blood cell types including lymphocytes, or from a pluripotential 
stem cell capable of producing myeloid, erythroid and megakaryocytic 
cells, or from a granulocyte-monocyte stem cell (Figure 27) (Harvey, 
1981) (Quesenberry & Levitt, 1979). Evidence for this concept in 
human myeloproliferative disorders has been obtained by demonstrating 
the presence of shared chromosomal abnormalities or the presence of a 
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single isoenzyme of X-linked glucose-6 phosphate dehydrogenase within 
the proliferative, heterogenous cell types (Quesenberry & Levitt, 
1979). These shared characteristics suggest the presence of a single 
progenitor cell for a morphologically heterogeneous population of 
cells. In addition, some disorders appear to evolve or change mani-
festation with time. Although in humans the intermediate, myelo-
erythroid pluripotential stem cell is thought to be most frequently 
involved, several lines of evidence has been presented suggesting 
that in some cases of chronic myelogenous leukemia, the neoplastic 
transformation may involve a more primitive stem cell common to both 
the pluripotential stem cell and the lymphoid system (Quesenberry & 
Levit~, 1979). In addition, approximately 20% of humans with chronic 
myelogenous leukemia undergo blast transformation with blasts which 
have distinct lymphoid morphology, as well as certain characteristics 
of cells of the T-lymphocyte lineage (Peterson et al., 1976). In 
cases of myelomonocytic leukemia, the affected cell may be a more 
differentiated granulocyte-monocyte stem cell. 
Myeloproliferative disease occurs relatively frequently ~n the 
cat, manifests as an abnormal proliferation of granulocytes, mono-
cytes, eosinophils, megakaryocytes or erythrocytes, or as a simulta-
neous proliteration of more than one cell type (Schalm et al., 1975). 
In some cases, disease manifestation may change dramatically from a 
disorder predominantly of one cell type to another (Gilmore et al., 
1964) (Quesenberry & Levitt, 1979) (Schalm & Theilen, 1970) (Schalm, 
1975) (Schalm et al., 1975) (Ward et al., 1969). Electron micro-
scopic observations of type-C viral particles budding from marrow 
cells of cats with myeloproliferative disease (Herz et al., 1970), 
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and the high incidence of feline leukemia virus (FeLV) infection in 
affected cats imply a causal relationship between FeLV and myelopro-
liferative disorders (Harvey, 1981). Only once, however, has a FeLV 
isolate produced this disorder experimentally (Jarrett et al., 
1971). 
Cats with myeloproliferative disease generally present with 
hepatic, splenic and sometimes lymph node enlargement and often have 
nonregenerative anemias which are either normocytic, normochromic or 
macrocytic, normochromic. Nucleated red blood cells are frequently 
present in circulation. Leukocyte, platelet and erythrocyte numbers 
and morphology vary depending upon the cytologic classification of 
the disorder (Harvey, 1981) (Schalm et al., 1975). The proliferating 
cell lines are variably distributed in the bone marrow, liver, 
spleen, and lymph nodes and are usually confined to vascular and 
lymphatic space, although in more aggressive proliferations 
neoplastic cells (erythroid, myeloid and/or megakaryocytes) can be 
found throughout most tissues (Gilmore et al., 1964) (Moulton, 1978) 
(Ward et al., 1969). 
The progressive transition of hematopoietic proliferative 
disease in this cat from erythroid to myeloerythroid to myeloid 
predominance was preceded by and associated terminally with a blast 
transformation which had lymphoblastic morphology. Widespread organ 
infiltration and a large pelvic-abdominal mass of neoplastic cells 
were present at post-mortem examination. Malignant infiltrates were 
not confined to vascular, lymphatic space and frequently formed 
variably sized nodular masses with parenchyma and outside capsules. 
Central nervous system, ocular and urinary tract infiltrates were 
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most extensive. Extensive tissue infiltration and central nervous 
system involvement are common in the 20% of humans with chronic 
myelogenous leukemia that undergo blast transformation with blasts of 
lymphoid morphology (Peterson et al., 1976) (Quesenberry & Levitt, 
1979). 
Malignant transformation of the primitive pluripotential or 
possibly the myelo-erythroid pluripotential stem cell represent 
potential origins for this eat's proliferative disease. Lesions of 
the magnitude and variability recognized in this cat have not been 
reported previously. With declining clinical condition, most cats 
with myeloproliferative disorder are euthanized. The experimental ex 
vivo immunoadsorption therapy using staphylococcal protein A filtra-
tion columns employed in this study has produced regression of breast 
cancer 1n dogs (Terman et al., 1980) and humans (Terman et al., 
1981), as well as regressions of FeLV-induced neoplasia and even to a 
virus-negative state in a few cats (Day et al., 1984) (Jones et al., 
1980) (Liu et al., 1984a,b) (Snyder et al., 1984). The possible 
mechanisms by which this experimental immunotherapy causes reduction 
in the extent of FeLV-induced malignant disease have not been 
completely elucidated, but have been discussed elsewhere (Liu et al., 
1984a,b) (Snyder et al., 1984). These treatments may have played a 
role in selectively reducing more susceptible blood cell populations, 
thereby contributing to the successive changes in manifestation of 
disease in this cat. It is also possible that these changes in 
manifestation were observed because the survival of the cat was 
prolonged. 
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If treatment with staphyloccocal protein A can indeed partici-
pate in altering the morphologic expression of lympho-myeloprolifera-
tive disease in cats, and/or prolonging the survival of cats with 
this disease, future studies may permit opportunity to analyze 
definitively whether these proliferative disorders are attributable 
to several clones of malignant cells derived from a common progenitor 
stem cell, or alternatively, represent a single malignant clone whose 
morphologic expression is influenced by protein A immunotherapy. 
Important will be initial chromosomal and/or enzymatic analyses of 
the malignant cells and successive similarly detailed analyses of the 
cells that predominate at different stages of response. 
CHAPTER VI 
SUPPRESSION OF GAMMA INTERFERON PRODUCTION BY 
INACTIVATED FELINE LEUKEMIA VIRUS 
A. Summary 
Supernates from cultures of normal feline lymphocytes stimulated 
with Staphylococcus enterotoxin A (SEA) effected antiviral activity 
characterized as a gamma-like interferon. With the addition of 
inactivated feline leukemia virus (FeLV), markedly less interferon 
was produced. This reduction in interferon production was not 
attributable to either lowered lymphocyte viability or reduced SEA 
mitogenic properties and appears to be a direct retroviral effect. 
This finding may reflect clinically relevant events which may con-
tribute to the development of either the feline (FeLV-induced) or the 
human (HTLV-III-induced) states of acquired immunodeficiency. 
B. Introduction 
The feline leukemia v1rus (FeLV), a contagious retrovirus which 
1s transmitted primarily via salivary secretions, causes either 
neoplastic or non-neoplastic diseases in the infected cat including a 
state of immunodeficiency characterized by diminution of both cellu-
lar and humoral immunity. Retrovirus-induced immunosuppression, 
which is the most frequent sequelae of persistent FeLV viremia, 
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predisposes the animal to secondary illness of infectious or auto-
immune origin and accounts for a majority of the FeLV-related deaths 
(Hardy, 1980a,b) (Hardy, 1982). Viremic cats have suppressed 
blastogenic responses to T-cell mitogens, reduced lymphocyte membrane 
con A receptor mobility, suppressed antibody responses to synthetic 
polypeptides, prolonged allograft rejection times, and exhibit 
varying degrees of hypocomplementemia, thymic atrophy and depletion 
of the paracortical zones of lymph nodes (Cockerell et al., 1976b) 
(Dunlap et al., 1979) (Trainin et al., 1983) (Olsen et al., 1981) 
(Kobilinsky et al., 1979). In addition, our earlier investigations 
demonstrated that peripheral blood and splenic lymphocytes from FeLV 
infected cats when stimulated with T-cell mitogens could not be 
induced to produce or when induced produced only low titers of 
interferon (IFN) (Liu et al., 1984b). Although little is known about 
the way in which FeLV initiates immunosuppression, the virus may 
mediate immuno-modulating events independent of cellular infection 
since UV-light inactivated FeLV and certain FeLV structural proteins 
have been shown to impair lymphocyte proliferative responses and 
membrane receptor capping to con A in vitro (Hebebrand et al., 1977) 
(Mathes et al., 1979). Further studies suggest that this inability 
of lymphocytes to respond to mitogenic stimuli during co-incubation 
with inactivated virus may be due to decreased elaboration of T-cell 
growth factor (possibly interleukin-2) activity (Wainberg et al., 
1983). In this report, we show that the in vitro synthesis of a 
gamma-like interferon by normal feline lymphocytes which have been 
stimulated with Staphylococcus enterotoxin A (SEA) is reduced when 
UV-light inactivated FeLV is also present in culture during the 
period of stimulation. 
C. Material and Methods 
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Seven healthy domestic cats free of FeLV maintained in our 
laboratory served as donors of peripheral blood lymphocytes (PBL). 
These cells were isolated from defibrinated whole blood by Ficoll-
hypaque density centrifugation. Cell viabilities were determined by 
vital dye exclusion. Five million lymphocytes per milliliter in 
complete medium supplemented with 5 x lo-s M 2-mercaptoethanol were 
placed in 16mm diameter flat-bottom microplate wells and cultured 
either in the absence of mitogen, in the presence of 1.0 ~g/ml SEA 
(Microbial Biochemistry Branch, Division of Microbiology, Food and 
Drug Administration, Cincinnati, OH), or with both 1.0 ~g/ml SEA and 
between 10 and 625 ~g of UV-inactivated KT-FeLV. KT-FeLV was 
purified and UV-inactivated as described (Mathes et al., 1979). 
Final culture volume in all cases was 1.0 ml. Microplates were 
placed in culture boxes, incubated at 37°C in a humidified atmosphere 
containing 10% C02 and rocked at 8 cycles/min for 72 hrs. Cultures 
were then harvested, cells pelleted by slow centrifugation and 
supernates collected and stored at 4°C. The antiviral activity of 
supernatant fluids from these cultures were titrated for ability to 
inhibit the cytopathic effects of approximately 40 plaque-forming 
units (PFU) of vesicular stomatitis virus (VSV) on a monolayer of 
feline lung cells (FL, American Type Culture Collection, Rockville, 
MD), using a plaque reduction method. All titrations were carried 
out in duplicate. IFN units/ml were determined as the reciprocal of 
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the dilution which reduced the number of PFU by 50%. A laboratory 
feline IFN reference sample was used to monitor the assays. 
To determine whether the inactivated FeLV we were using 
suppressed mitogen-induced lymphocyte proliferation, four separate 
lymphocyte blastogenesis assays were performed using the methodology 
previously reported (Mathes et al., 1979), except that between 2.5-
10.0 ~g con A/well or 0.05-0.5 ~g SEA/well served as mitogens and 
18.75 ~g of inactivated FeLV was used in test wells. Under these 
conditions, the inactivated virus to lymphocyte ratio was 18 x lo-s 
~g/cell and the percent residual proliferative response ranged 
between 22.4% and 78.5% which is comparable to the reported determi-
nations. 
D. Results 
Two, three or four separate culture series were established 
using lymphocytes from each of the seven cats. The induced antiviral 
activity of the supernate is presented as an average of 2-4 determi-
nations in Table XIV. Supernate from wells containing only lympho-
cytes and complete medium demonstrated no antiviral activity (except 
for 2 of the 4 cultures using cells from cat 248). Cultures 
containing SEA-stimulated lymphocytes produced between 47 and 768 
U/ml IFN. When 625 ~g of inactivated FeLV was co-incubated with SEA 
in lymphocyte cultures, the supernate demonstrated no antiviral 
effect. With the addition of 400 ~g of virus to SEA-stimulated 
lymphocyte cultures, the induced antiviral activity of the supernate 
was markedly reduced as compared to the positive control. Under 
these conditions, the virus to lymphocyte ratio was 8 x lo-s ~g/cell 
TABLE XIV 
TITER OF INTERFERON GENERATED AND PERCENT VIABILITY OF PERIPHERAL BLOOD LYMPHOCYTES 
AFTER 72 HOURS OF CULTURE 
IFN (U/ml) 
SEA (1.0 pg/ml) 
II UV-inactivated FeLV (pg/ml) 
of No 
Cat Exps. Mitogen 625 400 300 200 100 50 10 
301 2 <10 214 ND 19 52 61 134 150 196 
249 3 <10 168 ND 39 67 124 150 141 378 
1225 2 <10 47 <10 <10 <10 17 ND ND 25 
1264 2 <10 200 ND 39 43 99 112 83 ND 
302 2 <10 289 ND 35 125 44 119 150 130 
248 4 367 768 ND 409 89 734 980 875 815 
000 2 <10 287 <10 ND ND 160 367 ND ND 
Viability (post-culture) 
II Samples 
tested 15 28 ND 14 11 13 11 6 8 
% Viable 90±10 93±4 ND 86±11 90±6 89±6 92±7 95±2 96±2 ....... 
..p-
V1 
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and the percent residual antiviral activity ranged between 8.8% and 
53.2%. With further dilution of the virus, the induced antiviral 
activity of the supernate increased. In some cases, when small 
amounts of inactivated FeLV were incorporated in cultures the 
resultant antiviral effect exceeded the positive control (cats 249, 
248). 
To characterize the antiviral activity of supernates, in 
separate tests supernates were dialyzed at pH 2, heat-treated at 56°C 
for 30 min, or submitted to ultracentrifugation at 110,000 x g for 90 
min. No antiviral activity remained in samples dialyzed to pH 2 or 
subjected to heat treatment, while ultracentrifugation did not reduce 
the antiviral effect (Table XV). Supernates that effected plaque 
reduction when VSV was used as the challenge virus also demonstrated 
this protective antiviral effect when feline calicivirus (FCV, F-9) 
was substituted as challenge virus, showing that the antiviral sub-
stance inhibited effectively the replication of other viruses. 
Feline herpesvirus (FHV-1, C27) was insensitive to any antiviral 
activity in any of the tested supernates. Variation in the sensi-
tivity of different viruses to interferon has previously been 
described. Samples that demonstrated antiviral activity in feline 
lung cell monolayers showed no activity in a heterologous system of 
IFN assay using MDBK bovine kidney cell monolayers (American Type 
Culture Collection, Rockville, MD), and VSV as a challenge virus. 
Based on these findings, the antiviral effect resulting from the 
treatment of feline lung cell monolayers with supernates from 
cultures containing SEA-stimulated lymphocytes was attributable to an 
TABLE XV 
CHARACTERIZATION OF THE ANTIVIRAL ACTIVITY OF CULTURE 
SUPERNATES AS A GAMMA-LIKE INTERFERON 
IFN (U/ml) 
A. Treatment at pH 2 
pH 7.2 
767 
147 
249 <10 339 
1264 <10 246 
B. Treatment at 56°C/30 min 
Cat Control 
1276 44 <10 
1264 246 <10 
C. Activity against Other Viruses 
Cat vsv FCV FHV-1 
301 150 267 <10 
D. Heterologous Cells 
Cat FL MDBK 
302 200 <10 
301 150 <10 
interferon. This interferon was a gamma-like (immune) interferon 
based on pH 2 susceptibility. 
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The reduction in IFN production 1n lymphocyte cultures where 
cells were co-incubated with virus and SEA was not solely attribut-
able to a reduction in the number of cultured viable lymphocytes. By 
resuspending individual cell pellets in 1.0 ml of complete medium 
after harvesting the supernates, average lymphocyte viability after 
72 hrs of incubation was determined in 106 cultures from three 
experiments involving 4 of the cats (Table XIV). Post-culture 
lymphocyte viabilities differed only slightly, regardless of the 
conditions of culture. 
To show that the addition of virus did not neutralize the 
mitogenic properties of SEA, 1250 ~g of inactivated FeLV and 50 ~g of 
SEA were incubated together at 37°C for 18 hr in 4.0 ml of complete 
medium. The virus was then removed by ultracentrifugation at 100,000 
x g for 90 min. The remaining SEA-containing supernate, used in 
place of stock SEA for the stimulation of lymphocytes, induced 
comparable IFN titers when compared to stock SEA (Table XVI). To 
determine whether IFN was produced but subsequently neutralized by 
the presence of inactivated virus, 400 ~g of FeLV was added to SEA-
stimulated lymphocyte cultures for the final two hours of incubation. 
Subsequent testing of these supernates showed no reduction in 
antiviral activity (Table XVI), suggesting that the FeLV-induced 
impairment of anti-viral activity was a result of reduced IFN 
synthesis and not reduced IFN effectiveness caused by the presence of 
FeLV. 
Cat 
1276 
249 
Cat 
301 
301 
301 
TABLE XVI 
FeLV DOES NOT ALTER THE MITOGENIC PROPERTIES OF SEA OR THE ANTIVIRAL 
ACTIVITY OF SEA-STIMULATED LYMPHOCYTE SUPERNATES 
IFN (U/ml) 
Stock SEA 
550 
150 
No treatment 
123 
150 
138 
A. Treatment of SEA 
SEA after 
Incubation with FeLV 
727 
139 
B. Treatment of Culture Supernate 
Addition of 400 ~g FeLV 
80 
150 
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1--' 
.j::--
1.0 
150 
E. Discussion 
FeLV-mediated reduction in interferon synthesis in vitro may 
reflect clinically relevant impaired lymphocyte function in cats 
persistently infected with FeLV. Gamma interferon appears to occupy 
a pivotal regulatory position in cellular immune responses and has 
be~n shown to enhance human macrophage antimicrobial activity, as 
well as to augment cytotoxic and natural-killer cell activities and 
the expression of interleukin-2 receptors on T-cells (Kawase et al., 
1983) (Nathan et al., 1983) (Johnson & Farrar, 19838). Deficient 
synthesis of this lymphokine may be clinically relevant to the patho-
genesis of the state of immunodeficiency of FeLV infected cats. This 
finding 1s especially provocative in light of the proposed retrovira1 
etiology (HTLV-III) of the human acquired immunodeficiency syndrome 
(AIDS) (Marx, 1984) (Popovic et al., 1984) (Gallo et al., 1984) 
(Schupbach et al., 1984) (Jaffe et al., 1984). A recent study of 16 
patients with AIDS who had opportunistic infections showed that 
mononuclear cells from 11 of the 16 produced sub-normal amounts of 
gamma interferon in response to mitogen (Murray et al., 1984). 
Although this sub-normal synthesis of interferon may reflect a 
quantitative deficiency in the principal T-cell subset responsible 
for interferon synthesis, impaired interferon synthesis in the 11 
patients and substantial interferon synthesis in the other 5 could 
not necessarily be attributed with assurance to alterations in 
lymphocyte numbers. It is possible that in addition to or indepen-
dent of a reduction in IFN-synthesizing cells, the presence of 
immunosuppressive quantities of retrovirus at the cellular level may 
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markedly impair the synthesis of IFN and, perhaps, other lymphokines 
in vivo. The immunologic amplification attributable to these media-
tors would then be significantly ·reduced resulting in a diminution of 
functional immunity and an increased susceptibility of the patient to 
serious secondary illness. 
CHAPTER VII 
POLYCLONAL INDUCTION OF IMMUNOGLOBULIN SYNTHESIS 
BY FELINE LEUKOCYTES AS IDENTIFIED IN 
A REVERSE HEMOLYTIC PLAQUE ASSAY 
A. Summary 
Optimal conditions of culture and assay for identification of 
feline immunoglobulin secreting mononuclear cells were determined for 
the staphylococcal protein A-reverse hemolytic plaque assay (SpA-
RHPA). Hemolytic plaques were most distinct and numerous when 
peripheral blood mononuclear cells were stimulated with 6.9 g/ml 
pokeweed mitogen for seven days. Immunoglobulin secreting cells were, 
identified morphologically within a zone of hemolysis utilizing a 1:5 
dilution of rabbit anti-cat IgG and a 1:30 dilution of guinea pig 
complement as developing reagents. The SpA-RHPA system should con-
tribute to an understanding of normal feline T and B-lymphocyte 
interactions and will likely aid in the identification and under-
standing of immune cell dysfunctions associated with chronic feline 
leukemia virus infection. 
B. Introduction 
Cells secreting immunoglobulin (Ig) can be identified as hemo-
lytic plaque forming cells (PFC) in assays in which focal lysis in 
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the vicinity of the Ig-synthesizing cell is revealed in a field of 
erythrocytes after incubation with complement. A direct hemolytic 
PFC secretes IgM which either reacts specifically with determinants 
of naturally occuring sheep erythrocytic membrane antigens (Jerne & 
Nordin, 1963), or with a highly haptenated sheep erythrocytic 
membrane surface (Nespoli et al., 1979). Cells secreting low 
efficiency hemolysin (primarily IgG) are identified in the presence 
of optimal dilutions of anti-immunoglobulin and are termed indirect 
PFC (Dresser & Wortis, 1965; Fauci et al., 1980a). 
Cells secreting immunoglobulin of unknown specificity can be 
identified in a reverse hemolytic plaque assay (RHPA) in which the 
target erythrocyte is directly coated with anti-Ig by a chromium 
chloride method (Gold & Fudenberg, 1967; Molinaro & Dray, 1974; Eby 
et al., 1975). In the RHPA system, total or class specific immuno-
globulin production against multiple specificities can be measured by 
coating the target erythrocyte with an appropriate anti-immunoglobu-
lin reagent which binds immunoglobulin secreted by the PFC. A modi-
fication of the RHPA utilizes staphylococcal protein A (SpA), coupled 
to the erythrocytic membrane by chromium chloride treatment, which 
binds the constant fragment (Fe) of the anti-Ig which in turn binds 
the immunoglobulin secreted by the PFC (Gronowicz et al, 1976). In 
each assay, after incubation in the presence of complement, PFC in a 
field of erythrocytes are identified morphologically within a zone of 
hemolysis. 
The in vitro production of Ig subsequent to pokeweed mitogen 
(PWM) induced polyclonal lymphocyte activation is a function of 
opposing T-lymphocyte helper and suppressor influences (Fauci et al., 
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1980b; Pryjma et al., 1980a) and, under appropriate culture condi-
tions which limit cell to cell interactions, is apparently monocyte 
dependent (Rosenberg & Lipsky, 1979). These cellular interactions 
which regulate the generation of immunoglobulin can be evaluated 
using the protein A-reverse hemolytic plaque assay (SpA-RHPA). 
Domestic cats transmit horizontally a type C retrovirus (feline 
leukemia virus, FeLV) which can induce leukemia-lymphoma or a state 
of immunodeficiency in the chronically infected cat (Hardy, 1980a,b). 
Some FeLV-induced diseases have been proposed to serve as experi-
mental models of preleukemia, aplastic anemia and acute lymphoblastic 
leukemia of humans (Cotter & Essex, 1977; Maggio et al., 1978). A 
means of evaluating feline immune cell interactions has been needed, 
since understanding of retroviral-induced states of immunodeficiency 
and hematopoietic-lymphoreticular neoplasms neccessitates definition 
of helper and suppressor !-lymphocyte influences as well as functions 
of B-lymphocytes. 
Previous efforts in cats using the SpA-RHPA system failed to 
identify feline plaque forming cells using a one-step procedure where 
all developing reagents were added simultaneously (Langweiler, 1983). 
The present report describes for the first time the optimal culture 
and assay conditions for the demonstration of feline PFC using a two-
step SpA-RHPA procedure where developing antiserum, SpA-SRBC and 
mononuclear cells are mixed, plated then bathed in complement. 
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C. Material and Methods 
1. Culture Conditions 
Defibrinated whole blood was obtained by external jugular veni-
puncture from normal adult male and female cats ranging in age from 
2-6 years. Cats used were shown to be free of FeLV as demonstrated 
by the indirect immunofluorescent antibody test (IFA) for FeLV in 
leukocytes (Hardy et al., 1973b) (Antibodies Inc., Davis, CA) and the 
enzyme-linked immunosorbent assay (ELISA) for the detection of FeLV 
antigen in serum (Mia et al., 1981) (Pitman-Moore Inc., Washington 
Crossing, NJ). Mononuclear cell suspensions were derived from 
defibrinated blood by Ficoll-hypaque (Histopaque 1077; Sigma, 
St. Louis, MO) density centrifugation and washed three times in 
Hank's balanced salt solution without ca++ and Mg++ (incomplete 
HBSS; Gibco, Grand Island, NY). Cells were then adjusted to 1 X 
106/ml in Complete Medium (RPMI-1640 with L-glutamine (Gibco) 
supplemented with 10% heat inactivated and SRBC-absorbed fetal calf 
serum (FCS), 100 U/ml penicillin and 100 ~g/ml streptomycin). 
Stock pokeweed mitogen (Gibco) was suspended at 1450 ~g/ml, ali-
quoted in 500 ~1 quantities and frozen at -20°C. On the day of 
culture, stock PWM was diluted 1:5, 1:10 or 1:15 in Complete Medium. 
50 ~1 of the diluted PWM was placed at the bottom of 12 X 76 mm 
plastic culture tubes and followed by 1.0 ml of mononuclear cell 
suspens~on. Final PWM concentrations were 4.6 ~g/ml, 6.9 ~g/ml and 
13.8 ~g/ml. Tubes were loosely capped and incubated at 37°C in a 10% 
C02 humidified atmosphere for 3-8 days. 
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2. Coupling of SpA to SRBC 
Sheep blood was collected in citrate-phosphate-dextrose-adenine 
solution collection bags (Fenwal Labs, Deerfield, IL), kept at 4°C 
and used within 2 weeks. SRBC were washed five times with phosphate 
buffered saline (PBS; Gibco) and pelleted. One milliliter of staphy-
lococcal protein A (SpA; Pharmacia, Piscataway, NJ) stock solution at 
1.0 mg/ml was added to 4.0 ml of PBS and used to resuspend each 
milliliter of washed, packed SRBC. To this suspension, 5.0 ml of 6.0 
~g/ml CrC1 3 solution (J.T. Baker Co., Phillipsburg, NJ) at pH 5 was 
slowly added. The cellular suspension was then incubated in a 30°C 
water bath for 60 minutes with gentle inversion every 10 minutes. 
The labeled cells were washed twice with PBS, once with complete HBSS 
(with ca++ and Mg++) and resuspended to a 35-40% suspension in com-
plete HBSS. Labeled erythrocytes (SpA-SRBC) were kept at 4°C and 
used within 5 days. 
3. Assay for PFC 
After 3-8 days of incubation, supernate from each PWM-stimulated 
mononuclear cell culture tube was removed using a Pasteur pipet and 
discarded. The cellular pellet was suspended and washed twice with 
250 ~1 of complete HBSS. Supernate was decanted following the second 
wash leaving the cells suspended in 100 ~1 of complete HBSS. SpA-
SRBC were washed once and suspended to 35-40% in complete HBSS. 250 
mg of agarose (Sigma) in 50 ml of complete HBSS was brought to a boil 
with constant stirring. 500 ~1 of this agarose solution was added to 
individual 12 X 76 mm glass tubes in a 46°C water bath and allowed to 
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equilibrate. The IgG fraction of either goat anti-cat serum, goat 
anti-cat IgG, rabbit anti-cat serum or rabbit anti-cat IgG (Cappel, 
Cochranville, PA) was diluted 1:2, 1:5 or 1:10 in complete HBSS or 
used undiluted. 
Within a minimum amount of time, 25 ~1 of antiserum, 50 ~1 of 
35-40% SpA-SRBC and 100 ~1 of mononuclear cell suspension were added 
to a tube containing 500 ~1 of agarose kept at 46°C. The mixture was 
then spread over an agarose-coated slide and allowed to harden at 
room temperature. Slides were inverted onto a developing tray and 
flooded with complement diluted in complete HBSS. Complement sources 
tested included a 1:15, 1:20, 1:30, 1:40 or 1:80 dilution of SRBC-
absorbed guinea pig complement (GPC; Gibco), a 1:4, 1:8 or 1:16 
dilution of baby rabbit complement (RbC; Pel Freeze, Rogers, AR), or 
a 1:10, 1:20 or 1:40 dilution of fresh cat serum. 
Trays of slides were kept at 37°C until plaques were macroscopi-
cally visible, approximately 3-4 hours. The number of plaques per 
slide were counted at 10-40X magnification using a dissecting micro-
scope. The presence of a mononuclear cell (PFC) located centrally 
within an individual plaque was confirmed periodically using light 
m~croscopy. The number of plaques per slide are reported as PFC/106 
originally cultured mononuclear cells. 
In addition to performance in the SpA-RHPA system, the efficacy 
of different antisera and sources of complement to induce SpA-SRBC 
lysis was evaluated using 100 ~1 of a 1% SpA-SRBC suspension and 50 
~1 of 1.0 mg/ml cat IgG (Cappel) incubated 20 minutes at 37°C in 
glass tubes. Following two washes in complete HBSS, 100 ~1 of anti-
serum was added to the cat IgG-SpA-SRBC suspension and incubated at 
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37°C for 15 minutes. The supernate was then decanted to a 50 ~1 
volume and 50 ~1 of complement was added. Cat IgG-SpA-SRBC suspen-
sions were observed for agglutination and/or hemolysis. 
D. Results 
Optimal dilutions of appropriate developing reagents (antiserum 
and complement) were selected after testing for hemolysis of cat IgG-
SpA-SRBC cells in glass tubes and after evaluating for ability to 
demonstrate hemolytic PFC in the RHPA system (Table XVII). Lysis of 
cat IgG-sensitized SpA-SRBC was complete when the IgG fraction of 
rabbit anti-cat IgG serum and guinea pig complement were used as 
developing reagents. Other reagents produced only slight to mild 
lysis or were unable to lyse cat IgG-sensitized SpA-SRBC. A 1:30 
dilution of SRBC-absorbed guinea pig complement exhibited the least 
background hemolytic activity to washed SpA-SRBC and still aided ~n 
the complete hemolysis of cat IgG-sensitized SpA-SRBC as well as in 
the development of complete hemolytic plaques when used with rabbit 
anti-cat IgG serum in the RHPA system (Table XVII). The IgG fraction 
of rabbit anti-cat IgG serum diluted 1:5 was selected as the optimal 
antiserum based on similar criteria. Other dilutions and other 
complement sources either showed moderate to marked background hemo-
lytic activity to SpA-SRBC, were unable to lyse cat IgG-SpA-SRBC, or 
led to development of incompletely hemolyzed plaques in the RHPA 
system. 
In order to determine the optimal PWM concentration and time of 
mononuclear cell culture for the demonstration of PFC, cells from 
three cats were cultured in the presence of either 4.6, 6.9 or 13.8 
TABLE XVII 
EFFICACY OF SpA-RHPA DEVELOPING REAGENTS 
---------·---------------------· 
Method of 
evaluation 
Lysis of cat 
IgG-sensitized 
SpA-SRBC 
(tube method)* 
Development 
of hemolytic 
plaques in 
RHPA system:f: 
Complement 
source 
. . gu1.nea p1.g 
baby rabbit 
cat serum 
guinea pig 
goat 
anti-cat 
serum 
++ 
++ 
Source and specificity 
of antiserum (IgG fraction) 
goat 
anti-cat 
IgG 
+ 
·rabbit 
anti-cat 
serum 
++ 
rabbit 
anti-cat 
IgG 
++++ 
+ 
++++ 
*Goat anti-cat serum or IgG, rabbit anti-cat serum or IgG and three sources of complement, guinea pig, 
baby rabbit and fresh cat serum, were evaluated for ability to lyse cat IgG-treated SpA-SRBC. Hemolysis 
was judged slight (+) to complete (++++). - indicates no hemolysis. 
:f:The four antisera were evaluated for ability to develop hemolytic plaques with a 1:30 dilution of guinea 
pig complement in the SpA-RHPA system. Plaque development was judged slight (+) to complete (++++). 
indicates no hemolytic plaque development. 
1-' 
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~g/ml PWM for 3-8 days. PFC were not demonstrated in any animal 
after 3 or 4 days of incubation and rarely on day 8. Hemolytic 
plaques were most distinct and numerous, and varied least in number 
when developed in the RHPA system after 7 days of culture (Table 
XVIII). When mononuclear cells were stimulated with 4.6 ~g/ml PWM, 
the mean number of PFC identified increased slightly. Yet, when 
using PWM at this concentration, variability in the number of devel-
oped PFC also increased as evident in the larger standard deviation 
values (Table XVIII). Separate paired t-tests were used to compare 
the mean number of PFC produced when mononuclear cells were stimu-
lated with either 4.6 or 6.9 ~g/ml PWM. No significant difference in 
the number of PFC produced at either of these two PWM concentrations 
after 5, 6 or 7 days of culture was identified. 6.9 ~g/ml PWM was 
selected then as the optimal mitogen concentration since the number 
of PFC identified was relatively more consistent. 
Mononuclear cells from 16 cats were cultured ~n the presence of 
optimal (6.9 ~g/ml) and suboptimal (13.8 ~g/ml) PWM concentrations 
for 7 days. PFC were demonstrated using mononuclear cells from 15 of 
the 16 cats with considerable individual variation. The results from 
seven representative animals are listed in Table XIX. 
E. Discussion 
The protein A-reverse hemolytic plaque assay provides a means of 
evaluating both the capacity of B-lymphocytes to differentiate into 
immunoglobulin secreting cells and the roles of T-lymphocyte helper 
or suppressor influences on the induction of immunoglobulin synthesis 
and release (Fauci et al., 1980b: Pryjma et al., 1980a). Herein we 
TABLE XVIII 
PLAQUE FORMING CELLS IDENTIFIED AFTER 5, 6 OR 7 DAYS OF CULTURE* 
Cat Cat 
PWM lJg/ml IH225 IH279 
13.8 137 ± 91 ND 
Day 5 6.9 179 ± 45 79 ± 23 
4.6 224 ± 53 74 ± 25 
13.8 155 ± 26 ND 
Day 6 6.9 318 ± 68 128 ± 23 
4.6 367 ± 39 146 ± 52 
13.8 156 ± 31 ND 
Day 7 6.9 386 ± 50 133 ± 24 
4.6 415 ± 91 160 ± 52 
*Values represent the mean number of PFC/106 originally cultured mononuclear cells ± one standard 
deviation identified in four separate determinations. 
ND = not done. 
Cat 
1#!265 
ND 
112 ± 9 
128 ± 33 
ND 
269 ± 31 
297 ± 41 
ND 
276 ± 25 
274 ± 61 
....... 
"' ....... 
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TABLE XIX 
PLAQUE FORMING CELLS IDENTIFIED AFTER 7 DAYS OF CULTURE:F 
PWM JJg/ml 
Cat 6.9 13.8 
901 8 ± 7 10 ± 13 
902 256 ± 102 219 ± 83 
904 288 ± 98 187 ± 24 
905 204 ± 27 34 ± 23 
1276 800 ± 146 543 ± 165 
1278 49 ± 10 34 ± 24 
1284 0 0 
1480 183 ± 11 78 ± 7 
:I:Va1ues represent the mean number of PFC/106 originally cultured 
mononuclear cells ± one standard deviation identified in 4-6 sepa-
rate determinations. 
describe for the first time the optimal conditions of culture and 
assay for the feline SpA-RHPA system. Plaque forming cells were 
i 
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identified in cultures of 106 mononuclear cells stimulated with PWM 
after 5-7 days of incubation using the IgG fraction of rabbit anti-
cat IgG serum diluted 1:5 and guinea pig complement diluted 1:30 as 
developing reagents. No plaques were observed when mononuclear cells 
were assayed for PFC in the absence of antiserum. Considerable 
individual dispersion of the number of PFC is expected and has been 
demonstrated in the human SpA-RHPA system (Tauris, 1983a). Indivi-
dual PFC-nonresponsiveness (as in cat 1284) has in cultured human 
mononuclear cells been attributed to a high level of radiosensitive 
T-lymphocyte suppressor cell activity (Tauris, 1983b). 
In addition to being more sensitive than direct hemolytic plaque 
assays (Lanzavecchia et al., 1979), the SpA-RHPA system has the 
advantage of being able to enumerate and evaluate the function of 
cells that secrete a given class of Ig (Pryjma et al., 1980b) by 
us1ng immunoglobulin class specific developing antiserum. It has 
also been used to demonstrate excessive suppressor cell activity in 
patients with primary humoral immunodeficiencies (Herrod & Buckley, 
1979), and deficient helper T-cell activity in patients with chronic 
graft-versus-host disease following HLA-identical bone marrow trans-
plantation (Lum et al., 1981). 
The feline SpA-RHPA system should prove useful in evaluating 
normal feline cellular interactions that culminate in the release of 
immunoglobulin. In addition, it should aid in the identification and 
understanding of immune cell dysfunctions associated with chronic 
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retroviral (FeLV) infection that have been partially described using 
other methodologies (Hardy, 1982). 
CHAPTER VIII 
CHARACTERIZATION OF A NEWLY ESTABLISHED FELINE 
LYMPHOMA-DERIVED CELL LINE (BKD) LACKING 
T AND B CELL SURFACE MARKERS 
A. Summary 
A new feline lymphoma-derived cell line, designated BKD, was 
isolated from an anterior mediastinal tumor. Cells of this line were 
characterized as lymphoid based on morphology, the lack of intracel-
lular esterase and peroxidase activity and absence of phagocytic 
function. In contrast with other established feline lymphoma-derived 
cell lines, cells of the BKD line lack characteristics of both feline 
T-cells and B-cells in that they neither form rosettes with guinea 
pig erythrocytes or have demonstrable surface or cytoplasmic immuno-
globulin. Approximately one third of BKD cells form EAC rosettes, a 
significant number of rosette forming cells (p = 0.0001) when 
compared to background sheep E-rosetting activity. In addition, a 
consistently titratable level of interleukin-2-like activity was 
produced when BKD cells were co-incubated with concanavalin A and 
phorbol-12-myristate-13-acetate. Chromosome analysis showed that a 
majority of BKD cells are diploid. This new cell line has been 
continuously replicating in culture for over one year and produces 
feline leukemia virus as demonstrated by several analyses. 
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B. Introduction 
The feline leukemia v~rus (FeLV), a contagious retrovirus trans-
mitted primarily via salivary secretions, causes either neoplastic or 
non-neoplastic diseases in the chronically infected cat (Hardy, 
1980a). FeLV-associated disease includes leukemia-lymphoma, the most 
common feline neoplasm (Moulton, 1978), and a state of immunodefi-
ciency characterized by diminution of both cellular and humoral 
immunity (Hardy, 1982). 
Major feline lymphoid populations are defined by a set of 
surface markers and functional attributes. T-cells form spontaneaous 
rosettes with guinea pig erythrocytes (GPE), lack surface membrane 
and cytoplasmic immunoglobulin (Sig and Cig), and exhibit mitogenic 
responses to certain plant lectins, while B-cells synthesize immuno-
globulin, do not form GPE-rosettes, and may bear receptors for· 
complement or the constant fragment of IgG (Hardy, 1982) (Cockerell 
et al., 1976a) (Taylor et al., 1975a) (Mackey et al., 1975) (Rojko et 
al., 1982b). Yet when utilizing these methodologies, previously 
reported determinations have left between 20-64% of normal feline 
peripheral blood lymphocytes unclassified. Feline leukemia-lymphomas 
have been primarily classified based on the anatomical distribution 
of the tumor(s). Characterization of the neoplasms' cytoidentity has 
been limited to the identification of surface membrane markers (Hardy 
et al., 1977). 64% of all forms of feline lymphoma, and 73% of the 
more common multicentric and anterior mediastinal forms are comprised 
of cells that exhibit T-cell surface characteristics (Hardy et al., 
1977). In addition, all readily available feline lymphoma-derived 
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cell lines possess T-cell markers (Theilen et al., 1969) (Rickard et 
al., 1969) (Neil et al., 1984) (Grant et al., 1984) (Grant & 
Michalek, 1981). 
Feline lymphoma-derived cell lines have served as a source of 
FeLV and FeLV-infected transformed lymphoid cells for detection and 
characterization studies of FeLV-specified antigens and proposed 
transformation-associated cellular antigens (Theilen et al., 1969) 
(Rickard et al., 1969). Further, such cell lines have been invalu-
able ~n sera-epidemiological studies of the role of FeLV in develop-
ment of neoplastic and non-neoplastic disease (Grant & Michalek, 
1981) (Hardy, 1980b) (Grant et al., 1980), in studies of therapeutic 
development for assessing induction of anti-viral and anti-tumor 
activity ~n the treated cat (Liu et al., 1984a,b), and for analysis 
of molecular mechanisms involved ~n retroviral leukomogenesis (Neil 
et al., 1984). They have also served as a source of immunogen for 
development of monoclonal antibodies directed against viral derived 
antigens (Vedbrat et al., 1980) (Wang et al., 1983). 
Nearly all feline anterior mediastinal lymphomas are comprised 
of cells with T-cell surface characteristics and are thought to ar~se 
from T-cells of the thymus (Hardy, 1980a) (Hardy et al., 1977). 
Herein we describe a new feline lymphoma-derived cell line designated 
BKD which was isolated from an anterior mediastinal tumor. This cell 
line is comprised of lymphoid cells which actively replicate FeLV and 
which lack characteristics of both T-cells and B-cells. 
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C. Material and Methods 
1. Animals 
Clinically healthy kittens and adult cats free of FeLV as deter-
mined by the indirect immunoflourescent antibody (IFA) test for FeLV 
in leukocytes (Hardy et al., 1973b) (Antibodies Inc., Davis, CA) and 
the enzyme-linked immunosorbent assay (ELISA) for the detection of 
FeLV antigen in serum (Mia et al., 1981) (Pitman-Moore Inc, 
Washington Crossing, NJ) served as donors of normal peripheral blood 
mononuclear cells (PBM), thymocytes, and lymph node leukocytes. 
2. Cellular Preparations 
PBM were obtained by centrifugation of defibrinated whole blood 
over Ficoll-hypaque gradients (Sigma, St. Louis, MO). Thymuses and 
lymph nodes were collected aseptically, minced, and passed through a 
stainless steel screen to obtain single cell suspensions. The estab-
lished feline lymphoma-derived T-cell line FL-74 (Theilen et al., 
1969) was maintained at 37°C in a 10% C02 humidified atmosphere, in 
McCoy's SA medium supplemented with 15% fetal calf serum (FCS), 4 mM 
L-glutamine, 100 U/ml penicillin, and 100 ~g/ml streptomycin (Gibco, 
Grand Island, NY). Culture medium was changed every 3 or 4 days 
based on microscopic evidence of cellular proliferation. All cells 
were washed and adjusted to concentrations appropriate for assays as 
described below. 
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3. Establishment of the BKD Cell Line 
A two year old female mixed breed domestic cat with a clinical 
history of anorexia, dyspnea and FeLV infection died soon after 
presentation at the Oklahoma Medical Research Foundation on January 
20, 1984. At post mortem, a 3.5 x 4.0 x 6.5 em tumor occupied the 
anterior thoracic cavity and was adherent to the pericardia! sac and 
anterior lung lobes. A portion of the tumor was immediately removed 
and placed in RPMI-1640 medium (Gibco), minced and gently pushed 
through a stainless steel screen. The suspended cells were washed 
twice, adjusted to 1 X 106/ml in RPMI-1640 supplemented with 15% FCS, 
4 mM L-glutamine, 100 U/ml penicillin, 100 ~g/ml streptomycin, 250 
ng/ml fungizone (Gibco) and 5 X 10-SM 2-mercaptoethanol (Eastman-
Kodak, Rochester, NY), and maintained at 37°C in a 10% C02 humidified 
atmosphere. Counts of total cells cultured and the percent viable 
were determined by the vital dye exclusion method. Culture medium 
was changed every 3 or 4 days based on microscopic evidence of 
cellular proliferation. FeLV infection of the cultured cells was 
periodically documented using the IFA test. Twofold dilutions of the 
culture supernatant were periodically screened for FeLV antigens 
using the ELISA procedure. 
4. E-Rosette Assays 
Heparinized guinea pig or rat blood was collected by cardiac 
puncture. Sheep blood was collected in citrate-phosphate-dextrose-
adenine solution collection bags (Fenwal Laboratories, Deerfield, IL) 
by external jugular venipuncture. Erythrocytes were packed, washed 
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three times with phosphate buffered saline (PBS; Gibco), once with 
RPMI-1640 (Gibco), and resuspended to 5%. 0.2 ml of Vibrio cho1erae-
derived neuraminadase (Calbiochem-Behring Corp., La Jolla, CA) at 50 
units/ml was added for each ml of the 5% erythrocyte suspension and 
incubated at 37°C for 60 minutes with inversion once every 15 
minutes. The erythrocytes were then washed twice in RPMI-1640, once 
in RPMI-1640 supplemented with 10% FCS, and adjusted to 1%. 
Neuraminadase-treated erythrocytes were stored at 4°C and used within 
2 days. 
Guinea pig erythrocytes (GPE) were also treated separately with 
0.143 M aminoethylisothiourium bromide (AET; Sigma, St. Louis, MO) 
according to the methods previously described (Rojko et al., 1982b) 
(Kaplan & Clark, 1974) with minor modification. After AET treatment 
and incubation, the erythrocytes were resuspended in RPMI-1640 
supplemented with 10% FCS and adjusted to 1%. 
For E-rosette assays, thymic, peripheral blood, FL-74 and BKD 
cells were washed twice in RPMI-1640, once in 10% FCS supplemented 
RPMI-1640 and adjusted to 2.5 X 106/ml. 100 ~1 of a 1% suspension of 
either neuraminadase or AET treated guinea pig erythrocytes (GPE-N, 
GPE-AET), rat erythrocytes (RE-N), or untreated sheep erythrocytes 
(SRBC) were added to 100 ~1 of cells in 10 X 75 mm glass tubes 
(Fischer Scientific, Pittsburg, PA), centrifuged at 200 X g for 5 
minutes and left on ice for 60 minutes. In the case of SRBC, cellu-
lar mixtures were handled as in EA and EAC rosetting assays, were 
kept in unsupplemented RPMI-1640 and were incubated at 37°C for 30 
minutes (see below). 150 ~1 of the supernate was then removed and 
the cellular pellet gently resuspended. 150 ~1 of 0.01% Gentian 
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violet in 0.15 M NaCl (J.T. Baker Co., Phillipsburg, NJ) was added 
and a minimum of 200 viable cells were counted. A rosette forming 
cell (RFC) was defined as a viable mononuclear cell with three or 
more attached erythrocytes. 
5. EA-rosette Assays 
Equal volumes of washed SRBC adjusted to 5% in RPMI-1640 and 
either the 7s(IgG) or 19s(IgM) fraction of anti-sheep erythrocyte 
serum (Cordis Labs, Miami, FL) diluted to the maximum subagglutina-
ting titer (1:2560 for 7s, and 1:160 for 19s) were mixed and incuba-
ted at 37°C for 30 minutes. Following incubation the SRBC were 
washed three times, adjusted to a I% suspension in RPMI-1640, stored 
at 4°C and used within 2 days. 
Cells were washed three times and adjusted to 4.0 X 106/ml in 
RPMI-1640. 100 ~1 of 7sEA or 19sEA suspension were added to 100 ~1 
of cells, pelleted at 200 X g for 5 minutes, incubated at 37°C for 30 
minutes, gently resuspended, stained and quantitated. 
6. EAC-rosette Assays 
Equal volumes of sheep 19sEA cells adjusted to 5% in RPMI-1640 
and a 1:10 dilution of fresh mouse serum were mixed, incubated at 
37°C for 30 minutes, then washed three times and adjusted to a 1% 
suspension. EAC complexed cells were then mixed with cells to be 
tested, and evaluated as in the EA-rosette assay above. 
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7. Demonstration of Surface or Cytoplasmic Immunoglobulin 
For the demonstration of Sig, cells were washed three times and 
adjusted to 8.0 X 106/ml in Hank's balanced salt solution (HBSS; 
Gibco). 50 ~1 of the cellular suspensions were added to individual 
wells of a 96-microwell plate and mixed with 50 ~1 of the IgG 
fraction of a rabbit anti-cat IgG serum (Cappel Labs, Cochranville, 
PA) diluted 1:20 in HBSS. Microwell plates were then left on ice for 
30 minutes. Cellular pellets were washed three times with 250 ~1 of 
FA buffer (Difco, Detroit, MI), then mixed with 50 ~1 of flourescein-
conjugated goat anti-rabbit immunoglobulin (Cappel) diluted 1:20 in 
HBSS. Plates were left on ice for 30 minutes. Pellets were then 
washed three times with FA buffer, resuspended and evaluated for 
membrane flourescence. 
For the demonstration of cytoplasmic immunoglobulin, cytocentri-
fuge cellular preparations were fixed in 5% glacial acetic acid-95% 
methanol at -20°C for 5 minutes, washed three times in PBS, and 
stained with the reagents used to demonstrate surface membrane 
immunoglobulin. 
8. Assay for "Phagocytic Activity 
Cells were washed three times and adjusted to 2.0 X 106/ml in 
HBSS. 100 ~1 of 0.81 ~m diameter latex beads (Difco) diluted 1:50 
was added to 1.0 ml of cellular suspension. The mixture was incuba-
ted at 37°C for 60 minutes with continuous rotation (Multipurpose 
rotator, Scientific Industries, Springfield, MA). Cells were washed 
three times with HBSS, then evaluated with the aid of a hemocyto-
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meter. Cells ingesting three or more latex beads were considered 
positive. Contaminating monocytes in PBM preparations were used as 
control. 
9. Cytochemical Analysis 
Cytocentrifuge cellular preparations were evaluated for intra-
cellular chloracetate esterase, nonspecific esterase (with and 
without sodium fluoride), peroxidase, and acid phosphatase enzymatic 
sites using described methods (Yam et al., 1977) (Wachstein & Wolf, 
1977) (Bennett, 1977). Additional cytocentrifuge preparations were 
stained with periodic acid Schiff and Wright's-Giemsa stains. 
Electron micrographs of FL-74 and BKD cells were kindly provided 
by S.H. Chang at the University of Maryland School of Medicine, 
Department of Pathology. 
10. Chromosome Analysis 
Chromosome analysis of the BKD cell line was performed us~ng 
previously described methods with minor modification (Moorhead et 
al., 1960). Ten milliliters of BKD cells were adjusted to 1.0 X 
107/ml. 0.4 ~g of colchicine (Sigma) was added per milliliter of 
cellular suspension and incubated for three hours at 37°C. Cells 
were then pelleted, the supernate discarded, and cells were resus-
pended in 5 ml of 0.075 M KCl solution. After twenty minutes of 
incubation at 37°C, the cells were again pelleted and resuspended in 
1.0 ml of 0.075 M KCl. A fixative solution consisting of one volume 
glacial acetic acid and three volumes of methanol was then added 
dropwise to a final volume of 5 ml. After 15 minutes of incubation 
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at room temperature, the process of fixation was repeated this time 
to a final volume of 2 ml. Smears of this suspension were heat fixed 
and stained with Giemsa. Approximately 100 groups of spread chromo-
somes were evaluated for number and morphology, and compared to the 
normal feline karyotype (Hsu & Rearden, 1965). 
11. Induction and Assay for Interleukin-2-like Activity 
The induction and analysis for interleukin-2-like (IL-2-like) 
activity by BKD cells was performed using previously described 
methods (Farrar et al., 1980). FL-74 and BKD cells were adjusted to 
a concentration of 2.5 X 106/ml and cultured in 16 mm wells with 4, 8 
or 16 ~g/ml concanavalin A (con A; Pharmacia, Piscataway, NJ) or with 
con A and 10 ng/ml phorbol-12-myristate-13-acetate (PMA; P.L. 
Biochemicals, Milwaukee, WI) added. Cell free supernates were 
collected after 24 hour incubation at 37°C and filtered through 0.45 
~m filters. Supernates were assayed for IL-2-like activity using the 
IL-2 dependent cell line, HT-2 (Watson, 1979). Serial twofold dilu-
tions of supernates, or a murine IL-2 standard (123 U), were added to 
triplicate wells containing 5 X 104 HT-2 cells. Following incubation 
at 37°C for twenty hours, 1.0 ~Ci of 3H-thymidine was added to each 
well and incubation continued for an additional four hours. Cells 
were harvested and the incorporation of 3H-thymidine determined by 
liquid scintilation counting. 
12. Induction and Assay for Interferon 
The induction and analysis for antiviral activity in supernatant 
fluids from cultures of BKD cells stimulated with Staphylococcous 
enterotoxin A were performed using previously described methods 
without modification (Engelman et al.: 1985c) (Liu et al., 
1984b). 
D. Results 
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During the first month of isolation, cultured BKD cells varied 
in viability between 60-90%. When viability was less than 60%, dead 
cells were removed by centrifugation of cultured cellular suspensions 
over ficoll-hypaque gradients. Four months following the initial 
isolation, BKD cell viabilities exceeded 90%. Periodically, ampules 
containing between 1.0 X 107 - 2.0 X 107 cells/ml were stored in 
liquid nitrogen after being frozen in 10% dimethylsulfoxide and 90% 
FCS. When ampules were thawed at 37°C, BKD cells were readily re-
established in culture. Under our culture conditions, cell doubling 
time for the FL-74 line ranged between 36-72 hours, while cultured 
BKD cells doubled in number after 72-120 hours of incubation. Both 
cell lines were always positive for FeLV by IFA and ELISA. 
1. Morphological and Cytochemical Analysis 
Morphologically, the FL-74 cells were typically lymphoid. BKD 
cells grew singly or in aggregates, measured approximately 12-16 ~m 
in diameter and possessed an oval to deeply-indented nucleus and one 
or more prominent nucleoli (Figure 31). Cytochemical stains for 
intracellular enzymatic sites were all negative in both BKD and FL-74 
cell preparations, except for a moderate, diffuse cytoplasmic posi-
tive reaction for acid phosphatase 
Figure 31: Light photomicrograph of lymphoid cells of the BKD cell 
line showing the variation in nuclear morphology from oval to deeply 
indented. One or more prominent nucleoli are present within each 
cell nucleus (Wright-Giemsa, X2000). 
Figure 32 Electron photomicrograph of type-C v1rus particles bud-
ding from and neighboring the plasma membrane of two BKD cells 
(Xl7000). 
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Figure 31 
Figure 32 
Figure 33: Chromosome analysis of the BKD cells showed that 88% 
possess a karyotype of 36+XX; diploid for this species. 
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Electron micrographs of BKD cells taken on the second day of 
culture demonstrated type-C virus particles adjacent to and budding 
from the plasma membrane of the cultured cells (Figure 32). Greater 
numbers of virus particles were evident in electron micrographs of 
cells of the established FL-74 cell line. 
2. Chromosomal Analysis 
The number of BKD cellular chromosomes ranged from 31+XX to 
37+XX, with 88% of the evaluated cells possessing 36+XX chromosomes 
(Figure 33). Thus, the majority of cells of this line are 
diploid. 
3. Induction and Assay for Interleukin-2-like Activity 
The induced production of interleukin-2-like activity was 
studied using both FL-74 and BKD cells. IL-2-like activity, measured 
by the IL-2 dependent proliferation of HT-2 cells, was not detectable 
when either cell line was cultured with con A alone. Induced IL-2-
like activity, however, was enhanced only with BKD cells when the 
cells of this line had been stimulated with both con A and PMA (Table 
XX). Although the induced HT-2 proliferation achieved with superna-
tants of BKD cells resulted in an approximately 10-fold less stimula-
tion than was achieved with a standard supernatant obtained from con 
A stimulated murine splenic leukocytes, this BKD-induced IL-2-like 
activity was consistently titratable (on eight seperate occasions). 
By contrast, FL-74 cells did not produce any IL-2-like activity after 
comparable stimulation. 
Dilution of 
Supernatant 
1:2 
1:4 
1:8 
1:2 
1:4 
1:8 
TABLE XX 
INDUCED INTERLEUKIN-2-LIKE ACTIVITY IN BKD CELL CULTURE SUPERNATANTS 
HT-2 Cell Proliferation (cpm) 
BKD Cell Cultures (2.5 x 106/ml) 
PMA Con A (J.tg/ml) 
10 ng/ml 0 4 8 
450 498 240 
352 420 286 
400 314 450 
+ 426 6052 5700 
+ 412 2452 1975 
+ 485 290 410 
16 
684 
400 
421 
3838 
1072 
358 
f-' 
00 
f-' 
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4. Induction and Assay for Interferon 
Supernatant fluids from separate cultures of PBM and BKD cells 
stimulated with Staphylococcous enterotoxin A were evaluated for 
antiviral activity on two occasions. Although interferon activity 
was present in supernates from PBM cultures, no antiviral activity 
was induced in cultures of BKD cells (data not shown). 
5. E-Rosette Formation 
Normal feline thymocytes, peripheral blood mononuclear cells, 
and cells from the FL-74 and BKD cell lines were next evaluated for 
ability to form E-rosettes with either neuraminadase-treated or AET-
treated guinea pig or rat erythrocytes. As shown in Table XXI, 
approximately 76% of thymocytes, 24% of PBM, and 79% of FL-74 cells 
formed spontaneous rosettes with GPE-N. These values are consistent 
with previously reported determinations. Fewer rosettes were formed 
with each of the cellular preparations when GPE-AET or RE-N were 
used. In no instance did cells from the BKD cell line form rosettes 
with GPE-N, GPE-AET or RE-N. During the rosetting assay, BKD cells 
did show a tendency to aggregate in small clumps, the size and number 
of which increased moderately when medium with increased FCS 
concentration was used. These clumps occasionally included small 
numbers of erythrocytes. True BKD E-rosettes were never 
identified. 
TABLE XXI 
CELL MARKER AND FUNCTIONAL ASSAYS 
Thymocytes PBM FL-74 BKD 
GPE-N 76 ± 5 24 ± 6 79 ± 5 0.0 
GPE-AET ND 14 ± 3 30 ± 4 0.0 
RE-N 45 ± 2 15 ± 1 0.0 0.0 
Sig <1 24 ± 4 <1 <I 
Cig ND +(LN)* <1 <1 
Ph ago ND +(M):J: 0.0 0.0 
Acid Phos ND ND + + 
IFA-FeLV - - + + 
ELISA-FeLV -- - + + 
Normal feline thymocytes and peripheral blood mononuclear cells (PBM) and cells of the FL-74 and BKD cell 
lines were evaluated for E-rosette forming cells using neuraminadase or AET-treated guinea pig erthrocytes 
(GPE-N, GPE-AET) or neuraminadase-treated rat erythrocytes (RE-N), for surface and cytoplasmic 
immunoglobulin (Sig, Cig) for phagocytic function (Phago), for acid phosphatase enzymatic activity (Acid 
Phos), and for the presence of feline leukemia virus (FeLV). Values represent the mean± one standard 
deviation of 4-8 separate determinations. 
*Cytocentrifuge lymph node (LN) leukocytic preparations served as positive control for cytoplasmic immuno-
globulin assays. 
=!=Contaminating monocytes (M) in PBM preparations served as positive control for phagocytic functional 
assays. 
f-0 
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TABLE XXII 
ASSAYS FOR CELL Fe AND COMPLEMENT RECEPTORS 
-------
Thymocytes PBM FL-74 BKD 
SRBC ND 0.0 10 ± 3 10 ± 4 
7sEA 3 ± 1 17 ± 6 14 ± 7 21 ± 6 
19sEA 0.0 1 ± 1 14 ± 5 13± 1 
EAC 2 ± 1 21 ± 5 16 ± 6 35 ± 11 
Normal feline thymocytes and peripheral blood mononuclear cells (PBM) and cells of the FL-74 and BKD cell 
lines were evaluated forE-rosette forming cells using sheep erythrocytes (SRBC), for 7sEA and 19sEA-
rosette forming cells, and for EAC-rosette forming cells. Values represent the mean± one standard 
deviation of 4-12 separate determinations. 
....... 
00 
.t:--
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6. Studies of Surface Immunoglobulin and Phagocytic Activity 
The results of determinations for Sig, and Cig and phagocytic 
function are also presented in Table XXI. Cells from both the FL-74 
and BKD lines were negative for Sig, Cig, and the ability to ingest 
latex particles. 
7. EA and EAC-Rosette Formation 
Table XXII presents data concerning 7sEA, 19sEA and EAC rosette 
forming cells in thymocyte, PBM, FL-74 and BKD cellular preparations. 
Untreated, washed SRBC were handled 1n an identical manner as EA and 
EAC complexed cells with incubation at 37°C for 30 minutes prior to 
resuspension and evaluation. As shown in Table XXII, washed SRBC did 
not form rosettes with normal PBM but did form rosettes with approxL-
mately 10% of either FL-74 or BKD cells. Little variation was noted 
from this background E-rosetting activity when FL-74 cells were incu-
bated with 7sEA, 19sEA or EAC complexed erythrocytes. In contrast, a 
significant three fold increase (p = 0.0001) in rosette forming cells 
from background E-rosetting activity was seen when BKD cells were 
mixed with EAC complexed cells in twelve experiments. When SRBC in 
Alsever's solution (Gibco) were used in two experiments, however, no 
E, EA or EAC rosette forming cells were demonstrated. 
E. Discussion 
Two well established feline lymphoma-derived cell lines, FL-74 
and F422 (Theilen et al., 1969) (Rickard et al., 1969), and other 
incompletely described feline lymphoma cell isolates that are presum-
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ably maintained as continuously replicating cell lines (3272, 3281, 
79-14940, 3191, 3201B and T3) (Neil et al., 1984) (Grant et al., 
1984) (Grant & Michalek, 1981) serve as resource for FeLV and FeLV-
infected transformed cells, and are all comprised of lymphoid cells 
bearing T-cell surface markers. To the best of our knowledge, the 
BKD cell line represents the first FeLV-producing feline lyphoma-
derived cell line that lacks both demonstrable surface or cytoplasmic 
immunoglobulin and ability to form rosettes with guinea pig or rat 
erythrocytes. Approximately 6% of feline lymphomas are comprised of 
cells lacking both T and B-cell characteristics (Hardy et al., 
1977). 
The possibility that the BKD cell line was derived from myeloid 
or monocytic cells was investigated because of the BKD cell's hetero-
genous nuclear morphology (oval to deeply-indented). The lack of 
phagocytic activity and absence of chloracetate esterase, non-speci-
fic esterase and peroxidase enzymatic activity, and the negative 
results with periodic acid Schiff stain suggests that the BKD cell 
line was derived from lineages other than the myelo-monocytic. 
Approximately 100 groups of spread chromosomes from BKD cells 
were evaluated for number and morphology. 88% of the BKD cells 
evaluated possessed a karyotype of 36+XX chromosomes which is consis-
tent with the normal feline karyotype (Hsu & Rearden, 1965). Thus, a 
majority of the cells of this new line are diploid. 
Several reports have described murine, primate or human leuke-
mias which when exposed to mitogens secrete interleukin-2 in high 
titer (Grant et al., 1984) (Friedman et al., 1982) (Rabin et al., 
1981). None of the feline lymphoma cell lines previously tested 
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secrete IL-2 after addition of mitogen (Grant et al., 1984). Consis-
tently titratable amounts of IL-2-like activity was produced only by 
BKD cells when coincubated with PMA and con A suggesting that at 
least a small subpopulation of BKD cells are IL-2 producers or that 
cells of this line can produce small amounts of IL-2. An alterna-
tive possibility is that feline IL-2 is produced by cells of this 
line in larger amounts than is apparent ~n the assay, but that IL-2 
of feline origin is less effective than either mouse or human IL-2 ~n 
promoting proliferation of HT-2 cells. Observations with normal 
feline PBM which also produced relatively low IL-2-like activity 
indicates that the latter possibility is likely the correct one. 
Further subcloning of these cells in order to establish a subline for 
use in the production and characterization of higher titer feline IL-
2 is currently underway in this laboratory. 
Less than 1% of normal feline PBM form rosettes with sheep 
erythrocytes (Taylor et al., 1975a). In a previous report, cells of 
the FL-74 cell line did not form EAC rosettes (Cockerell et al., 
1976a). It seems likely that the observed rosette formation between 
FL-74 and SRBC, EA or EAC cells seen in our study represents a 
nonspecific interaction between cells since the percent of FL-74 
cells that formed rosettes in each assay was approximately 10-15%. 
However, the threefold increase in BKD rosette forming cells when EAC 
are substituted for SRBC may indicate the presence of a membrane 
receptor for complement on BKD cells. This data was evaluated using 
an analysis of variance with Duncan's multiple comparison test. The 
mean number of BKD rosette forming cells identified with EAC was 
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significantly greater (p = 0.0001) than the BKD background sheep E-
rosetting activity. 
Further characterizations of this surface immunoglobulin-nega-
tive and E-rosette-negative lymphoma-derived cell line are currently 
underway but beyond the scope of this paper. In addition to a 
usefulness in feline leukemia-lymphoma and feline leukemia virus 
research, this new cell line may prove valuable in defining that 
portion of feline lymphocytes and lymphomas which as yet remain 
undefined and unclassified. 
CHAPTER IX 
PRELIMINARY DEVELOPMENT OF MONOCLONAL ANTIBODIES WHICH 
DEFINE FELINE T-LYMPHOCYTE HETEROGENEITY 
A. Introduction 
A family of human retroviruses, the human T-lymphotropic viruses 
(HTLV), which share a tropism forT-lymphocytes and Unpair T-cell 
function have been identified during the last seven years (Gallo, 
1984) (Popovic, et al., 1984). Though viruses of this group have 
common morphological and genomic properties, they have been linked to 
two diseases of opposite manifestation (Wong-Stall and Gallo, 1985). 
Apparently, HTLV-I is the etiologic agent of adult T-cell leukemia 
(ATL) and HTLV-III is the etiologic agent of the acquired hmmunodefi-
ciency syndrome (AIDS) (Gallo, 1984) (Popovic, et al., 1984) (Wong-
Stall and Gallo, 1985). 
Numerous animal retroviruses have served as precedents for the 
HTLV family. Though retroviruses of other species are considered 
more closely homologous in genomic structure and virion morphology to 
the HTLV isolates, the leukemia immunodeficiency inducing viruses of 
the cat (feline leukemia viruses, FeLV) are uniquely appropriate for 
study as a clinical model of HTLV associated leukemia and immunodefi-
ciency (Derse et al., 1985) (Gonda et al., 1985). Like HTLV, FeLV is 
transmitted horizontally and is responsible for inducing either the 
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malignant proliferation of lymphocytes or the development of 
lymphocytic abnormalities and immunodeficiency (Hardy, 1980). Iso-
lates of the FeLV family have been attributed with lymphoprolifera-
tive, cytopathic, lymphosuppressive and anemigenic effects (Rojko and 
Olsen, 1984). The feline retroviral model is considered a useful 
clinical reflection of human acute lymphoblastic leukemia (Cotter and 
Essex, 1977), aplastic anemia, states of immunodeficiency and preleu-
kemia (Maggio, et al., 1978) (Sarngadharan, et al., 1984). It has 
served in the evaluation of new forms of cancer immunotherapy 
(Engelman, et al., 1985d) (Liu, et al., 1984a,b) (Snyder, et al., 
1984) and has contributed to an understanding of the molecular 
mechanisms of retroviral induced leukemogenesis (Neil, et al., 
1984). 
A major impairment of the elucidation of leukomogenesis 1n the 
cat has been the lack of understanding of feline immune cell regula-
tory and effector mechanisms due to an inability to define normal 
feline lymphoid cell populations. Although heteroantisera, Fe recep-
tor binding and erythrocyte resetting have been used to describe 
major feline lymphocyte populations, precise delineation of feline 
immunoregulatory and effector cells has not yet been possible (Rojko, 
et al., 1982) (Taylor, et al., 1975). In addition, feline leukemia-
lymphomas have been classified based only on the anatomical distribu-
tion of the tumor(s) and on the predominant cellular morphology 
present (Hardy, 1980). 
It has been suggested that a state of immunodeficiency, though a 
frequent sequelae of retroviremia independent of the development of 
malignancy, may also precede and allow for the rare development of 
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detectable lymphoid malignancies in the FeLV infected cat, and that 
this preiod of deficient immunity is T-cell specific (Rojko and 
Olsen, 1984). However, because of the absence of appropriate 
technology the nature of the T-cell defect as well as the cytoiden-
tity of the subsequent neoplasms have yet to be clearly defined. 
Cats with retroviremia manifest delays in skin allograft rejection 
decreased in vitro lymphocyte proliferation to mitogen and antigen 
(Cockerell. et al., 1976) and reduced antibody responses to aT-cell 
specific synthetic polypeptide (Trainin, et al., 1983). Addition-
ally, purified UV-inactivated FeLV and certain FeLV envelope proteins 
(pl5E) have been shown to impair normal lymphocyte in vitro prolifer-
ation to mitogen (Mathes, et al., 1979), the synthesis of gamma 
interferon (Engelman, et al., 1985c), and in human and murine systems 
of assay have been shown to suppress the generation of interleukin-2 
(IL-2) (Yorosz, et al., 1985) (Wainberg, et al., 1983). Whether 
these abnormalities are due to alterations in cell number within a 
given lymphocyte subset, or to qualitative functional abnormalities 
of the subset, or are related to the multiple intercurrent infectious 
and immune mediated diseases that develop in the cat with retro-
viremia is not known. 
In order to aid in the identification of quantitative and quali-
tative aberrations in specific subsets of T-lymphocytes in the cat 
with retroviremia, immunodeficiency, and leukemia, monoclonal anti-
bodies which will characterize T-cell subpopulations by their pattern 
of reactivity with lymphoid cell surface antigens will be developed. 
A panel of monoclonal antibodies which describe T-cell surface pheno-
type heterogeneity will aid in the identification of thymocytic 
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differential and maturational stages. Coupled with appropriate 
immunological assays, monoclonal antibodies of this specificity will 
contribute to the definition of T-cell functional subsets, and 
provide the foundation for defining and subclassifying feline lympho-
cyte disorders such as leukemia, lymphoma, autoimmunity and immuno-
suppression. Accurate identification of the cell lineage and stage 
of differentiation of leukemia cells will also be possible. 
B. Material and Methods 
1. Animals 
Clinically healthy kittens and adult cats free of FeLV as deter-
mined by the indirect immunofluorescent antibody (IFA) test for FeLV 
in leukocytes (Hardy, et al., 1973) (Antibodies Inc., Davis, CA) and 
the enzyme linked immunosorbent assay (ELISA) for the detection of 
FeLV antigen in serum (Mia, et al., 1981) (Pitmann-Moore, Inc., 
Washington Crossing, NJ) served as donors of normal peripheral blood 
lymphocytes (PBL), thymocytes, bone marrow, splenic and lymph node 
leukocytes. Five to six week old Balb/c mice served as hosts for the 
immunogens. 
2. Cells and cell lines 
Single cell suspensions were obtained by the centrifugation of 
defibrinated whole blood over Ficoll-hypaque gradients (Sigma, St. 
Louis Mo), and by the mincing and passage of lymphoid parenchymal 
tissues through a stainless steel screen. Counts of total cells and 
the percent viable were determined by the vital dye exclusion 
method. 
3. Immunization 
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Balb/c m~ce were injected intraperitoneally (IP) with 2 x 107 
feline thymocytes or nylon-wool filtered PBL. Two to five immuniza-
tions, 2-3 weeks apart were administered. Two days following the 
last immunization, mice were selected based on their plasma level of 
anti-cat thymocyte antibodies as detected in a micro-well IFA test. 
Immunofluorescent preparations were scored with a Leitz (Dialux 20) 
microscope under epi-illumination. 
4. Fusion 
Spleenocyte-myeloma fusion protocols originally described by 
Kohler and Milstein were followed (1976). Spleens from selected 
immunized mice were collected aseptically and dispersed into single 
cell suspensions. Spleenocytes were suspended in maintenance medium 
consisting of Dulbecco's Modified Eagle's Medium with glucose and L-
glutamine (Gibco, Grand Island, NY) and supplemented with 20% heat 
inactivated fetal calf serum (FCS), 100 mM sodium pyruvate, 200 mM L-
glutamine and 10,000 U/ml penicillin-streptomycin. Prior to fusion, 
sp2/0 myeloma cells were grown in maintenance medium with 0.13 mM 8-
azaguanine. 
For fusion, 108 spleenocytes were mixed with 2 x 107 sp2/0 cells 
in the presence of 45% polyethylene glycol 1000 (Sigma). After wash-
ing, the cells were resuspended in medium containing 10% NCTC 109 
medium (M.A. Bioproducts), 0.15 mg/ml oxaloacetate, 0.2 U/ml bovine 
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insulin, 13.6 ~g/ml hypoxanthine and 3.78 ~g/ml thymidine (referred 
to as hybridoma medium HY-HT). Approximately 2 x 105 cells in 50 ~1 
were placed in flat-bottom wells of 96 well plates. After 24 hours, 
the cells received 150 ~1 of selection medium (HY-HAT) containing 0.8 
uM aminopterin. Medium was aspirated and replaced with fresh HY-HAT 
medium on several occasions over a 2-4 week period prior to screening 
hybridoma supernatants for anti-cat thymocyte antibody. 
5. Screening by FACS analysis 
4 x 105 cells were incubated with 50 ~1 of supernatant for 30 
minutes on ice. After two washes with RPMI-1640 (Gibco) with 5% FCS, 
the cells were treated with 10 ~1 of fluorescein-conjugated goat 
anti-mouse kappa light chain or a fluorescein-conjugated goat anti-
mouse IgG, M, A heavy chains sera and incubated on ice for 30 
minutes. After three washes, positive staining were assessed on a 
EPICS V (Coulter, Hialeah, FL) by comparing cells treated with 
culture supernatant or rabbit anti-cat thymocyte serum and second 
antibody, or second antibody alone. 
6. Establishment of hybridoma clones 
Hybridomas secreting antibodies which bind to feline T-lineage 
lymphocytes were gradually adapted to larger culture volumes in main-
tenance medium. Hybridoma lines were subcloned by limiting dilution 
and retested by flow microfluometry. Clones and subclones were 
frozen in 90% FCS and 10% dimethylsulfoxide (DMSO, Sigma) and stored 
in liquid nitrogen. 
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7. Complement mediated microcytotoxity 
2.5 x lOS cells and 25 ul of supernatant were incubated on ice 
for 30 minutes. After washing, 50 ul of 1:15 diluted guinea pig 
complement (Gibco) was added and the cellular mixture incubated at 
37° C for 45 minutes. Cell viability was determined by the exclusion 
of vital dye. 
8. Preparation of monoclonal antibodies 
Supernatants were concentrated by precipitating overnight at 4~ 
C with 40% saturated ammonium sulfate solution. Precipitates were 
pelleted at 48.000 x g for 30 minutes, resuspended and dialyzed 
extensively with 0.1 M PBS, and stored at -70° C. Hybridoma-derived 
ascites were produced by inoculating 5-10 x 106 cells IP into Balb/c 
mice primed 10 days to 3 weeks previously with 0.5 ml of pristane 
(Aldrich Chemical Inc.). The ascites fluid was drained, clarified 
and stored at -70° C. 
C. Results 
Six fusions of sp2/0 myeloma cells and spleenocytes from 
immunized mice resulting in 866 hybridomas have thus far been com-
pleted. Two spleens were from mice immunized first with nylon-wool 
filtered PBL and second with thymocytes. The other four spleens were 
derived from mice receiving 2-5 IP injections of thymocytes. Spleen-
ocytes from mice immunized by the second immunization protocol, when 
fused with sp2/0 myeloma cells resulted in the greatest number of 
hybridomas. Supernatant fluids from these 866 hybridomas were 
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screened for reactivity with thymocytes by indirect immunofluores-
cense and flow microfluorometry and some have been evaluated for 
thymocytolytic activity. 120, or 13% of the 866 supernatant fluids 
from wells with growth reacted with between 10% and 96% thymocytes 
with all levels of reactivity represented. Thymocytolytic activity 
has been demonstrated in some of the supernatants with between 10% 
and 46% of thymocytes being killed as determined by the inclusion of 
vital dye. In addition, the supernatant fluids from the 866 
hybridomas were screened for reactivity with peripheral blood lympho-
cytes by indirect immunofluorescence and flow microfluometry. 97, or 
11% of the 866 supernatant fluids from wells with growth reacted with 
between 14% and 95% peripheral blood lymphocytes with all levels of 
reactivity represented. 
D. Discussion 
Monoclonal antibodies to feline !-lymphocytes would serve as 
invaluable tools in defining and following aberrations in cellular 
number or function within T-lymphocyte subsets. These antibodies 
could be used to document improvements in immunoregulatory and 
effector functions during experimental treatment of viral infected 
and leukemic cats. New forms of anti-leukemia and anti-immunodefi-
ciency therapy could be more precisely assessed. In addition. these 
monoclonal antibodies may be evaluated for their therapeutic poten-
tial in the treatment of retroviral associated clinical diseases. 
All studies of this sort, utilizing the feline retroviral model, 
will aid not only in the characterization and treatment of feline 
leukemia, preleukemia, immunodeficiency and retroviremia but since 
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these are well accepted reflections of similar human conditions, 
should almost certainly contribute to the understanding, diagnosis 
and treatment of human disease. 
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